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Abstract 
Cross-linking of the B cell receptor (BCR) induces transcriptional activation of 
immediate early genes (IEGs) including EGR1 and DUSP2 in chronic lymphocytic 
leukaemia (CLL). In this work, we have shown that this transcriptional activation 
correlated with histone H3 threonine 6 and 11 phosphorylation. We have 
identified Zipper-Interacting Protein Kinase (ZIPK/DAPK3) as the kinase 
mediating these histone phosphorylation marks in response to activation of the 
BCR signalling pathway. We show that this kinase is recruited to RNA 
polymerase II in an anti-IgM-dependent manner where it appears to be involved 
in pre-mRNA processing. Both IEG transcription and histone post-translational 
modifications are repressed by ibrutinib, a small molecule inhibitor used in CLL 
treatment. DAPK inhibition mimics Ibrutinib-induced repression of both IEG 
mRNA and histone H3 phosphorylation, and has anti-proliferative effects 
comparable to ibrutinib on CLL cells in vitro. DAPK inhibitor (DAPKi) has a 
broader anti-tumour effect than ibrutinib in that it can repress both anti-IgM- and 
CD40L- (NF-kB) dependent activation. We suggest that the broader effect of 
DAPKi is a result of ZIPK functioning as one of the final downstream enzymes in 
the transcription cascade. This is also beneficial in a clinical sense concerning 
disease resistance, in that ZIPK seems to function far downstream of both BTK 
and PLCγ2 – both of which can be mutated in ibrutinib-resistant CLL. Our data 
suggests that ZIPK inhibition could be an alternative to ibrutinib treatment in CLL 
and other DAPK1-silenced malignancies. 
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T265P – threonine 265 phosphorylation 
T299P – threonine 299 phosphorylation  
TCR – T cell receptor 
TdT – terminal deoxynucleotidyl transferase 
TES – transcription end site 
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TFH – T follicular helper cell 
TLK1 – tousled-like kinase 1 
TLR – toll like receptor 
TNF – tumour necrosis factor 
TSS – transcription start site 
UM-CLL – unmutated CLL 
UNG – uracil-DNA glycosylase 
USTAT3 – unphosphorylated STAT3 
V region – variable region/variable gene segment (referring to VDJ) 
VDJ recombination – variable, diversity, joining gene recombination 
VH – variable heavy domain 
VL – variable light domain 
ZAP70 – zeta-chain-associated kinase 70 
ZIPK – zipper interacting protein kinase
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Chapter 1 Introduction 
1.1 B Cell Development 
A B cell is a white blood cell which is produced in the bone marrow and circulates 
in the blood and lymphatic systems. B cells participate in our immune system to 
combat foreign antigens and infectious agents in our bodies e.g. pathogens and 
viruses. This immune function is mediated by a B cells ability to produce 
antibodies specific to particular antigens [1]. Immune responses are classified as 
cellular or humoral. Cellular responses are mediated by T cells which recognize 
and attack their targets directly or indirectly by enlisting the help of other immune 
cells, while humoral responses are characterized by the production of antibodies 
by B cells [2]. 
 
1.1.1 Antibody and antigen receptor structure 
Lymphocytes express highly diverse antigen receptors which are capable of 
recognising a near limitless range of foreign substances. This diversity is 
generated during the development of mature B and T lymphocytes from 
committed progenitor cells in the bone marrow and thymus respectively. 
Committed progenitor cells are driven by B cell specific gene expression 
programmes to rapidly proliferate and undergo highly ordered antigen receptor 
gene rearrangements [3]. These gene rearrangements not only fully commit a 
developing lymphocyte to a B cell fate, but create a vast array of antigen receptor 
proteins with different antigen specificity from a relatively limited amount of 
germline DNA. Further, selection events act as checkpoints to ensure the 
preservation of B cells with functional antigen receptors in the reactivity 
‘goldilocks zone’: that being receptors which are they are not strongly auto-
reactive, but reactive enough to be beneficial to the organism [4]. This section will 
focus on the maturation and development of B lymphocytes, including their 
structure, function and the generation of their antigen receptors.   
 
1.1.1.1 Immunoglobulin structure 
With regard to B cells, antibodies or immunoglobulins (Ig) are the major antigen 
receptors in the lymphoid system (with the TCR present on T cells) [5]. Igs are 
glycoproteins that are either secreted from mature B cells to combat pathogens 
or remain bound to the cell surface as receptor molecules e.g. the B cell receptor 
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(BCR). Igs are ‘Y’ shaped molecules composed of four polypeptide chains where 
each Ig is comprised of two paired heavy (H) and two light chains (L) [6, 7]. Of 
note, there are two types of L chain – the Ig κ L chain and the Ig λ L chain. Any 
given Ig will have either κ or λ L chains, but never a mixture of each. 
 
For descriptive purposes, taking the Ig to be a 3-segment structure comprised of 
a base and two arms, the ends of each arm are termed variable (V) regions and 
interact with antigen. There are three areas in the V regions of both H and L 
chains which are highly variable and known as the complementary determining 
regions (CDR1, CDR2 and CDR3) [8]. These regions form distinct loops in the Ig 
protein structure and are also termed hypervariable regions. In both variable H 
and  variable L chains, CDR3 possesses the greatest variability because it is 
generated as a result of recombination events (discussed below) [8]. The ‘tail’ of 
the Ig, termed the constant region (C), is less variable and instead interacts with 
effector cells and other molecules. The term constant region is slightly misleading 
as the five different classes of Ig (IgM, IgD, IgG, IgA and IgE) are distinguished 
by their C-region H chains [9]. 
 
Per a single Ig, each L chain is made up of one variable (VL) and one constant 
(CL) domain. The H chains are comprised of one variable domain (VH) and three 
constant domains (CH1, CH2 and CH3). Disulphide bonds link the H and L chains 
as well as H chains in the hinge region of the C region. In any given Ig molecule, 
the two H and two L chains are identical – giving an Ig two identical antigen-
binding sites [9] (summarised in Figure 1.1). 
 
1.1.1.2 Antigen receptor generation and the immunoglobulin gene loci 
structure 
The V region of an Ig molecule allows a lymphocyte to recognise the vast and 
ever-expanding array of antigens that exist in the environment. The capacity for 
our immune system to generate millions of different antibodies from a relatively 
limited amount of coding DNA baffled scientists for decades and the elucidation 
of this mechanism is considered a hallmark in modern immunology. This 
receptor-diversity is achieved through a process of gene rearrangement termed 
V(D)J recombination, where the Ig germline DNA is recombined to form exons 
unique to each antigen receptor.  
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V(D)J recombination fuses different variable (V) gene segments with diversity (D) 
and joining (J) segments which give rise to functional Ig proteins with 
considerably different N-terminal chains in their Ig V regions [10]. At the level of 
germline DNA, the genes that encode B cell Igs are present in a non-functional 
state, separated by vast amounts of non-coding DNA, and require effective V(D)J 
recombination to generate functional protein products. Three separate loci 
encode the Ig H chains, the Ig κ L chain and the Ig λ L chain on chromosomes 
14 [11], 2 [12] and 22 [13] respectively. The 5’ portion of each of these genes 
consists of arrays of V, D (H chain only) and J segments separated by non-coding 
sequences [14] (the Ig heavy and light chain loci are summarised in Figure 1.2).  
 
At the 5’ most end of each gene is the V gene promoter sequence for transcription 
initiation. Next, there is a leader sequence (or signal sequence) exon that 
encodes the first 20-30 N-terminal residues of the translated protein. This 
sequence is responsible for guiding the nascent polypeptides, which are 
undergoing translation on membrane-bound ribosomes, to the endoplasmic 
reticulum. Here, the leader sequence is rapidly cleaved and is therefore not 
present in the mature, functional Ig protein. 3’ of the leader sequence are the 
~300 base pair V gene segment clusters [15]. The number of V segments varies 
not only between species but also between the H chains and the κ L and λ L 
chain loci. For example, there are approximately 100 V gene segments in the 
human H chain locus, 35 in the κ L chain locus and 30 in the λ L chain locus [14, 
16]. 
 
Upstream of the V gene segments in the H chain locus only are D segments 
which are not present in either L chain loci. At varying distances 3’ of the V gene 
in the loci of both the H and L chains are numerous J segments. Similar to the V 
gene segments, the number of D and J gene segments vary between Ig locus 
and between species [15].  
 
The 3’ end of each Ig locus holds the C region genes. In humans the κ L chain 
locus has just one C gene (Cκ) while the λ L chain locus has four (Cλ) – these 
regions are composed of a single exon which encodes the entire constant region 
of each L chain  [17]. In contrast, the H chain locus contains nine C genes (CH) 
of five different classes (µ, γ, δ, ε, α). The greater diversity of CH genes allows for 
these genes to encode each and every Ig isotype and subtype e.g. Cµ H genes 
are responsible for the translation of IgM H chains. Typically, the C region of a 
functional Ig H chain will consist of three to four of the available nine exons, with 
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two smaller exons coding for the carboxyl-terminal ends of the membrane bound 
Ig H chains [15, 17]. Of the five Ig isotypes, IgG is the most common in human 
serum and has four subclasses: IgG1, IgG2, IgG2 and IgG4 which differ in their 
constant region, at their hinges and upper CH2 domains [18]. These differences 
alter the binding affinity of IgG to the FcγR receptor (a receptor family for the Fc 
region of IgG of which there are three classes: FcγRI, II and III) and ultimately 
allow different IgG subtypes to respond to a variety of antigen and stimulate the 
appropriate immune response. For example, IgG1 is the most abundant subclass 
(to the extent that a lack of IgG1 in serum is seen in a variety of antibody 
deficiencies) and is typically activated in response to soluble protein antigens and 
membrane proteins [18]. 
 
To summarise, the V region of an Ig L chain (κ or λ) is composed of V and J gene 
segments only and accordingly the process of its rearrangement is termed VJ 
recombination. The V region of the Ig H chain is comprised of V, D and J 
segments and is therefore constructed via VDJ recombination. In the latter 
process two distinct rearrangement processes must occur whereby initially a D 
segment is joined to a J segment before a V segment is fused to the DJ segment. 
In all cases, the rearrangement of these gene segments forms a single V(D)J 
exon that will code for the variable region of an Ig protein. 
 
1.1.1.3 Antibody fragmentation 
An antibodies antigen-binding region, or variable region, can also be referred to 
as the Fab segment (fragment antigen binding segment). These segments 
therefore consist of the aforementioned VL, CL, VH and CH1 domains [19]. The 
two identical Fab segments are connected via a hinge region to the paired 
CH2/CH3 domains of the constant region, or Fc segment (fragment crystallisable 
segment – named for the original observation that they crystallised well [20]), thus 
forming the Y-shaped Ig configuration.  
 
Cleavage with specific agents can fragment an antibody into its component 
sections for research, study or therapeutic applications. Two identical Fab 
segments which retain their antigen binding capabilities can be cleaved from the 
Ig structure via protein digestion with papain, leaving the Fc fragment [21]. 
Alternatively, Ig digestion with pepsin results in the formation of a F(ab’)2 
fragment. Unlike Fab fragments, the F(ab’)2 fragment contains both ‘arms’ of the 
Ig joined at the hinge via disulphide bonds and similarly retains its antigen-binding 
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capabilities. The F(ab’)2 fragment is written with a prime signification as it contains 
extra amino acids, including cysteine, as a result of the pepsin digestion. Both 
Fab and F(ab’)2 fragments have therapeutic applications [22]. 
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Figure 1.1: Antibody structure. Igs are ‘Y’ shaped molecules composed of four polypeptide chains where each Ig is comprised of 
two paired heavy (H) and two light chains (L). For descriptive purposes, taking the Ig to be a 3-segment structure comprised of a 
base and two arms, the ends of each arm are termed variable (V) regions and interact with antigen. There are three areas in the V 
regions of both H and L chains which are highly variable and known as the complementary determining regions (CDR1, CDR2 and 
CDR3)  The ‘tail’ of the Ig, termed the constant region (C), is less variable and instead interacts with effector cells and other molecules. 
Per a single Ig, each L chain is made up of one variable (VL) and one constant (CL) domain. The H chains are comprised of one 
variable domain (VH) and three constant domains (CH1, CH2 and CH3). Disulphide bonds link the H and L chains as well as H chains 
in the hinge region of the C region. In any given Ig molecule, the two H and two L chains are identical – giving an Ig two identical 
antigen-binding sites. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons 
Attribution 3.0 Unported License; https://smart.servier.com. 
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Figure 1.2: Immunoglobulin heavy and light chain organisation. At the level of germline DNA, the genes that encode B cell Igs 
are present in a non-functional state, separated by vast amounts of non-coding DNA, and require effective V(D)J recombination to 
generate functional protein products. Three separate loci encode the Ig H chains, the Ig κ L chain and the Ig λ L chain on 
chromosomes 14, 2 and 22 respectively. The 5’ portion of each of these genes consists of arrays of V, D (H chain only) and J 
segments separated by non-coding sequences. At the 5’ end of each gene is leader sequence (L1-n) exon that encodes the first 20-
30 N-terminal residues of the translated protein. 3’ of the leader sequence are the ~300 base pair V gene segment clusters. There 
are approximately 100 V gene segments in the H chain locus, 35 in the κ L chain locus and 30 in the λ L chain locus. Upstream of 
the V gene segments in the H chain locus only are D segments. At varying distances 3’ of the V gene in the loci of both the H and L 
chains are numerous J segments. Similar to the V gene segments, the number of D and J gene segments vary between Ig locus and 
between species. The 3’ end of each Ig locus holds the C region genes. In humans the κ L chain locus has just one C gene (Cκ) while 
the λ L chain locus has four (Cλ1,2,3,7). In contrast, the H chain locus contains nine C genes (CH) of five different classes (µ, γ, δ, ε, α).
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1.1.2 The stages of B cell development 
1.1.2.1 Haematopoietic stem cells & commitment to the B cell lineage
  
All lineages of blood cells are derived from pluripotent stem cells in the bone 
marrow, referred to as haematopoietic stem cells (HSCs), which through a 
process of successive fate-decision programmes undergo a progressive loss of 
differentiation potential and self-renewal capacity [23]. Initially, HSCs mature into 
common lymphoid progenitors (CLPs) which can differentiate further into B cells, 
T cells and natural killer (NK) cells [24]. 
 
CLP commitment to the B cell lineage is ultimately guided by signals from cell-
surface receptors to activate or repress transcriptional regulators specific to the 
B cell program. This transcriptomic activity encompasses one of the earliest 
definable stages of B cell development. Transcription factors that control early B 
cell development include Early B cell factor (EBF), E2A (E12/E47), Ets family 
member PU.1, Ikaros and Paired Box 5 (Pax 5) [25]. These proteins cooperate 
in a hierarchical regulatory network to direct a HSC towards a mature B cell [26].  
 
Such key transcription factors upregulate distinct gene networks to drive CLPs 
towards a B cell fate. These proteins are tasked with beginning the process of 
V(D)J antigen receptor gene rearrangement, promoting display of the pre-B cell 
receptor (pre-BCR), as well as further altering chromatin structure to allow access 
to particular antigen receptor gene loci [27]. The different stages of B cell 
development are characterised by changing cellular characteristics including 
specific bouts of proliferation, distinct cell surface markers, rearrangement of Ig 
genes and their subsequent expression (summarised in Figure 1.3).  
 
1.1.2.2 The stages of B cell development: Pro and Pre-B cells 
CLPs which have activated transcriptional programmes to commit to the B cell 
lineage undergo extensive proliferation to generate a large number of progenitor 
cells. This ensures an eventual large population of diverse lymphocytes with 
varying antigen-specificity. The earliest definable and committed B cell is the pro-
B cell – a progenitor cell which does not express Ig but presents with B-lineage 
specific surface molecules such as CD19 and CD10, thus differentiating itself 
from those HCSs driven towards the T cell lineage [28]. The cluster of 
differentiation (CD) proteins are cell-surface markers which are dynamically 
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expressed throughout the lifetime of any given B cell which can be used to 
differentiate cellular life stages [29]. Some CD proteins may be tightly restricted 
to a specific cell type or development stage (e.g. CD+/CD-) while others may vary 
in relative expression between several such stages (e.g. CD+++/CD---). These 
proteins have diverse functions, serving as receptors for growth factors, adhesion 
molecules and a variety of signal transduction enzymes [30]. 
 
At this stage the process of V(D)J recombination occurs in the developing B 
lymphocyte, now termed an early pro-B cell. This process can only occur in cells 
which are committed to the B cell lineage, and is one of the earliest 
characterisable stages of pro-B cells [31]. V(D)J occurs in a series of controlled 
steps. First, recombination events mediated by chromatin remodelling bring 
together one D segment with one J segment, deleting the intronic DNA, to form 
a H chain DJ gene segment [32]. DNA double strand breaks (DSBs) are carefully 
introduced in a tightly regulated mechanism by the RAG recombinase protein 
complex at specific recombination signal sequences (RSSs) flanking the coding 
regions of each V, (D) (and J) gene segments. Recombination activating gene 1 
and 2 (RAG1 and RAG2) code for a series of proteins which make up the RAG 
complex and are first expressed at the pro-B cell stage [15]. Following this, as a 
late pro-B cell, one of the many 5’ V region genes is rearranged and brought into 
close proximity with the DJ exon to form the complete H chain VDJ exon (V(D)J 
recombination of the Ig H chain locus is summarised in Figure 1.4). Transcription 
and subsequent expression of the VDJ exon with a C region exon as a completed 
Ig H chain is a hallmark of committed B cell lineage precursors.   
 
Expression of terminal deoxynucleotidyl transferase (TdT) is increased during the 
early pro-B and late pro-B cell stages to promote junctional diversity at the 
genomic region which codes for the hypervariable CDR3 region [33]. V(D)J gene 
segment joining is often imprecise and nucleotides can be lost during  
asymmetrical RAG/Artemis-cleavage at RSSs. TdT catalyses the addition of 
templated P nucleotides to the asymmetrically cleaved DNA ends present at VD, 
VJ or DJ junctions. After the addition of P nucleotides, TdT then also adds 
between 2-20 non-templated base pairs, termed N nucleotides, at the now 
symmetrical DNA ends [34]. The action of TdT at gene segment junctions 
changes the amino acid sequences in the CDR3 region and vastly increases its 
diversity [8]. The addition of P and N nucleotides generates new DNA sequences 
for V, D and J gene sequences that are not even present in the germline DNA 
allowing TdT to promote further diversity in antigen receptor proteins [35, 36]. Of 
note, TdT expression decreases as B cells develop to the pre-B cell stage where 
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the L chains are recombined. Thus, junctional diversity linked to the addition of N 
nucleotides is greater in rearranged H chains than in rearranged L chains [37]. 
Repair is initiated by a large group of proteins composed of many of the classic 
non-homologous end joining (NHEJ) repair pathway enzymes [31]. The ligated 
product forms the functional mRNA encoding the V region of an Ig gene.  
 
In order to complete the H chain rearrangement, the C region exons need to be 
joined with the rearranged VDJ exon. The joining of the C region exons with the 
V(D)J exon does not occur through a DSB-mediated mechanism but instead 
takes place at the RNA level through more traditional RNA splicing [10]. The C 
regions are downstream towards the 3’ end of the loci, separated by a J-C intron. 
In pro-B cells, the rearranged Ig H chain gene is transcribed post VDJ with the J-
C intron and remaining J segments still present in the rearranged DNA. Through 
splicing, the RNA primary transcript is processed via the removal of intronic DNA 
between the leader exon and the VDJ exon, between the VDJ exon and the first 
exon of the Cµ locus, and between the individual Cµ exons [38]. The Cµ gene 
region (the CH gene responsible for IgM expression) is brought alongside the 
rearranged VDJ exon as a complete mRNA transcript for the µ Ig H chain [38]. If 
the VDJ recombination event was productive i.e. bases were added at junctions 
during recombination in the correct reading frame ensuring the rearranged DNA 
will encode a functional protein, the µ Ig H chain mRNA is translated into one of 
the Ig H chains [27, 31, 39]. 
 
Typically, half of all committed pro-B cells will rearrange and synthesise a 
productive µ H chain protein and differentiate further, those cells which make 
unproductive rearrangements are prompted to apoptose [40].  Productive Ig H 
chain locus rearrangements leading to Ig µ protein expression progress the 
developing B cell to the pre-B cell stage, presenting with a pre-BCR, but still 
needing to rearrange its Ig L chain locus [41]. 
 
1.1.2.3 The stages of B cell development: Pre-B cell receptor 
Successful formation of the pre-BCR acts as the first major checkpoint of B cell 
development [42]. The pre-B cell will express rearranged Ig µ H chain protein with 
surrogate L chains – these are L chains made up of the VpreB and λ5 proteins, 
which act as surrogates for the V and C regions of a L chain respectively [43]. 
The surrogate L chain is structurally homologous to a typical κ or λ L chain, but 
is un-rearranged and identical in all pre-B cells [43]. The pre-BCR is also 
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complexed with signal-transducing proteins named Igα and Igβ. Signals from the 
pre-BCR are responsible for an enormous proliferative burst and the greatest 
expansion of committed B cell progenitors in the bone marrow [44]. Signalling 
from the pre-BCR activates a pivotal kinase in B cell development in Bruton’s 
tyrosine kinase (BTK), an enzyme responsible for proliferation, survival and 
maturation. It has been suggested that the pre-BCR is assembled in a tonic state 
i.e. it functions in a ligand-independent manner and is permanently switched on 
to promote the requisite proliferative signalling [45].  
 
The pre-BCR also regulates the next stage in B cell development by promoting κ 
L chain rearrangement. Interestingly, formation of the pre-BCR regulates the 
rearrangement of Ig genes in another way. If a productive Ig µ H chain is 
produced through VDJ recombination on one chromosome, the formation of the 
pre-BCR signals to permanently inhibit further rearrangements on the other 
chromosome. Similarly, if the first rearrangement is non-productive, the H chain 
allele on the other chromosome is given a chance to complete productive VDJ 
recombination. Therefore, in any given B cell one H chain locus is productively 
rearranged while the other is retained as either germline DNA or in a non-
productive rearrangement. This process is known as allelic exclusion and 
ensures each B cell will not have two differentially rearranged H chains and 
instead will maintain clonal specificity by expressing a single receptor [46]. 
 
1.1.2.4 The stages of B cell development: Immature B cells 
Pre-B cells quickly mature to immature B cells following expression of the pre-
BCR. Here, developing B cells rearrange their κ L chain locus through VJ 
recombination [47]. VJ recombination is similar to V(D)J recombination, but L 
chain loci lack D gene segments. Recombination in the κ L chain locus involves 
rearranging the germline DNA to bring one V segment into close proximity with a 
J segment [48]. The ensuing VJ exon is transcribed with a 3’ intron separating it 
from the C region exons. Primary transcript processing removes the VJ-C intron 
and creates the completed κ or λ L chain mRNA. The κ L chain locus has only 
one Cκ region exon, but alternative splicing in the λ L chain locus can lead to 
functional mRNA containing one of four possible Cλ region exons. Despite this, 
there are no known functional differences between λ L chains using any of the 
four possible Cλ exons [48]. 
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The synthesised L chain protein associates with the Ig µ H chain, replacing the 
surrogate L chains, to produce a completed IgM protein [49]. If the κ L chain locus 
in un-productively rearranged, the cell has a second chance and can rearrange 
its λ L chain locus to produce a functional IgM. It is the expression of IgM that 
denotes the immature B cell stage [50]. If a productive κ L chain is synthesised, 
functional IgM prevents rearrangement of any further λ L chain, and λ L chain 
rearrangement is only attempted if κ L chain rearrangement results in a non-
productive L chain. Therefore, through a process called light chain isotype 
exclusion, any given B cell clone will only express one of the two types of L chain 
[51]. Similar to the H chain, expression of the κ or λ L chain is allelically excluded 
– with expression of each L chain driven from only one chromosome at a time 
[40]. If both κ and λ L chain rearrangement fails and the gene products are non-
functional, the developing B cell will fail to receive the requisite survival signals 
from the BCR and the cell will apoptose.  
 
The newly assembled IgM molecules are expressed on the cell surface and 
function as antigen receptors. Accordingly, RAG gene expression is 
systematically shut-off to prevent further rearrangement of Ig genes [52]. There 
are three broad outcomes for these immature B cells. First, if their receptors are 
not strongly self-reactive they may function in a ligand-independent manner 
similar to the pre-BCR. Second, strongly self-reactive B cells that recognise 
antigens in the bone marrow with high avidity may undergo cell death in a form 
of negative selection [53]. Additionally, some B cells with strong autoreactive 
receptors have a chance to escape negative selection through a secondary 
rearrangement process termed receptor editing which modifies the already 
functional gene. Receptor editing allows the B cell to alter the specificity of its 
BCR and is mediated by the same enzymes (RAG) which coordinate the initial 
V(D)J recombination. Finally, those immature B cells which are not strongly self-
reactive (or are receptor edited to this state) will leave the bone marrow to 
complete maturation.  
 
1.1.2.5 The stages of B cell development: Mature B cells and IgM+IgD+ co-
expression 
Bone marrow derived mature B cells can be termed B-2 B cells and will either 
commit to continue developing into a marginal zone B-2 B cell or a follicular B-2 
B cell with the majority of B cells committing to the latter [54]. Follicular B cells 
produce IgD in addition to IgM through RNA splicing. As described previously, in 
the early stages of B cell development, immature B cells express Cµ region genes 
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only (IgM expression). For a singular B cell to express both IgM and IgD with the 
same rearranged VDJ exon, a particularly long primary RNA transcript is 
produced containing the rearranged VDJ exon as well as the Cµ and Cδ genes. 
Specific polyadenylation sites guide splicing to occur either between the Cµ and 
Cδ genes (resulting in a typical µ mRNA for IgM) or 3’ of the Cδ gene, removing 
the intervening Cµ gene (resulting in an δ gene for IgD) [50]. Co-expression of 
IgM and IgD is a hallmark of a mature B cell – this cell now has the capacity to 
recirculate and considered functionally competent, but in many respects, it is still 
a precursor or naïve-B cell. These cells can however effectively respond to 
antigen, and in doing so can undergo further antigen-induced B cell differentiation 
in a germinal centre reaction. 
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Figure 1.3: B cell development. As HSCs undergo a series of successive fate-decision programmes and commit to the lymphoid 
lineage, they progress through the stages of B cell development from a Pro-B, Pre-B and immature-B cell to a mature, naïve B cell. 
As B cells reach this stage they develop and express their B cell receptors. We categorise CLL into two subtypes depending on the 
nature of the BCR, which refers to the stage in B cell development from which they originate. U-CLL refers to naïve B-cells whose 
BCRs have not been somatically hypermutated in the germinal centre. When these naïve B cells are exposed to antigen they enter 
the germinal centre and undergo affinity maturation – they purposefully mutate the variable genes which make up the BCR to generate 
the best possible receptor for a specific antigen. When these cells exit the germinal centre, they have a more specific, less 
promiscuous BCR and these cells give rise to M-CLL. The U-CLL cells have a BCR which is less specific and more likely to react 
with a wide array of antigen lending to a worse prognosis. This figure was created using Servier Medical Art templates, which are 
licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com.   
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Figure 1.4: Immunoglobulin heavy chain rearrangement. V(D)J occurs in a series of controlled steps. First, recombination events 
mediated by chromatin remodelling bring together one D segment with one J segment, deleting the intronic DNA, to form a H chain 
DJ gene segment. DNA double strand breaks (DSBs) are carefully introduced in a tightly regulated mechanism by the RAG 
recombinase protein complex at specific recombination signal sequences (RSSs) flanking the coding regions of each V, (D) (and J) 
gene segments. Following this, as a late pro-B cell, one of the many 5’ V region genes is rearranged and brought into close proximity 
with the DJ exon to form the complete H chain VDJ exon. Transcription and subsequent expression of the VDJ exon with a C region 
exon as a completed Ig H chain is a hallmark of committed B cell lineage precursors.    
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1.1.3 The germinal centre reaction 
1.1.3.1 The germinal centre reaction: initiation 
While V(D)J recombination creates a large number of varied antibodies, the 
repertoire is still not great enough to combat the millions of possible antigens in 
our environment. The low-affinity (for the antigen to the Ig binding site) IgM 
expressing antibodies generated in the bone marrow are deemed a first line of 
defence but are not the end of the story. When these B cells bind antigen, they 
undergo rapid proliferation within secondary lymphoid organs in transient 
structures termed germinal centres (GCs) to generate high-affinity antibodies 
[55].  
 
This process can begin in the lymph node (LN) where naïve IgM+IgD+ B cells are 
present in follicles (regions of the LN) separated by interfollicular regions. T cell 
rich areas border these follicles and GCs form within the centre of the follicles 
themselves. Upon antigen-activation, the naïve, mature B cells migrate to the 
border of the T cell zone and B cell zone where they interact with antigen-specific 
T cells, become activated and begin to proliferate [56]. For any given antigen, 
only the subset of B cells with the highest affinity antibodies proceed to the GC 
reaction as to prevent competition for T cell signals with those B cells with a low-
affinity for said specific antigen [57]. 
 
The T cells responsible for the above interaction will then commit to become T 
follicular helper cells (TFH cells) and migrate from the interfollicular region into the 
follicle which is initially comprised of resident IgM+IgD+ follicular B cells and 
follicular dendritic cells (FDCs). There, through priming by dendritic cells, they 
upregulate expression of the master regulator of the GC reaction, B cell 
lymphoma 6 (BCL-6) [58]. B cells also migrate into the follicle and begin to 
proliferate rapidly, expelling the resident IgM+IgD+ follicular B cells, and leading 
to the formation of dark and light zones as a mature GC. The dark zone is 
characterized be densely packed B cells, whereas the light zone is comprised of 
far less B cells and is populated with TFH cells and FDCs. 
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1.1.3.2 The germinal centre reaction: somatic hypermutation & GC positive 
selection 
Within the dark zone of GC reactions, a process known as somatic hypermutation 
(SHM) takes place to induce further diversity to the Ig V region genes. SHM 
produces a large number of B cell clones that will have a varying range of affinities 
for the immunizing antigen [55]. The process involves the incorporation of single 
nucleotide substitutions per 1,000 bases into the rearranged V genes to promote 
antibody affinity maturation via affinity-enhancing mutations [59]. SHM is 
mediated by the enzyme activation-induced deaminase (AID) which can convert 
deoxycytidines to deoxyuracils causing both transition (purine-purine 
substitution) and transversion (purine-pyrimidine substitution) mutations in V 
region genes [60]. Affinity maturation ensures that the B cells where these 
mutations result in increased antigen binding affinity undergo selective 
expansion, and those inferior antibody mutants with low antigen affinity or 
autoreactivity are outcompeted and/or encouraged to apoptose [55]. 
 
Post-SHM, B cells transit into the light zone of the GC reaction to ‘test’ their newly 
mutated BCR against antigen presented on FDCs. Here, those B cells with high-
affinity antigen receptors undergo TFH-mediated positive selection. It is these 
high-affinity B cells which are preferentially recirculated between the two zones 
for further rounds of SHM and selection. It has only recently been shown that TFH 
cells promote selection within the light zone and that these cells are in fact the 
driving force behind selecting high-affinity B cells [61]. This process occurs via B 
cells presenting processed antigen on major histocompatibility complexes (MHC) 
to the T cell receptor (TCR) of TFH-cells. There is a direct correlation between 
greater antigen capture and peptide-MHC presentation resulting in more TFH-
cell assistance for those B cells with the highest affinity BCRs [61]. Novel 
techniques allowing cell division within the GC to be tracked have shown that 
when such high-affinity B cells, which have received the most TFH-cell assistance, 
recirculate into the dark zone they are programmed to divide, undergo further 
SHM, and proliferate more than their lower-affinity counterparts in a form of 
selective expansion [62].   
 
By encouraging those B cells with the highest antigen-affinity to undergo further 
rounds of proliferation and successive SHM, while selectively removing low-
affinity B cell clones via apoptosis, the GC reaction is quickly dominated by a 
population of the ‘strongest’ B cells in an elegant example of Darwinian evolution 
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in fast-forward. This iterative process of selection results in memory B cells and 
plasma cells with the capacity to produce high-affinity antibodies to combat 
invading pathogens. 
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1.1.3.3 The germinal centre reaction: class-switch recombination 
A subset of B cells taking part in the GC reaction also undergo class-switch 
recombination (CSR). CSR, like SHM, is mediated by AID and is a process which 
targets the Ig H chain locus for a further recombination event [63]. Each CH gene 
(except Cδ/IgD) is preceded by a unique DNA region known as a switch (S) region 
and the CSR recombination event occurs between two S-regions, deleting the 
intervening CH genes, including Cµ. This phenomenon brings the VDJ exon closer 
to the more 3’ Ig H chain CH genes (Cγ, Cε, Cα) and allows a switch from IgM to 
IgG, IgA or IgE [64].  
 
Studies have implicated transcription through S-regions as a mechanism for the 
initiation of CSR, and that the S-regions themselves are not the primary 
recognition site. These groups suggest that single-stranded DNA is stabilised by 
transcription-dependent higher order structures, and these structures are the 
primary substrate for CSR [65, 66]. An example of such a structure is the R-loop, 
whereby when S-regions were observed to be transcribed, the primary transcripts 
stably associated with the template DNA strand to form an RNA-DNA hybrid [67, 
68]. These R-loops provide a substrate for AID, whose catalytic activity induces 
mutations in the exposed single-stranded DNA. Enzymes which target the AID-
induced mismatched base pairs (uracil-DNA glycosylase (UNG) and 
apurinic/apyrimidinic endonuclease 1 (APE1)) induce a series in nicks on the 
non-template stand which together with nicks on the opposite strand induce 
DSBs in the S-region [64]. Similar to V(D)J, the breaks are processed via 
synapsis before fusion of two S-region DSBs, likely via the NHEJ pathway [69, 
70]. Productive CSR results in a recombined Ig H locus with the VDJ exon aligned 
with a new CH gene. 
 
Cytokines are responsible for directing the initial transcription through the H chain 
locus and determining which Ig isotype the B cell will switch to e.g. 
lipopolysaccharide (LPS) is thought to drive the switch to IgG while a combination 
of LPS, transforming growth factor-β (TGF- β) and interleukin-5 (IL-5) are 
required to switch to IgA [64]. 
 
1.1.3.4 The germinal centre reaction: outcomes  
B cells harbouring newly developed, high-affinity antigen receptors generated 
from repeated selection in GC reactions will ultimately differentiate into memory 
B cells (MBCs) and plasma cells/plasmablasts (PCs), leaving the GC and 
  
20 
 
entering circulation to combat pathogens and confer long-lived antibody mediated 
(humoral) immunity [71].The decision to commit to a PC or MBC fate is driven by 
contrasting signals and gene expression programmes in the light zone of the GC, 
allowing cells with particular BCRs to be selected for and halt dark zone re-
circulation [72]. MBC differentiation is predominantly restricted to low-affinity B 
cells while maturing PCs require high-affinity BCRs and assistance from TFH cells 
[72]. In brief, short-lived PCs produce antibody to tackle infection, while repeated 
encounter with the same antigen (secondary infection) triggers the reactivation of 
long-lived MBCs to differentiate into PCs [73]. The process of MBC reactivation 
is thought to involve a new GC reaction as during secondary infection the PC 
response is often dominated by IgG+ IgA+ PCs which have previously undergone 
CSR [74].  
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1.2 Chronic Lymphocytic Leukaemia Pathogenesis 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the 
Western world, with an estimated incidence of ~6 cases per 100,000 annually 
and a median diagnosis age of 72 years. Yet despite its prevalence the complete 
picture of its pathogenesis and genetic landscape remain unclear. This is in part 
due to the heterogeneity observed between patients whereby some present with 
stable disease and do not require therapy while others have a more aggressive 
disease course and require early treatment [75] [76]. The well-established Rai 
[77] and Binet [78] CLL staging systems help categorise patients and define their 
treatment needs by considering lymphocyte count, LN enlargement and how 
many nodes are affected, spleen size, anaemia and platelet count. 
 
1.2.1 CLL biological and genetic features 
CLL is a malignancy of CD5+CD19+ B cells characterised by the accumulation 
and clonal expansion of functionally abnormal B cells in the blood, bone marrow 
and lymphoid tissues [79]. CLL cells typically present with high levels of cell 
surface markers which are upregulated after antigen exposure (e.g. CD23, CD25, 
CD69) and low levels of those which are downregulated after cellular activation 
(e.g. CD22, CD79b). The level of soluble CD23 found in the serum of a patient is 
considered one of the most important prognostic markers for the disease [80]. 
CLL cells also express the memory B cell marker, CD27, and often have gene 
expression profiles similar to memory B cells [81].  
 
CD38 [82] and ZAP70 [83] are two further important prognostic markers in CLL. 
CD38 is important for B cell differentiation through an interaction with CD31, a 
cell surface marker found on NLCs and T cells in the microenvironment. Patients 
overexpressing CD38 are considered to have a more aggressive disease and a 
shorter life expectancy. ZAP70 enhances BCR signalling and is an important 
signalling molecule in B, T and NK cells. Similarly, patients with high levels of 
ZAP70 have a worse prognosis. 
 
Cytogenetic abnormalities play a large and important role in the pathogenesis of 
CLL and in disease prognosis. The most frequent abnormalities are deletions of 
chromosomal material, with the most common found in band 13q, followed by 
deletions in 11q and 17p. Gain of chromosomal material in the form of 
chromosome 12 trisomy is also common. 13q deletions are typically considered 
to be predictive of low risk disease, while the 17p and 11q deletions effect the 
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critical TP53 and ataxia telangiectasia mutated (ATM) genes respectively, and 
predict much poorer disease outcome [84]. TP53 deletion or mutation remains 
the strongest marker of reduced progression free survival (PFS) and overall 
survival (OS) in CLL. 
 
The mutational landscape of CLL has been elucidated somewhat through 
advents in next-generation sequencing. While there are less mutations globally 
in CLL than in most solid tumours, recurrent mutations have been detected 
effecting the NOTCH and Wnt signalling pathways, RNA splicing and processing 
machinery (SF3B1), DNA damage response proteins and chromatin modifiers 
[85, 86]. More recently, the MYC suppressor, MGA, and proteins in the MAPK-
ERK pathway including NRAS, KRAS and BRAF have been identified as drivers 
in CLL [86]. 
 
The CLL epigenome has been extensively studied in recent years with aberrant 
patterns discovered in DNA methylation, chromatin accessibility and histone 
modifications [87-89]. Often, epigenetic alterations in CLL are linked to other 
prognostic factors e.g. U-CLL patients have been observed to harbour more 
active, open chromatin than M-CLL [87]. The epigenetic background of a CLL cell 
is also thought to provide a glimpse at its cell of origin with recent work suggesting 
CLL-specific differences in methylation reflect the stage of B cell development 
from which they arise [90]. Of note, silencing of the pro-apoptotic Death 
Associated Protein Kinase 1 (DAPK1) via hypermethylation of its promoter has 
been suggested to influence tumour progression and metastasis in cancers such 
as CLL [91] and DLBCL [92] and is a marker of poor survival.  
 
1.2.2 CLL microenvironment 
In the bone marrow, CLL cell survival is highly dependent on cellular and 
molecular interactions with stromal cells and the matrix, collectively referred to as 
the tissue microenvironment (or sometimes a ‘pseudofollicle’ or proliferation 
centre) [93]. To expand, nurselike cells (NLCs), mesenchymal stromal cells, T 
cells and NK cells are critical components of the microenvironment and 
communicate with CLL cells through a complex network of adhesion molecules, 
chemokine receptors, tumour necrosis factor (TNF) family members, and soluble 
factors [94]. These signals regulate specific gene expression profiles, different 
from those observed in circulating CLL cells, to promote survival and proliferation 
and are often associated with strong BCR and NF-κB pathway activation [95]. 
  
23 
 
The importance of the CLL microenvironment is reinforced by the efficacy of CLL 
therapeutics which target this dependency, such as ibrutinib, a small molecule 
inhibitor which impacts BCR signalling and disrupts CLL cell trafficking to the LN 
[96]. 
 
1.2.3 CLL subtypes 
CLL is often divided into two main subtypes defined by the mutational status of 
their Ig H chain V region gene which reflects the stage of normal B cell 
development from which the CLL cell has originated [97]. Unmutated CLL (U-
CLL) cells originate from a B cell that has not undergone differentiation and SHM 
in GCs and patients typically present with a more aggressive disease. U-CLL 
cells are thought to be CD5+ B cells that are readily expressing IgM and/or IgD 
prior to any potential CSR in the GC. 
 
Mutated CLL (M-CLL) cells arise from post-GC parental B cells (e.g. MBCs) with 
Ig V regions that have undergone SHM and/or CSR and these cases have a more 
indolent disease course. These cells may therefore also be found expressing IgA 
and IgG. There are some exceptions to this division linked to particular BCR 
V(D)J recombination events which do not abide by the M-CLL/U-CLL prognoses. 
A paradigm example are those Igs which have undergone V(D)J recombination 
of the Ig H chain and selected the V3-21 gene for their V region gene segment. 
These patients suffer from a shorter overall survival (OS) regardless of SHM 
status and their disease is more alike to U-CLL [98].  
 
Interestingly, despite the enormous potential for variation that is associated with 
V(D)J recombination, the repertoire of potential Ig molecules of CLL patients are 
significantly more limited than in healthy B cells and patients often present with 
nearly identical or highly homologous CDR3 regions. This phenomenon is termed 
Ig stereotypy and is so extreme that around one third of CLL patients have 
virtually identical Ig molecules arising from shared sequence motifs in the CDR3 
region, reflecting the bias for specific Ig genes [99]. This limited diversity seems 
to stem from the binding activity of the surface Ig and supports the idea that the 
recurrent binding of a restricted set of antigens drives the CLL pathogenic 
process [100]. In many cases, stereotyped CLL BCRs can recognise various 
autoantigens as well as environmental or microbial antigens including 
cytoskeletal components, the Fc-tail of IgG, single stranded or double stranded 
DNA and apoptotic cells [101, 102]. These stereotyped BCRs are grouped into 
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different subsets, where subset 2 expresses a BCR with the aforementioned 
IgHV3-21in combination with IgLV3-21. Recent work has highlighted that the 
subset 2 light chain carries a single point mutation at R110 at the junction 
between the variable and constant LC regions (termed IgLV3-21R110) and that 
these patients represent a new, distinct subset with a particularly poor prognosis 
as the mutation promotes constitutive BCR-signalling [103]. This group provides 
another example of patients which can be high risk regardless of IgHV status.   
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1.2.4 NF-κB signalling in CLL 
The nuclear factor-κB (NF-κB) pathway plays an essential role in the regulation 
of cellular processes vital to healthy development including proliferation, 
inflammation and cell survival – processes closely linked to cancer progression. 
It is therefore unsurprising that NF-κB is also constitutively active in most CLL, 
playing a major role in the development of the disease.  
 
The NF-κB family comprises five members: p105/p50, p100/p52, p65 (RelA), 
RelB and c-Rel encoded by NFKB1, NFKB2, RELA, RELB, and REL respectively. 
Only p65, c-Rel and RelB are transcriptionally active [104]. Without activatory 
stimuli, NF-κB proteins remain sequestered in the cytoplasm by inhibitory IκB 
family members such as IκBα. In addition, p50 and p52 are inhibited by way of 
their precursor proteins, p105 and p100, from which the active subunits are post-
translationally cleaved [105]. NF-κB signalling is classified as either canonical or 
non-canonical/alternative. Canonical NF-κB signalling is activated via inducible 
degradation of IκBα by a multi-subunit IκB kinase (IKK) complex resulting in 
nuclear translocation of p50/p65 and p50/c-Rel dimers. Non-canonical NF-κB 
signalling is activated via the processing of the p52 precursor protein, p100, by 
the NF-κB-inducing kinase (NIK) and typically results in the nuclear translocation 
of p52/RelB dimers [106]. 
 
In CLL, NF-κB proteins can be activated downstream of many cell surface 
receptors promoting CLL proliferation and survival in the microenvironment 
including the BCR, CD40 and toll-like receptors (TLR) [107]. A handful of low-
frequency mutations in the NF-κB pathway have been detected in CLL including 
MYD88, NKFBIE [108] and BIRC3 but the majority of aberrant NF-κB activation 
is thought to arise through external stimuli activating the aforementioned 
signalling cascades [109]. Aberrant epigenetic regulation of NF-κB has also been 
reported in CLL whereby genes enhancing NF-κB signalling were observed to be 
differentially methylated in different IgHV subgroups e.g. these genes (including 
ADORA3 and CARD15) remained unmethylated and overexpressed in poor 
prognosis U-CLL patients but remained methylated in M-CLL [110]. Further 
studies have indicated that NF-κB and STAT3, another transcription 
overexpressed in the disease, are both activated by BCR signalling in CLL.  NF-
κB and STAT3 can cooperate to inhibit CLL cell apoptosis whereby the strongest 
cooperation predicts a poor response to therapy [111, 112].  
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1.2.5 BCR signalling in CLL 
As discussed previously, the BCR is formed during B cell development from an 
Ig molecule (IgA, IgD, IgE, IgG or IgM) which is presented on the cell surface of 
mature B cells. Like mature B cells, CLL cells will typically co-express IgD and 
IgM, although at much lower levels than normal B cells [113]. As a functional BCR 
is of utmost importance to healthy B cell survival, it is of no surprise that B cell 
malignancies such as CLL often co-opt this pathway for their own aberrant 
proliferation. It has been suggested that CLL cells harbour constitutively active 
BCR signalling through either antigen-dependent or antigen-independent 
signalling (BCR is engaged by autoantigen), or through mutations in one of many 
of the downstream enzymes involved in the signalling cascade [114] (pathways 
summarised in Figure 1.5). 
 
In CLL cells, STAT3 is activated downstream of the BCR, whose activation 
promotes JAK2/STAT3 signalling, induction of STAT3 phosphorylation and its 
subsequent nuclear shuttling to transcribe pro-proliferative genes [115]. 
Constitutive STAT3 tyrosine phosphorylation is common in many malignancies, 
yet in CLL STAT3 is uniquely and constitutively, phosphorylated at serine 727 
(STAT3 S727-P) regardless of cell count, disease stage or treatment status. 
STAT3 S727-P has been shown to translocate to the nucleus and bind DNA, 
promoting the transcription of genes for CLL cell survival and proliferation [116]. 
 
The importance of the BCR signalling pathway is highlighted by the efficacy of 
small molecule inhibitors that block BCR signalling and which have seen success 
in the clinic. These include the BTK inhibitor, ibrutinib and the phosphoinositide-
3 kinase (PI3K) inhibitor, idelalisib [117]. Typically, U-CLL cells are more sensitive 
to inhibitors of BCR-signalling than M-CLL cells [118]. This may be linked to the 
fact that U-CLL cells tend to respond to BCR signalling through enhancing B cell 
activation, while anergy is the dominant response for most M-CLL cells. Anergy 
is a state of cellular lethargy caused by chronic activation of the BCR and may 
explain the more indolent disease course observed in M-CLL patients [119]. The 
anergic cells in these patients are less likely to proliferate in response to BCR 
signalling than the more aggressive and proliferative U-CLL cells. It has been 
suggested that the outcome of BCR-activation (proliferation versus anergy) may 
be linked to the CLL cell of origin [113].  
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1.2.6 CLL treatment & resistance to therapy 
As stated previously, CLL disease progression is particularly heterogeneous and 
while some patients present with indolent disease, others require rapid treatment 
and therapy. Often, patients are diagnosed with completely asymptomatic 
disease and clinicians may opt to ‘watch and wait’ for further disease progression 
before beginning treatment [120]. As the median age of CLL diagnosis is in the 
early 70s and the disease is considered incurable (aside from allogeneic stem 
cell transplants), the decision not to treat indolent, asymptomatic CLL patients at 
diagnosis is understandable. Many patients will die with their disease long before 
their CLL becomes problematic. However, those that do suffer from more 
aggressive disease will typically die from CLL-driven causes such as bone 
marrow failure, infection, or transformation to a high-grade lymphoma [109]. 
Treatment options range from chemoimmunotherapy (CIT) with chlorambucil or 
FCR [121] (fludarabine, cyclophosphamide (FC) supplemented with the CD20 
antibody rituximab (R)) to targeted, small molecule therapies including the BTK 
inhibitors (BTKi) ibrutinib and acalabrutinib, idelalisib [122] (phosphatidylinositol 
3-kinase (PI3Kδ) inhibitor), venetoclax [123] (BCL-2 inhibitor) or the more novel 
CD20 inhibitor, obinutuzumab [124]. Combinations of these inhibitors are being 
considered worldwide in numerous clinical trials, typically comparing their efficacy 
to CIT, including combinations of ibrutinib with obinutuzumab [125] (iLLuminate 
trial), acalabrutinib with obinutuzumab [126] (ELEVATE TN trial) and venetoclax 
with obinutuzumab [127] (CLL 14 trial).  
 
Choosing the correct frontline therapy is an important decision and clinicians 
must consider patient fitness and history as well as their genetic and cytogenetic 
profiles such as 17p deletion, TP53 mutational status and their IgHV subtype 
classification. Clinicians treating patients with CLL are in the enviable position of 
having several, very effective frontline therapy options available. Choosing 
between the variety of targeted therapies is not cut and dry and the choice can 
depend on both patient characteristics and the clinician’s discretion. Generally, a 
patient diagnosed with CLL under the age of 65 who is considered fit, with 
mutated IgHV status and favourable cytogenetics, can enjoy long remission with 
all available regiments, including CIT (this being one of the only scenarios where 
CIT is comparable to targeted therapies). CIT (both FCR and chlorambucil) is 
often compared to targeted agents in clinical trials with both the RESONATE 2 
[128] and E1912 [129] trials demonstrating the superiority of single-agent ibrutinib 
compared to chlorambucil. CIT is, of course, associated with high levels of toxicity 
and a majority of patients face relapse concerns [130].  
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It is no surprise then that novel targeted agents are consistently shown to be 
superior to CIT in the context of patients with high risk factors such as 17p 
deletion or unmutated IgHV status. These patients are notoriously hard to treat 
and U-CLL represents a major challenge in CLL therapy, even for the newer 
targeted therapies using venetoclax and obinutuzumab. There are differing 
opinions on how to treat such high-risk patients and many clinicians prefer to 
either enrol their patients on clinical trials or opt for BTKi single-agent therapy 
which has seen success in this patient type in clinical trials [131]. This can be 
attributed to the fact that there is more long-term safety data for ibrutinib and there 
is some uncertainty about the benefit of venetoclax/obinutuzumab combination 
therapy for this subgroup of high-risk patients, although trials are ongoing [127]. 
 
1.2.6.1 Ibrutinib in CLL 
Ibrutinib has been approved for treatment of all subtypes of CLL and for patients 
of all ages regardless of any previous treatment with a particular focus on those 
patients presenting with adverse cytogenetics. A BTK inhibitor which irreversibly 
binds the cysteine-481 residue in BTKs ATP binding pocket, ibrutinib takes 
advantage of CLL cell dependency on BCR signalling.  
 
Ibrutinib monotherapy is effective to treat CLL and promotes a rapid reduction in 
LN enlargement with associated lymphocytosis redistributing the CLL cells from 
the LN into the peripheral blood (PB) [128]. There are extremely promising results 
from ibrutinib treatment in front-line therapy as well as in relapsed/refractory (RR) 
CLL [128, 132]. However, eradication of detectable CLL with ibrutinib 
monotherapy is rare and patients usually remain on ibrutinib indefinitely or until 
disease progression. In addition, side effects cause ~10% of patients on ibrutinib 
to discontinue the drug: these include diarrhea, fatigue, bruising and 
haemorrhage, hypertension, and atrial fibrillation [133]. Acalabrutinib is a novel, 
second generation BTK inhibitor currently under assessment in clinical trials. It is 
hoped this inhibitor will have less side effects, owing to an increased specificity 
for BTK and less off-target effects [134].  
 
At a transcriptional level, ibrutinib treatment has been shown to induce a rapid 
down-regulation of inflammatory markers and alter the transcription of genes 
known to promote CLL [135]. Studies have shown massive alterations to 
transcriptional networks after just two days of treatment with ibrutinib with the 
expected strong impact on BCR pathway target genes but also genes 
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downstream of NF-κB and MYC and additional transcription factors known to 
promote CLL pathogenesis e.g. (EGR2, EGR3 and IRF5). Similarly, ibrutinib has 
been shown to downregulate NOTCH1 activity and its downstream target genes 
in CLL cells [136]. 
 
From an epigenetic standpoint, ibrutinib has recently been reported to induce 
reorganisation of the chromatin landscape in CLL cells [137].  After prolonged 
ibrutinib treatment a loss of both trimethylation and acetylation of histone H3 
lysine 27 (H3K27me3 and H3K27ac) was observed in the cells from CLL patients. 
These alterations in response to treatment suggested a global reorganisation of 
chromatin structure which may serve to poise the cell for acquired resistance in 
the future. 
 
Ibrutinib presents a breakthrough in CLL treatment, but resistance is an emerging 
concern. Some patients whose disease progresses while on ibrutinib were found 
to have an acquired mutation of BTK at cysteine-481 (C481S) or gain of function 
mutations in PLCγ2, an enzyme downstream of BTK, both of which reactivated 
BCR signalling [138]. Further, there are cases of resistance which cannot be 
explained by genetic alterations [139-141].  Recent studies indicate that 
alternative, pro-proliferative signalling pathways can be activated to bypass BTK 
inhibition, particularly NF-κB, and are only partially blocked by ibrutinib and this 
may play a role in the development of resistance to ibrutinib molecule [142, 143]. 
For example, TLR signalling in the lymph node is only partially repressed by 
ibrutinib [142].  
 
In an effort to combat resistance and expand on the success of ibrutinib 
monotherapy, combination therapies of ibrutinib with rituximab [144], 
obinutuzumab [125] and venetoclax [145] are being evaluated and each 
combination has already seen success as a treatment option in CLL. Yet even in 
the context of combination therapy resistance can still be a difficulty. For example, 
while ibrutinib and venetoclax are an effective treatment option, resistance can 
still arise from strong activation of the NF-κB pathway via microenvironmental 
agonists such as CD40L and CpG-oligodeoxynucleotides [143]. The connection 
between BCR and CD40 has also been further demonstrated via experiments 
showing that CD40L treatment of B cells (healthy or malignant) circumvents the 
need for BTK in BCR-induced NF-κB activation. Further, CD40-mediated 
activation of the BCR signalling pathway operates without the need for PI3K or 
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PLCγ2, and thus bypasses both early (BTK and PI3K) as well as late (PLCγ2) 
BCR signalosome elements [146, 147]. 
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Figure 1.5: Chronic lymphocytic leukaemia (CLL) signalling pathways. The BCR and the BCR signalling pathway play a very 
important role in normal B cell development/growth but also in CLL progression where the pathway is very often overactive, providing 
constitutive growth and proliferation signals. Antigen-mediated triggering of the BCR induces activation of early kinases (blue), 
including LYN and SYK. LYN can activate ERK via RAF1 and RAS, and both LYN and SYK can transduce the signal to other early 
effectors of the signalling response, including BTK. Through the BLNK adaptor, BTK activates PLCγ2, and subsequent downstream 
responders (grey), including calcium signalling (Ca2 +), PKC, NF-κB, ERK and P38 while ultimately promoting activation of nuclear 
transcription factors (orange). T cell mediated CD40 activation can also activate the NF-κB pathway and its transcription factors. The 
positive co-receptor, CD19, contributes to the activation of the PI3K–AKT pathway and to survival induction. The signalling response 
is tightly modulated by negative coreceptors (green) (e.g. CD22, CD5) and phosphatases, including SHP1 and SHIP1/2. Recently, 
CLL treatments are focusing the use of targeted therapies which impact on several members of the BCR pathway – e.g. ibrutinib and 
idelalisib but also include the CD20 antibodies rituximab and obinutuzumab and the BCL2 inhibitor venetoclax. This figure is NOT to 
scale. This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 
Unported License; https://smart.servier.com. 
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1.3 Signalling to transcription via chromatin remodelling 
Having discussed the importance of the BCR and NF-κB signalling pathways in 
the pathogenesis, development and treatment of CLL we must consider the 
downstream processes which follow stimulation and activation of these 
pathways. Reorganisation and remodelling of the chromatin structure is 
necessary in order for BCR and NF-κB-driven gene expression programmes to 
be activated and promote CLL disease progression. Further, an understanding of 
how the processes which precede transcription are regulated can help us to fully 
understand the ibrutinib mechanism of action. As an inhibitor responsible for 
switching off a signalling pathway, it is important to understand what impact this 
may have on the regulation of downstream gene expression at the chromatin 
level. 
 
1.3.1 Chromatin structure 
The information necessary for supporting all of life’s processes is encoded in our 
genome on both a genetic and epigenetic level. While the genetic code 
provides a blueprint for each and every protein building block, additional 
regulation at an epigenetic level provides instructions on how, when and 
where this code should be used by the cell [148].  
 
In order to fit the entirety of the eukaryotic genome into the nucleus of a cell it is 
required to be both tightly packaged but also highly flexible to allow the plethora 
of DNA-regulatory factors access to the DNA when and where they are required 
[149]. This is achieved through the formation of chromatin; a higher-order 
structure defined as the complex of DNA wrapped around histone proteins to 
create nucleosomes, the basic units of chromatin [150]. An individual nucleosome 
is composed of eight histones proteins; two each of the core histones H2A, H2B, 
H3 and H4 with approximately 146 nucleotides of DNA wrapped ~1.65 times 
around the histone complex [151]. The tails of histone proteins can be covalently 
modified to fundamentally alter and reorganize the structure of chromatin to 
control DNA-based processes such as DNA repair, transcription and DNA 
replication [152] (summarised in figure 4) 
 
Histone tail modifications are initially laid down by a series of proteins termed 
epigenetic writers – these include protein kinases, histone methyltransferases 
(HMTs) [153] and histone acetyltransferases (HATs) [154]. In order for 
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transcription factors to bind at gene control regions, ATP-dependent chromatin 
modifying complexes recognise histone tail modifications and through ATP 
hydrolysis, mobilise, shuffle or unwrap nucleosomes to expose the sites 
necessary for transcription activation. Chromatin remodelling enzymes are an 
example of epigenetic readers which are recruited to and interact with these 
modifications via specific domains to reorganise the chromatin, often to make 
way for further proteins, including transcription factors [155]. Chromatin readers 
possess particular domains which allow them to recognise modified histones. For 
example, the bromodomains of HATs allow for recognition of acetylated histones 
in chromatin such as the double bromodomain of TAF1 [156]. Further domains 
include the chromodomain and Tudor domains which can recognises methylated 
lysine [157]. The most well studied histone readers include the closely related 
SWI/SNF [158] and RSC (Remodelling the Structure of Chromatin) families and 
the ISWI family [159]. 
 
Epigenetic editors work to remove epigenetic marks from histone tails and include 
phosphatases, lysine demethylases (KDMs) and histone deacetylases (HDACs) 
[155]. The placement of reversible histone modifications by epigenetic writers, 
subsequent interaction via readers and then removal by erasers allows for a 
complex layer of epigenetic regulation in modulating gene expression, amongst 
other processes.  
 
1.3.2 Histone modifications and transcription 
As discussed, histone protein tails can be post-translationally modified (histone 
PTMs) by histone-binding proteins to functionally alter the landscape and 
organisation of chromatin. Chromatin fundamentally controls gene expression as 
typically the presence of nucleosomes physically prevents the transcription 
machinery from accessing DNA. Aside from physical impediment, specific 
histone PTMs can be inhibitory or permissive to the proteins required for 
transcription.  
 
Histone tail lysine methylation can impact a number of transcriptional processes 
[160]. Lysine methylation is interesting in that it can be either inhibitory or 
activatory depending on the level of methylation of specific lysine residues (me1, 
me2 or me3). Generally, H3K4, H3K36 and H3K79 methylation marks active 
transcription and H3K9, H3K27 and H4K20 methylation marks silenced or 
inactive chromatin [161]. These modifications can also interact with one another 
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to promote or inhibit transcription. For example, chromatin marked 
simultaneously by methylation of H3K4 and H3K27 plays an important role in 
shifting gene expression from a poised to active or inactive state in embryonic 
stem cells [162]. 
 
Histone tail lysine acetylation is generally thought to be activatory for transcription 
in that the addition of an acetyl group by HATs neutralises lysine’s positive charge 
and weakens the histone-DNA electrostatic interaction [163]. For example, the 
chromatin remodelling enzyme, RSC, can interact with acetylated lysine 14 of 
histone H3 (H3K14ac) to promote nucleosome remodelling and the eventual 
recruitment of RNA polymerase II (RNA Pol II) to DNA to promote gene 
transcription [164]. 
 
Histone tail phosphorylation occurs predominantly at a series of serines, 
threonines and tyrosines found on histone tails. Addition of a phosphate group 
adds a significant negative charge to the histone tail and can drastically alter 
chromatin structure. Phosphorylation of histone H3 at serine 10 (H3S10-P), 
threonine 11 (T11-P) and serine 28 (S28-P) has been clearly associated with H3 
acetylation, strongly implicating these modifications in transcriptional activation 
[165]. H3S28-P works in combination with H3K27ac to displace Polycomb 
repressive complexes (PRC) from chromatin. This antagonistic relationship 
induces a methyl-acetyl switch of the adjacent K27 residue at these loci, thereby 
activating transcription [166]. 
 
1.3.3 Signalling kinases as chromatin remodelling enzymes 
Among the types of enzyme which modify chromatin, histone kinases typically 
require activation via upstream signalling cascade and the upstream kinases are 
not thought to directly phosphorylate histones. However, some histone kinases 
have been implicated in being able to directly regulate gene expression through 
specific kinase dependent histone phosphorylation. Interestingly, studies have 
also shown that these type of histone kinases can even modify additional non-
histone substrates including other types of chromatin remodelling enzymes and 
transcription factors to mediate both up- and downregulation of gene expression.  
 
A recent review [167] highlights the functions of such signalling-histone kinases. 
This class of kinase has been shown to phosphorylate histone H3 at threonines 
3, 6, 11 and 45 (H3T3-P, H3T6-P, H3T11-P and H3T45-P), serines 10 and 28 
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(H3S10-P and H3S28-P) and tyrosine 41 (H3Y41-P) and histone H2B at serines 
14 and 36 (H2BS14-P and H2BS36-P). Regarding serine phosphorylation of 
histone H3, one example is IκB kinase α (IKKα), a part of the cytoplasmic IKK 
complex responsible for regulating NF-κB activation. It has been shown that IKKα 
can be recruited directly to the promoters of NF-κB target genes to phosphorylate 
H3S10 and initiate transcription [168]. Interestingly, IKKα was shown to travel 
with elongating RNA pol II S2-P and heterochromatin protein 1 gamma (HP1γ) at 
NF-κB dependent genes in macrophages [168]. In this co-dependent relationship, 
IKKα binds to and phosphorylates non-histone substrate HP1γ, which in turn 
guides IKKα to phosphorylate histone variant H3.3 at serine 31 (H3.3S31-P) 
within gene bodies.  
 
IKKα also phosphorylates another non-histone substrate, CREB binding protein 
(CBP), at serine 1382 and 1386. CBP and its homolog p300 are transcriptional 
co-activators that mediate communication between transcription factors and the 
transcriptional machinery to regulate gene expression [169]. Phosphorylation of 
CBP by IKKα is responsible for accelerating cell growth by switching the binding 
preference of CBP from p53 to NF-κB. This switch activates pro-proliferative NF-
κB gene expression programmes while suppressing p53-mediated gene 
expression. 
 
Additionally, the serine/threonine kinase PIM1 which cooperates with MYC in cell 
cycle progression and tumorigenesis, has been shown to phosphorylate H3S10 
[170]. In this relationship, MYC recruits PIM1 to its target genes to phosphorylate 
H3S10 and activate their transcription. It is estimated that PIM1 is implicated in 
the transcription of ~20% of MYC target genes. H3S10-P in this context was 
specifically related to elongation of MYC through the genes in question. For 
tyrosine kinases, H3Y41 phosphorylation was shown to be catalysed by JAK2 – 
a kinase responsible for activation a diverse range of cellular processes through 
its modulation of various signalling cascades [171]. The presence of H3Y41-P 
was shown to exclude HP1α from chromatin and lead to the transcriptional 
activation of various JAK2-mediated genes.  
 
Adenosine monophosphate–activated protein kinase (AMPK) has been shown to 
directly activate transcription through an interaction with chromatin where it 
catalyses phosphorylation of H2B at S36. AMPK and H2BS36-P are found 
colocalised at the promoters of, and within, AMPK-dependent pathway genes, 
many of which are functionally pro-survival. The activation of AMPK and its 
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subsequent placement of H2BS36-P is therefore strongly linked to the activation 
of proliferative transcription programmes [172]. 
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Figure 1.6: Epigenetics & histone modifications. For DNA to be stored in the nucleus of cells it is packaged into structures known 
as nucleosomes which consist of histone proteins with DNA spooled around them. When they are arranged in close proximity in a 
compacted form which represses transcription of the DNA the resulting alignment is known as heterochromatin. The tails of histones 
can be modified e.g. methylated (Me), acetylated (Ac) or phosphorylated (P) by histone modifying enzymes (HATs; histone 
acetyltransferases, HMTs, histone methyltransferases, kinases) – these modifications can cause conformational changes in the 
chromatin compaction and structure. The state of chromatin structure can either allow or prevent the access of DNA-binding proteins 
for a variety of tasks including DNA repair, DNA methylation via DNA methyltransferases (DNMTs) or transcription. For transcription, 
this provides an epigenetic mechanism of controlling gene expression. This figure was partly created using Servier Medical Art 
templates, which are licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com.   
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1.4 Signalling outcome in CLL 
We have now discussed how the BCR and NF-κB pathways are activated in CLL 
and considered how downstream chromatin reorganisation is both necessary for 
activation of gene transcription and also how changes to the chromatin landscape 
can play a role in CLL progression. The next step in the signalling cascade, 
transcription of the target genes, is similarly important. Immediate early gene 
activation is the first wave of gene expression upregulated in response to 
pathway activation and will be discussed below as a model for transcriptional 
output following BCR and NF-κB signalling. 
 
1.4.1 Immediate early gene expression 
Many cell types, including lymphocytes, express a specific class of gene known 
as the immediate early genes (IEG). IEGs can be rapidly activated and 
transcribed in response to stimulation by antigen, cytokines and growth factors 
without the need for de novo protein synthesis. Regulation of IEG expression in 
the B cell response is critical for the rapid proliferation and differentiation required 
by this cell type in response to infection. Examples of well-known IEGs include 
the early growth response factor (EGR) and dual specificity phosphatase (DUSP) 
families, as well as the pro-proliferative partner proteins, FOS and JUN [173]. As 
the name suggests, IEGs are induced quickly (sometimes within minutes) and 
transiently and possess particular characteristics at the genomic and epigenomic 
level to facilitate this process. The transient nature of these genes means their 
expression can peak just 15-60 minutes post stimulation, often returning to basal 
levels after as few as 90 minutes [174] [Thomas et al., forthcoming 2020]. 
  
To support their transient nature, IEG protein products are often unstable and 
can be targeted for degradation by the proteasome without prior ubiquitylation 
[175]. To aid their immediate expression the proteins required for their synthesis 
(including the transcription factors) are already present in the cell and are not 
translated in response to the activation process. This is demonstrated by the fact 
that IEG mRNA can be transcribed in the presence of protein synthesis inhibitors 
[176].  
 
In addition, by genomic standards IEGs are relatively short (19 kb vs 58 kb) and 
contain far fewer exons than their delayed primary response and secondary 
response counterparts. Further, the promoter regions of IEGs tend to be over-
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enriched with binding sites for a variety of transcription binding including motifs 
for serum-response factor (SRF), NF-κB and cyclic AMP response element 
binding protein (CREB) binding sites, suggesting a predictable and redundant 
mechanism whereby various TFs can initiate IEG transcription [177]. For 
example, EGR1 and DUSP2 (the IEGs focussed on in the result chapter) are as 
short as 3.9 and 2.4 kb with 2 and 4 exons respectively, promoting their rapid 
transcription in response to BCR crosslinking.  
 
1.4.2 Immediate early gene – EGR1 in B cells 
Early growth response gene-1 is an IEG which encodes a transcription factor 
containing a zinc-finger motif and is widely dysregulated in haematological 
malignancies. EGR1 is expressed ubiquitously in many cell types and has 
specific roles in B cells where it is activated downstream of the BCR, but not 
CD40 or TLR signalling [178] [179]. Antigen-mediated crosslinking and activation 
of the BCR upregulates the levels of EGR1 to promote both B cell survival and 
proliferation/expansion of B cells. Once activated, EGR1 which has been shown 
to regulate the transcriptional activity of genes including TNF-alpha, IL-2 and the 
cell adhesion molecules CD44 and ICAM-1, which are important for B cell 
trafficking [180]. The level of EGR1 induced by BCR activation seems to depend 
on the stage of B cell development with the highest levels observed in mature B 
cells and more modest levels in immature B cells [181] and in pre-B cells, where 
it promotes development [182]. 
 
EGR1 expression has been shown to be upregulated in CLL [183] and high levels 
of EGR1 were shown to form part of a gene signature post BCR activation 
indicative of cell cycle entry and CLL cell proliferation [184]. EGR1 shares 90% 
homology with its family members EGR2 and EGR3 and they share some 
functional redundancy in B cell development while also having their own unique 
roles [185]. This is interesting when considering that recent clinical trial data has 
demonstrated that CLL patients carrying EGR2 mutations present a new clinically 
aggressive subgroup, with a poor prognosis similar to those patients with TP53 
mutations [186].  
 
1.4.3 Immediate early gene – DUSP2 in B cells 
In order to combat infectious agents, mitogen activated protein kinase (MAPK) 
family members, ERK, JNK and p38 are all activated in immune cells in response 
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to CpG or LPS-mediated TLR signalling. In order to regulate, modulate and 
inactivate MAPK proteins, various members of the dual specificity phosphatase 
family can dephosphorylate the threonine and tyrosine residues of the conserved 
TxY motif found on most all MAPK members. [187]. 
 
The expression of DUSP family member, DUSP2, is limited to haematopoietic 
lineages in non-transformed cells and DUSP2-/- mice have a considerably 
disturbed inflammatory response [188]. DUSP2 is an interesting case and it 
differs from most DUSP family members in that it can regulate MAPKs in both a 
positive and negative manner. Loss of DUSP2 function has been shown to 
increase JNK activity, as expected, but also lead to a reduction in ERK and p38 
activity [188], highlighting the complex interactions between MAPKs and their 
phosphatases.  Similar to EGR1, DUSP2 is upregulated in CLL [184] and large 
B cell lymphomas [189] specifically in response to activation of the BCR  
signalling pathway [179]. In the context of CLL, DUSP2 appears to function in its 
more traditional role as a negative regulator of MAPKs where it has been 
demonstrated to downregulate ERK activity [184]. 
 
In summary, both EGR1 and DUSP2 are examples of immediate early genes 
which are linked to the proliferation and survival of both healthy B cells and 
malignant CLL cells. 
 
1.4.4  Transcription of IEGs – RNA polymerase II 
RNA polymerase II (RNA pol II) is the main eukaryotic polymerase responsible 
for the transcription of messenger RNAs (mRNA). It is recruited to transcription 
start sites (TSS) in response to the binding of transcription factors to cis-
regulatory elements and begins the process of unwinding the DNA duplex for the 
transcription of mRNA [190]. The process of mRNA transcription is strictly 
regulated at multiple stages through polymerase recruitment, initiation, 
elongation and termination with release of both the polymerase and the primary 
transcript. One way in which these steps are regulated is through differential 
phosphorylation of the C-terminal domain (CTD) of the largest RNA pol II subunit, 
RPB1. Progression of the RNA pol II molecule through a gene relies on balancing 
phosphorylation of the CTD at serine 5 (S5-P) around the transcription start site 
and at serine 2 (S2-P) throughout the gene body and towards the termination 
site. RNA pol II S5-P is typically associated with a poised polymerase and S2-P 
denotes active transcription [190]. 
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The relationship between IEGs and RNA pol II is critical for their rapid 
transcription in response to stimuli and they tend to have an abundance of poised 
RNA pol II S5-P at their promoter regions compared to secondary response 
genes [191]. This suggests that IEG transcription elongation may begin from a 
paused polymerase already poised at the TSS, rather than by recruitment of RNA 
pol II following cellular stimulation, to provide a rapid ‘jump-start’ of IEG 
transcription. Indeed, studies have shown paused or stalled polymerases near 
the TSS of the IEGs FOS, MYC [192] and ARC [193], prior to cellular stimulation, 
ensuring a kinetic advantage for IEG transcription.  
 
1.4.4.1 Chromatin organisation – regulation of immediate early gene 
transcription 
In addition to the many characteristics of IEGs which promote their rapid and 
transient expression, there has long been suggestions that they possess distinct 
chromatin architecture and epigenetic traits key to their expression kinetics. Early 
literature demonstrated that the nucleosomal response associated with IEG 
transcription was mediated by a distinct MAPK signalling cascade, alternate to 
delayed or secondary response genes, and implicated MSK1, a histone H3 
kinase, as being activated specifically to modify the chromatin around IEGs [194]. 
 
Further examples have demonstrated the distinct modifications responsible for 
the chromatin remodelling of inflammatory IEGs and how they differ to secondary 
response genes. A rapid and transient increase in the acetylation of histone H3 
at lysine 14 and 27 (H3K14ac and H3K27ac) and histone H4 at lysine 5 (H4K5ac) 
occurs just 1 hour post cellular stimulation at IEG TSSs. Conversely, late and 
secondary response genes displayed marked increase in H3K14ac and H3 tri-
methylated at lysine 4 (H3K4me3) at 6 hours post stimulation [195]. Histone H3 
phosphorylated at serine 10 and serine 28 (H3S10-P and H3S28-P) has also 
been implicated in IEG-promoter chromatin remodelling to result in the induction 
of MAPK-specific IEGs, including JUN. 
 
Bivalent phosphorylation and acetylation of the same histone H3 tail may also be 
indicative of IEG transcription. One study demonstrated that the highly targeted 
induction of doubly-modified histone H3 associated with the IEGs FOS and JUN. 
Such phosphoacetylation was only observed on nucleosomes associated with 
active FOS and JUN [196].  
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Additionally, the chromatin remodelling associated with NF-κB signalling in the 
immediate response has been extensively studied [197]. It has been suggested 
that NF-κB target gene activation occurs in two waves and is largely determined 
by promoter accessibility [198]. A subset of immediate NF-κB target genes 
possess an open chromatin structure which is immediately accessible after 
stimulation and NF-κB nuclear entry. For those secondary and late response 
genes, a distinct second wave of NF-κB transcription occurs only after significant 
hyperacetylation of these promoters which were inaccessible in the immediate-
early response.  It has been suggested that the presence of such open, readily 
available, chromatin structures could be mediated by atypical activation of the 
well-known SWI/SNF chromatin remodelling complexes. IEG-specific activation 
of SWI/SNF saw no need for enzymatic activity of the typical catalytic subunits, 
BRG1/BRM, which are absolutely required for chromatin remodelling associated 
with delayed or secondary response genes [199].  
 
These types of data suggest several epigenetic mechanisms are capable of 
regulating IEG transcription. Distinct patterns of chromatin modifications or 
alternative signalling pathways may be necessary or activated to stimulate the 
recruitment of specific chromatin remodelling enzymes and transcription factors 
which are used specifically for rapid IEG transcription. 
 
1.4.4.2 Chromatin organisation – regulation of pre-mRNA processing 
Pre-mRNA processing of primary, nascent RNA transcripts occurs 
simultaneously with their transcription by RNA pol II and in the vicinity of 
chromatin. Epigenetic modifiers working to modify chromatin structure in concert 
with RNA processing enzymes carrying out capping, splicing and end processing 
duties is important to ensure the accuracy and efficiency of these processes 
[200].  
 
Nucleosomes can impact pre-mRNA splicing through physical means and 
several studies have highlighted how nucleosome positioning can contribute to 
exon selection. For example, differential nucleosome occupancy has been 
observed in introns compared to exons [201], constitutive exons compared to 
alternative exons and in exons flanked by long introns and weak splice sites 
compared to exons with strong splice sites [202]. Nucleosome density and 
position also strongly impacts RNA pol II elongation rates and splicing defects 
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have been attributed to increased elongation rates caused by dysfunctional 
chromatin organisation [203], highlighting the interconnectivity of co-
transcriptional pre-mRNA processing.  
 
Aside from nucleosomes acting as physical barriers, histone tail modifications 
can also promote, impact and guide pre-mRNA processing. Histone H3 tri-
methylated at lysine 36 and di-methylated at lysine 27 (H3K36me3 and 
H3K27me2) are both implicated in pre-mRNA alternative splicing. H3K36me3 is 
typically low around promoter regions and enriched in the gene body and it has 
been suggested that its presence can modulate exon choice by slowing RNA pol 
II transcript elongation rates [204]. Accordingly, both of these histone marks are 
enriched in exons, with H3K36me3 displaying the most intron-to-exon difference 
[201].  The majority of excluded exons, i.e. exons which are alternatively spliced, 
show very low levels of H3K36me3, while included exons tended to have higher 
levels. This difference suggests that the presence of this histone modification can 
guide exon-inclusion and alternative splicing. In addition, H3K36me3 seemed to 
be precluded from particularly short exons (less than 50 bp), controlling their 
exclusion from the transcript.  
 
The activatory H3K4me3 modification has been implicated in mediating the 
interaction between chromatin and the splicing machinery, specifically U2 
snRNP, one of five small ribonucleoprotein particles that binds 3’ splice sites and 
forms a key part of the spliceosome machinery [205]. A further splicing regulator, 
polypyrimidine tract–binding protein (PTB), associates with chromatin to 
modulate alternative splicing [206]. PTB-mediated regulation of alternative 
splicing implicates both H3K4me3 and H3K36me3, where the levels of 
H3K36me3 at a particular gene correlates with PTB recruitment to the pre-
mRNAs of that gene. 
 
Finally, histone H3 methylated at lysine 9 (H3K9me) can also play a role in 
alternative splicing with PTB and other splicing factors known to recognise 
H3K9me3 [207]. H3K9 is typically a silencing mark associated with 
heterochromatin [208], but it can also be detected at actively transcribed genes 
[209]. In the case of CD44, a gene with many alternatively spliced isoforms, 
H3K9me3 marks in the gene body are recognised by the heterochromatin 1 
protein (HP1γ). This recognition reduces local transcript elongation rates allowing 
for the inclusion of variable exons into the pre-mRNA [210]. A similar 
phenomenon is observed for fibronectin (FN1), with H3K9me3-mediated 
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recruitment of HP1α resulting in increased alternative splicing and inclusion of 
variable exons [211]. 
 
In summary, it is clear that nucleosomes, both physically and through histone tail 
modifications, control and mediate a vast number of processes involved in co-
transcriptional pre-mRNA processing, particularly alternative splicing. The 
importance of histone methylation marks in identifying splice sites amongst large 
numbers of exons is clearly evident.  
 
1.4.5 Preliminary data: immediate early gene expression is inhibited 
by ibrutinib in CLL 
The Lefevre group has previously assessed immediate early gene expression in 
CLL (Figure 1.7A-B). The genes EGR1 and DUSP2 were selected after an initial 
screening for genes responding to anti-IgM stimulation in primary CLL, and for 
which the response was repressed by addition of ibrutinib. For this screen, U-CLL 
cells were pre-treated with ibrutinib for 1 hour before stimulation with anti-IgM to 
crosslink the BCR and activate BCR signalling with RNA samples taken at 0-24 
hours for qPCR analysis. The genes assessed included EGR1, DUSP2, MYC, 
DUSP4, CCND2, BCL2A1, PRDX1, NCL, CDC25B, TLR10, PIM1, CXCR4, 
CXCR5, CCR6 and CCR7. From these genes, only the first 5 were convincingly 
stimulated by anti-IgM activation of the BCR. EGR1 and DUSP2 mRNA level 
rapidly and transiently increased, peaking at 30 minutes post anti-IgM stimulation 
whereas MYC, DUSP4 and CCND2 showed peak expression between 2 and 4 
hours post stimulation. Expression of both EGR1 and DUSP2 could be inhibited 
by the BTK inhibitor, ibrutinib. 
 
1.4.6 Preliminary data: H3T6-P and H3T11-P occupancy correlates 
with immediate early gene expression kinetics in CLL  
Additionally, the Lefevre group examined alterations to the chromatin landscape 
in CLL cells treated with ibrutinib, looking specifically at the IEGs which were seen 
to be upregulated in response to BCR signalling (EGR1 and DUSP2). The group 
screened for histone modifications which changed after treatment with ibrutinib 
through a series of ChIP experiments. For these experiments, U-CLL cells were 
pre-treated with ibrutinib for 1 hour before stimulation with anti-IgM for 30 minutes 
to activate BCR signalling. Of the numerous histone modifications which were 
examined, histone H3 was seen to be consistently phosphorylated at threonine 6 
  
45 
 
and threonine 11 (H3T6-P and H3T11-P) across IEG loci in response to anti-IgM 
stimulation (Figure 1.7C-D). The histone marks were primarily located in around 
the IEG TSSs and in the gene bodies (see EGR1 -0.1, +2.2 and +3.8 kb and 
DUSP2 -0.3 and +2.4 kb). Consistently, the placement of these histone marks 
could be prevented by pre-treating CLL cells with ibrutinib (Figure 1.7C-D). 
 
To summarise, the mRNA expression kinetics of EGR1 and DUSP2 correlate with 
the appearance of H3T6-P and H3T11-P across the loci of both genes. Ibrutinib 
can prevent both gene expression and the deposition of both histone marks.  
 
1.4.7 H3T6-P and H3T11-P histone modifications 
Our preliminary data highlighted phosphorylation of histone H3 at threonine 6 and 
11 (H3T6-P and H3T11-P) as potential epigenetic markers for activation of the 
immediate early genes EGR1 and DUSP2 (Figure 1.7 and Thomas et al., 
forthcoming 2020). Phosphorylation of histone H3 is a diverse histone 
modification that can be associated with both open chromatin during gene 
activation and tightly compacted chromatin during mitosis [212]. These histone 
marks have not previously been implicated in CLL, but have a selection of other 
functions as described below. Of note, these constitute examples of signalling 
kinases which also function as chromatin remodelling enzymes (see 1.3.3). 
 
Phosphorylation of H3T6 by protein kinase C beta I (PKCß-I) has been reported 
to control demethylation at histone H3 lysine 4 (H3K4) by directly preventing 
lysine-specific demethylase 1 (LSD1) from demethylating H3K4 during androgen-
receptor (AR) dependent gene activation [213]. Following AR-induced gene 
expression, PKCß-I co-localised with AR and LSD1 on target gene promoters to 
mediate H3T6-P and prevent removal of the active H3K4 methyl mark. Notably, 
increased levels of PKCß-I and H3T6-P correlate with poor prognosis in prostate 
carcinomas, and inhibiting PKCß-I can block AR-induced tumour cell 
proliferation. These findings indicate H3T6-P can be associated with gene 
activation and a tumorigenic phenotype.  
 
H3T11-P has also been implicated as an activatory histone mark which can 
promote gene transcription. Protein kinase-C related kinase 1 (PRK1) has been 
shown to catalyse H3T11-P at AR target genes [214]. Inhibition of PRK1 
diminished H3T11-P, reduced androgen-induced demethylation of histone H3 by 
the Jumonji C-domain-containing demethylase, JMJD2C, and removed RNA pol 
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II S5-P from AR target gene promoters. In addition, WDR5, a subunit of the 
SET1/MLL complex, is able to interact with H3T11-P marked regions of chromatin 
to recruit the MLL1 complex for subsequent placement of the activatory histone 
mark: H3K4me3 [215]. 
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Figure 1.7: Preliminary data linking critical CLL IEG expression with H3-T6 and H3-T11 phosphorylation.  (A) (B) qPCR data 
showing the rapid nature of IEG mRNA kinetics post anti-IgM stimulation. The CLL cells from 4 patients, indicated by the 4 different 
symbols (cross, diamond, triangle and square), were pre-treated with ibrutinib for 1 hour and then stimulated with anti-IgM with 
samples taken at the indicated timepoints from 0-24 hrs. These kinetics correlate with H3T6-P and H3T11-P deposition at the EGR1 
and DUSP2 loci. (C) (D) ChIP-qPCR data 30 minutes after anti-IgM-mediated activation of the BCR resulting in an increase of H3T6-
P and H3T11-P at the loci of the immediate early genes EGR1 and DUSP2. This histone deposition can be inhibited by ibrutinib. Data 
provided by S Kreuz (unpublished).  
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Figure 1.8: Preliminary data identifying ZIPK as a candidate kinase for H3-T6/H3-T11 phosphorylation and 
expression/histone PTM data demonstrating the inefficacy of other kinase inhibitors. (A) In silico kinase prediction software 
highlighted Zipper-Interacting Protein Kinase (ZIPK) as a candidate kinase for H3T6 and H3T11 phosphorylation. (B) (C) Primary 
CLL cells were cultured for 48 h and then treated with DMSO, 1 μM Ibrutinib, 1 μM Gö6983,10 μM RSK inhibitor II or 10 μM U0126 
for 2 h, before the BCR was cross-linked. (B) Expression of EGR1 and DUSP2 was assessed and the means and SD of at least three 
independent experiments from different patients are shown normalised to TBP and to the induction of EGR1 or DUSP2 mRNA 
expression in DMSO-treated cells after 30 min (ns > 0.05 in Student’s t test). (C) ChIP was performed before and after 30 min anti-
IgM stimulation using primers along the EGR1 and DUSP2 genes and antibodies against H3 and H3T6/T11-P. ChIP results after 30 
min anti-IgM stimulation are plotted. Results of one representative patient are shown normalised to H3 and the average of the CTCF1 
and CTCF3 control regions and, then, versus, unstimulated DMSO-treated cells. Data provided by S Kreuz (unpublished). 
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Figure 1.9: Preliminary data demonstrating that ibrutinib and DAPKi prevent H3T6 and H3T11 phosphorylation of the EGR1 
and DUSP2 loci and the effects of DAPK3 inhibition on CLL cell proliferation.  (A) (B) ChIP-qPCR data 30 minutes after anti-
IgM-mediated activation of the BCR resulting in an increase of H3T6-P and H3T11-P at the loci of the immediate early genes EGR1 
and DUSP2. This histone deposition can be inhibited by both ibrutinib and a ZIPK inhibitor. Data provided by S Kreuz (unpublished). 
(C) Flow cytometric analysis of CLL cells cultured on a CD40L-expressing cell feeder layer. CLL cells were pre-treated with either 
ibrutinib, increasing concentrations (10-80 µM) of DAPKi, both inhibitors, or DMSO for 1 hour as indicated. Proliferation was assessed 
via the percentage of cells positive for Ki-67 (** < 0.01, * < 0.05, ns > 0.05 in Student’s t test). 
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1.5 Zipper-interacting protein kinase 
1.5.1 Preliminary data: kinase prediction software highlights ZIPK as 
the potential writer for H3T6-P and H3T11-P 
Having observed a link between EGR1 and DUSP2 gene expression and the 
appearance of H3T6-P and H3T11-P, the group wanted to understand which 
kinase may be responsible for the catalysis of these histone modifications.  
 
In silico kinase predication software highlighted a series of kinases (Figure 1.8A) 
which have already been observed to phosphorylate H3T6 or H3T11. Among the 
kinases identified, MEK2, RSK1/2 and PKCs are known downstream elements of 
the BCR signalling pathway. In order to examine which kinase was functioning at 
IEGs in CLL, inhibitors for all the predicated kinases were tested to see which 
could impact on EGR1 and DUSP2 gene expression and corresponding 
H3T6/T11 phosphorylation. In these experiments, U-CLL cells were pre-treated 
with the inhibitors ibrutinib, Gö6983, a pan-PKC inhibitor, RSK inhibitor II, a pan-
RSK inhibitor, and U0126, a MEK1/2 inhibitor before anti-IgM stimulation for 30-
90 minutes before qPCR and ChIP analysis. Apart from ibrutinib, none of the 
other three inhibitors significantly inhibited the induction of EGR1 or DUSP2 
expression or prevented histone H3 phosphorylation after 30 and 90 min anti-IgM 
stimulation (Figure 1.8B-C). The data were varied with some PKC and RSK 
inhibitors able to prevent IEG expression and/or histone modifications to some 
degree while most could only impact one or the other.  
 
However, both ibrutinib (Figure 1.8) and DAPKi treatment completely abrogated 
deposition of H3T6-P and H3T11-P occupancy (Figure 1.9) and reduced CLL cell 
proliferation to comparable levels for 20 µM DAPKi and beyond. Moreover, 
combining both drugs had a synergistic effect on cell proliferation (Figure 1.9C). 
Despite the same outcome, it was hypothesised that the impact of ibrutinib and 
the DAPKi on histone phosphorylation most likely arose through differing 
mechanisms e.g. prevention of ZIPK activation via BTK inhibition (ibrutinib) vs 
the direct inhibition of ZIPK kinase activity (DAPKi). Based on these data, we 
were able to hypothesise ZIPK was the histone kinase functioning to activate IEG 
expression in CLL via H3T6-P and H3T11-P, but more data was needed to 
confirm this. 
  
  
51 
 
1.5.2 ZIPK structure & family 
ZIPK is a serine/threonine kinase originally cloned in 1998 when it was identified 
as an interacting partner of ATF4, a member of the activating transcription 
factor/cyclic AMP-responsive element-binding protein family (ATF/CREB), and 
as a mediator of apoptosis [216]. ZIPK, also known as DAPK3, is a member of 
the death associated protein kinase family (DAPK) whose members include 
DAPK1 and DAPK2/DRP-1 (DAPK-related protein 1) and the more divergent 
DAPK-related apoptosis inducing kinases 1 and 2 (DRAK1, DRAK2) [217]. ZIPK 
is ubiquitously expressed throughout mammalian tissues and is highly conserved 
between human, rat and mouse genomes. ZIPK interacts with family member 
DAPK1 via their catalytic domains. This interaction was shown to improve 
DAPK1-ZIPK cell death promoting activity [218]. DAPK1 phosphorylates ZIPK at 
six specific residues in its catalytic domain and these modifications effect both 
the localisation and oligomerisation of ZIPK (summarised in Figure 1.10).  
 
While these molecules differ in size and subcellular locations, DAPK1, DAPK2 
and ZIPK share significant homology at the N-terminus catalytic domain (80% 
and 83% respectively) whereas DRAK1 and DRAK2 have only ~50% homology 
with DAPK1 [219]. The C-terminal extra-catalytic domains of the DAPK family 
members are substantially different however. The ZIPK C-terminal domain 
comprises several nuclear localisation signal (NLS) sequences and a leucine 
zipper domain [216]. Such domains are required for homo-oligomerisation and 
ZIPKs interaction with other leucine zipper containing proteins [220] as well as 
being critical for its pro-apoptotic effects [221]. Phosphorylation of threonine 180, 
225 and 265 are required for full ZIPK kinase activity and phosphorylation of 
threonine 299 regulates its cytoplasmic localisation [222], with threonine-265 
(ZIPK T265-P) highlighted as the major autophosphorylation site critical for ZIPK 
kinase activity [223]. 
 
1.5.3 ZIPK function 
All members of the DAPK family have roles associated with cell death signalling. 
ZIPK has been shown to be a pro-apoptotic mediator of mitochondrial-dependent 
cell death [224], as well as play a role in autophagy [225]. DAPK1, DAPK2 and 
ZIPK are found throughout various tissues in mammals yet ZIPK is unique in that 
it possesses nuclear localisation signals [226].  
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There is ongoing debate over the intracellular localisation of ZIPK. Indications of 
a predominant cytoplasmic localisation come from reports that over-expression 
of active human ZIPK can induce cell death as evidenced by the characteristic 
membrane blebbing and cell rounding [227]. In the cytoplasm, ZIPK has been 
reported to regulate smooth muscle contraction by promoting Ca2+ independent 
contraction of smooth muscle cells via phosphorylation of the myosin light chain 
(MLC) and inhibiting smooth muscle myosin phosphatases [222]. To this end, by 
enhancing smooth muscle cell contractility ZIPK has been implicated in the 
development of some hypertensive cardiovascular diseases [38].  
 
Conversely, other studies propose a different picture for ZIPK subcellular 
localisation suggesting the protein is predominantly nuclear. For example, ZIPK 
has been identified in PML oncogenic domains (PODs). PODs are nuclear bodies 
that exist in all nucleated mammalian cells and ZIPK was shown to co-localise 
with the pro-apoptotic protein Daxx to regulate its recruitment to PODs to promote 
apoptosis [216]. Further, ZIPK has been shown to interact with and directly bind 
two transcription factors in the nucleus, ATF4 [216] and STAT3 [228]. 
 
1.5.4 ZIPK as a histone kinase 
Our preliminary data in combination with current literature suggest that ZIPK that 
may function as a chromatin modifying enzyme whose kinase activity can 
regulate transcription. One of the earliest observations of ZIPK was its interaction 
with chromatin and ability to phosphorylate the core histones H2A, H3 and H4 
[229]. Specifically, ZIPK was identified as capable of phosphorylating histone H3 
at threonine 11 (H3T11-P) in a mitosis-specific context [230]. H3 phosphorylated 
at serine 10 (H3S10-P) is typical of a mitotic chromosome, while ZIPK-mediated 
H3T11-P was enriched specifically at centromeres. In this unique case, ZIPK acts 
as a centromere-specific histone kinase that plays a role in depositing H3T11-P 
modifications during mitosis at specific regions of centromeric chromatin. ZIPKs 
histone kinase functions have yet to be implicated in disease. 
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Figure 1.10: DAPK protein family structures. A schematic representation of the domain organization of the main DAPK family 
members. The percentage in the red boxes, representing the kinase domains, indicates the extent of identity of each catalytic domain 
to that of DAPK. DAPK is the largest protein in the family, at 160 kDa, and it contains a Ca2+/CaM autoregulatory domain, eight 
ankyrin repeats, ROC-COR (Ras of complex proteins, C-terminal of ROC) domains, which overlap with a cytoskeletal-binding region, 
a death domain and a serine-rich C-terminal tail. ZIPK, at 55 kDa, lacks the Ca2+/CaM autoregulatory domain, and thus its regulation 
differs substantially from that of DAPK and DRP-1. Instead, it contains a nuclear localization signal (NLS) and a leucine zipper. 
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1.5.5 ZIPK in disease  
ZIPK has been demonstrated to have both pro- and anti-tumorigenic functions 
that vary by context, cell type and intracellular location. Some evidence suggests 
that ZIPK functions primarily as a tumour suppressor. For example, decreased 
ZIPK expression corresponding with a reduction in apoptosis has been 
demonstrated in squamous cell carcinoma [231]. Similarly, loss of ZIPK 
expression was associated with tumour invasion, metastasis and poor prognosis 
in gastric cancer [232]. Additionally, loss-of-function point mutations identified in 
colon, lung and ovarian cancers have been observed to decrease or abolish ZIPK 
kinase activity with a correlated increase in cell survival, proliferation and 
resistance to chemotherapy [233].     
 
Conversely, ZIPK can also display anti-apoptotic activity and functions which 
promote tumorigenesis. For example, in gastric cancer ZIPK has been reported 
to promote epithelial-mesenchymal transition (EMT) and metastasis through 
activation of AKT and NF-κB signalling [234]. ZIPK has also been observed as a 
novel transcriptional co-activator of the androgen receptor (AR) and it has been 
reported that ZIPK may provide a growth advantage to prostate cancer cells 
through regulation of AR anti-apoptotic proliferative functions [220]. Studies in 
gastric cancer highlights the diversity of ZIPK function where it may act as both a 
tumour suppressor gene at the primary tumour and an oncogene at distant sites 
after promoting EMT; underlining that its function is context and location 
dependent. 
 
For CLL, ZIPK was shown to be overexpressed in the sera of CLL patients who 
had been given allogeneic stem cell transplants was highlighted as an attractive 
target for CLL therapies outside of transplantation [235]. In addition, ZIPK 
expression was shown to be closely correlated with the apoptotic trio of prostate 
apoptosis response protein-4 (PAR-4), DAXX and BCL-2 [236]. In summary, the 
role of ZIPK in disease has been closely linked to its apoptotic functions and, to 
date, ZIPK has not been implicated as a histone kinase in CLL or otherwise. 
 
1.5.6 ZIPK-STAT3 relationship 
STAT3 is a cytoplasmic transcription factor of the STAT protein family which 
regulates expression of anti-apoptotic and pro-proliferative genes [237]. STAT 
family proteins are activated upon their phosphorylation by Janus kinases (JAKs) 
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which induce their nuclear translocation through the JAK-STAT signalling 
pathway [238]. Constitutive and aberrant tyrosine phosphorylation of STAT3 has 
been reported in many solid tumours [239] and haematological malignancies 
including acute myeloid leukaemia (AML) [240], chronic myeloid leukaemia 
(CML) [241], large granular lymphocytic leukaemia (LGL) [242] and CLL [115, 
116, 243].  
 
ZIPK has been shown to specifically interact with and phosphorylate STAT3 at 
S727 in the nucleus to enhance STAT3 transcriptional activity (ZIPK does not 
bind other STAT family proteins or STAT tyrosine residues) [228]. Further, 
reduced ZIPK expression or mutation of the important ZIPK T265 
autophosphorylation residue results in a decrease in interleukin 6 (IL-6) induced 
STAT3-mediated transcription. 
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1.6 Aims and Objectives 
Based on the initial observations outlined in our preliminary data (Figure 1.7-
Figure 1.9), we have highlighted ZIPK as the histone kinase potentially 
responsible for the phosphorylation of histone H3 at threonines 6 and 11. We 
have shown that ZIPK inhibition by DAPKi prevents the phosphorylation of these 
histone marks with a corresponding decrease in the mRNA expression of two 
IEGs, EGR1 and DUSP2. Of the other candidate kinases identified in our initial 
screen such as MEK2, RSK1/2 and PKCs, their inhibition did not significantly 
inhibit EGR1 and DUSP2 gene expression or prevent histone H3 phosphorylation 
after anti-IgM stimulation. These data suggested a link between IEG and 
expression and histone H3T6 and H3T11 phosphorylation in CLL. Further, we 
have shown that DAPKi treatment of CLL cells inhibits their proliferation, similarly 
to ibrutinib, and that combining these two drugs had a synergistic effect on CLL 
cell proliferation. 
 
With these data in mind, at the outset, this project aimed to examine the following: 
 
• Determine ZIPK function in CLL and the potential benefits of its inhibition 
in the treatment of the disease compared to ibrutinib, especially in cases 
of BTKi-resistance. 
• Assess IEG response in CLL and the role of ZIPK in mediating IEG 
expression. 
• Examine the dynamics of the transcription factors responsible for CLL IEG 
expression, particularly STAT3, due to its previously described 
associations with ZIPK. 
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Chapter 2 Materials & Methods 
2.1 Materials 
2.1.1 List of antibodies 
Table 1: Table of antibodies 
Antibody Manufacturer Application 
anti-Rat IgG e-Bioscience/Thermo; 18- 4818-12 Co-IP 
B-actin ThermoFisher; PA1-183 WB 
EGR1 CST; #4153 WB 
H3T11-P Abcam; ab5168R KA, WB, ChIP 
H3T6-P Diagenode; C15410282 KA, WB, ChIP 
HDAC2 Santa Cruz Biotech; C-19: sc-6296 WB 
Histone H3 Abcam; ab1791 WB, Co-IP, ChIP 
HRP-secondary 
anti-mouse 
Jackson-ImmunoResearch;  
315-035-003 
WB 
HRP-secondary 
anti-rabbit 
Jackson-ImmunoResearch;  
111-035-003 
WB 
p65 Santa Cruz Biotech; C-20: sc-482 
CST; #8242 
WB, Co-IP, ChIP 
WB, Co-IP, ChIP 
RNA pol II Abcam; ab817 Co-IP, ChIP 
RNA pol II S2-P  Abcam; ab5095 WB, Co-IP, ChIP 
STAT3 Santa Cruz Biotech; C-20: sc-482 
CST; #9139 
WB, Co-IP, ChIP 
WB, Co-IP, ChIP 
STAT3-S727-P  Abcam; ab30647 
CST; #9134 
WB, Co-IP, ChIP 
WB, Co-IP, ChIP 
STAT3-Y705-P CST; #9131 WB, Co-IP, ChIP 
Vinculin CST; #4650 WB 
ZIPK  Bethyl; A304-221A-1 WB 
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Bethyl; A304-222A-1 Co-IP, ChIP 
ZIPK-T265-P Abcam; ab63395  
ThermoFisher; PA5-40234 
WB, Co-IP 
WB, Co-IP, ChIP 
KA, kinase assay. WB, western blot. Co-IP, co-immunoprecipitation. ChIP, 
chromatin immunoprecipitation. RT-PCR, reverse-transcription polymerase chain 
reaction. qPCR, quantitative polymerase chain reaction. 
 
2.1.2 List of primers 
Primers were designed online using Primer3Plus and the NCBI Primer-BLAST 
tool in conjunction with the in-silico PCR function of the UCSC genome browser. 
The number following a primer indicates the distance from the transcription start 
site (TSS) in kilobases (kb) of the corresponding gene where negative values are 
upstream of the TSS and positive values are downstream of the TSS. 
Table 2: Table of primers 
Primer Sequence Application 
CTCF1 F GGCCCAGGACTCCACGTTCAGA ChIP 
CTCF1 R GCCCTCTGGTGTTTGGCAGCAA ChIP 
CTCF3 F CACCCAGCAGAGGGCCCAGATA ChIP 
CTCF3 R CCCTTCGCCTTCTCTCCAGCCA ChIP 
DUSP2 -0.3 F CTAAAGGGGGACCTGCATCTG ChIP 
DUSP2 -0.3 R GACTAAGGGAAGGGAAGGTGTT ChIP 
DUSP2 -0.6 F AGGTCTTGAAATCCCCGCAG ChIP 
DUSP2 -0.6 R CCAGGCCCCAGAGAGAAGTA ChIP 
DUSP2 -11.0 F CCTTGACTCCCTGCTGAAGG ChIP 
DUSP2 -11.0 R CCCATCACAGCCCAAGTCTT ChIP 
DUSP2 +0.5 F GCTGGTTTTGTCCCCTGTTG qPCR/RT-PCR 
DUSP2 +0.5 R CTGATCGTGCTCTTCCCCTC qPCR/RT-PCR 
DUSP2 +0.8 F CCAGTCCTCCTGACCTGAGA qPCR/RT-PCR 
DUSP2 +0.8 R GTGCCTGTATGGGTCTGTGT qPCR/RT-PCR 
DUSP2 +1.1 F GGTGCCCCCTTACCAATGAA qPCR/RT-PCR 
DUSP2 +1.1 R GGGCCTTTTCCGCTACAAGA qPCR/RT-PCR 
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DUSP2 +2.4 F GGAAGTGATGGGTGTGTCATGT ChIP 
DUSP2 +2.4 R AAATAATTTTCCAGCGCCAGCA ChIP 
DUSP2 +3.1 F CATTTGGAGTGTCATCCAGCCA ChIP 
DUSP2 +3.1 R ACAGACCACGGACAGATCCTTA ChIP 
DUSP2 +4.2 F AGGAGTGAGGTTGATCTGATGT ChIP 
DUSP2 +4.2 R CCAGCCGTTATGAGTGTCCAT ChIP 
DUSP2 F TACTTCCTGCGAGGAGGCTT qPCR/RT-PCR 
DUSP2 R GGCTGGTTTTGTCCCCTGTT qPCR/RT-PCR 
EGR1 -0.1 F GCCATATTAGGGCTTCCTGCTT ChIP 
EGR1 -0.1 R GATCCGCCTCTATTTGAAGGGT ChIP 
EGR1 -0.4 F TCTGGGAGGAGGGAAGAAGG  ChIP 
EGR1 -0.4 R TTCGGGGAAGCCTAGAGC ChIP 
EGR1 -0.85 F TACAGTGTCCCAAGAACCAAGT ChIP 
EGR1 -0.85 R CGATCTATGGCACGGTGTCTTT ChIP 
EGR1 -1.0 F CCCTCCACCTGGACTGGATA  ChIP 
EGR1 -1.0 R CCGAAGTGGGGAAGCTGATT ChIP 
EGR1 -6.1 F CCTGGGGTAGGAGCAGAACT ChIP 
EGR1 -6.1 R TGTCACACTTTCCGACTGACTT ChIP 
EGR1 +0.55 F CAGCACCTTCAACCCTCAGG qPCR/RT-PCR 
EGR1 +0.55 R ATGGTGGCGAAAGGGTTCC qPCR/RT-PCR 
EGR1 +1.0 F TCCGTATTTGCGTCAGCTGT qPCR/RT-PCR 
EGR1 +1.0 R GCTACCATTGACTCCCGAGG qPCR/RT-PCR 
EGR1 +2.2 F CTGCGACATCTGTGGAAGAAAG ChIP 
EGR1 +2.2 F GCCGCAAGTGGATCTTGGTAT ChIP 
EGR1 +3.8 F GCTGCGATTGGGTATGTGTTTC ChIP 
EGR1 +3.8 R AGAAAACCTCACAGCCCTCAAT ChIP 
EGR1 +4.2 F GGGCCTGTTCCTCTTCAGTC ChIP 
EGR1 +4.2 F CACACATGTCCCAGCCCTAA ChIP 
EGR1 F ACAAAAGTGTTGTGGCCTCTTC qPCR/RT-PCR 
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EGR1 R GTGGCCGGGGATGGATAAGA qPCR/RT-PCR 
EGR1 TSS F GCCATATTAGGGCTTCCTGCTT ChIP 
EGR1 TSS R GATCCGCCTCTATTTGAAGGGT ChIP 
GAPDH F ACAGTCAGCCGCATCTTCTT qPCR 
GAPDH R ACGACCAAATCCGTTGACTC qPCR 
PPP6C F TGGAAATGCTAATGCCTGGAGA qPCR 
PPP6C R TTCCTGATTCCGTTCGATGGTT qPCR 
TBP F TGCTCACCCACCAACAATTTAG qPCR 
TBP R TCTGGGTTTGATCATTCTGTAGATTAA qPCR 
ChIP, chromatin immunoprecipitation. RT-PCR, reverse-transcription 
polymerase chain reaction. qPCR, quantitative polymerase chain reaction. 
 
2.2 Cell culture 
2.2.1 Primary CLL cells and cell line maintenance 
CLL cells were obtained from the St James’s University Hospital (Leeds) 
Haematological Malignancy Diagnostic Service (HMDS) from patients with no 
previous treatment for their disease. The experiments using these cells were 
undertaken with the understanding and written consent of each patient and the 
study methodologies conformed to the standards set by the Declaration of 
Helsinki. These experiments were performed under ethical approval granted by 
the Leeds Teaching Hospital NHS Trust REC: 14/WS/0098. CLL, raji, ramos and 
HBL1 cells were grown in Roswell Park Memorial Institute (RPMI-1640; Sigma-
Aldrich) medium with 10% foetal calf serum (PAA Laboratories Inc.), L-glutamine 
(ThermoFisher; GibcoTM) and penicillin- streptomycin (ThermoFisher; GibcoTM). 
All cells were cultured at 37°C and 5% CO2. Raji, ramos and HBL1 cells were 
cultured at 0.1-1.0 x 106 cells/ml and CLL cells at 0.1-0.5 x 107 cells/ml aiming for 
~80% cell density. 
 
2.2.2 Isolation of PBMCs 
CLL peripheral blood mononuclear cells were isolated by density centrifugation 
from whole blood using LymphoprepTM (Stemcell Technologies). In brief, blood 
was diluted 1:2 in phosphate-buffered saline (PBS) and carefully layered over an 
equal amount of LymphoprepTM. After centrifugation at 2000 rpm for 20 min 
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(acceleration reduced to 60% and with the brake off), PBMCs were carefully 
recovered with a Pasteur pipette. PBMCs were transferred into a new tube and 
washed twice with PBS. No specific B cell enrichment step was performed as 
PBMCs from CLL patients are mostly B-CLL cells. Cells were counted and plated 
into T25 flasks at appropriate densities or frozen, as required. 
 
2.2.3 Cell counting 
For cell survival assays and cell counting in preparation for experiments, cells 
were stained with trypan blue (ThermoFisher) and counted manually using a 
standard haemocytometer with a cover slip. Depending on the observed density 
of cells in culture medium, they were diluted in the range of 1:5 – 1:50 with trypan 
blue, aiming to achieve a count of ~100 cells. Cell number per ml was determined 
using the following equation:  
 !"##	%&'(")	*")	'#	 +,")+-"	!"##	!.&%/%&'(")	.0	12&+)"1	!.&%/"3 	×	107 	× 	38#&/8.%	0+!/.) 
Equation 1: formula for counting cells in vitro using a haemocytometer. 
 
2.2.4 Cell freezing & thawing 
Exponentially growing cells were collected by centrifugation and resuspended in 
ice-cold freezing mix (90% FCS and 10% DMSO) at a density of 106 cells/ml for 
all cell lines and 107 cells/ml for CLL cells. 1 ml of the suspension was transferred 
into a cryotube and stored into a freezing container at -80°C for at least 24 h. The 
tubes were then transferred into the liquid nitrogen storage tank for long-term 
storage. For thawing, cells were removed from either -80°C or liquid nitrogen 
storage and warmed by gently swirling in a water bath set to 37°C until only a 
small amount of ice remained. The cells were then quickly added to fresh media 
and pelleted by centrifugation to remove the DMSO-containing freezing mix. 
 
2.2.5 Cellular stimulation and inhibition 
Cells were stimulated with F(ab')2 fragment goat anti-human IgM at 10 μg/ml 
(Jackson-ImmunoResearch; 109-006-129-JR) or recombinant human sCD40 
ligand (Peprotech; 310-02) at 5 μg/ml as required and where indicated. Cells 
were pre-treated with ibrutinib (Pharmacyclics, Sunnyvale, CA, US) at 1 μM or a 
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DAPK inhibitor (DAPKi) (Calbiochem; 324788-10MG) at 10-120 μM as required 
and where indicated. 
 
2.2.6 Transfection of lymphoid cell lines with siRNA  
ZIPK knockdown was achieved in HBL1 cells with a GenePulser® II 
electroporation system (BioRad) using siRNAs against ZIPK (ThermoFisher; 
siRNA ID #557 and #559) complete with a non-targeting negative control siRNA 
(ThermoFisher; 4390843). Post-electroporation, cells were transferred to flasks 
of pre-warmed media and left overnight. siRNA transfected cells were incubated 
for 3-5 days, with addition of fresh RPMI on day 1 and 3, and counted to check 
cell viability. Cells were subsequently harvested by centrifugation and prepared 
for western blot analysis to confirm ZIPK knock down. 
 
2.3 Kinase assays 
0.1 μg recombinant protein DAPK3-GST (Abcam; ab152327) and 1 μg 
recombinant protein histone H3-HIS (Abcam; ab198757) were added to kinase 
buffer (KB) (1 mg/ml BSA, 25 mM HEPES pH 7.9, 10 mM MgCl2, 50 mM NaCl, 1 
mM DTT, 10 mM KCl and 10% glycerol) complete with 1x protease inhibitor 
cocktail (NEB; 5871S) (added fresh). ATP was added where indicated to 200 μM 
final concentration. Ibrutinib (Pharmacyclics, Sunnyvale, CA, US) was added 
where indicated to 1 μM final concentration. A DAPK inhibitor (DAPKi) 
(Calbiochem; 324788-10MG) was added where indicated to 50 μM final 
concentration. Samples were warmed to 16oC to start the reaction. Aliquots were 
removed at the indicated time points and immediately heat inactivated for 5 
minutes at 65oC to halt the reaction. Reaction samples were spotted onto 
nitrocellulose membranes and air dried before blocking in 5% BSA at room 
temperature for 1 hour. Membranes were incubated at 4oC overnight with primary 
antibodies against H3T11-P (Abcam; ab5168) and H3T6-P (Diagenode; 
C15410282). HRP-conjugated secondary antibodies against rabbit (Jackson-
ImmunoResearch; 111-035-003) and mouse (Jackson-ImmunoResearch; 315-
035-003) were used at 1:10,000. Membranes were analysed using ECL 
(ThermoFisher; PierceTM) and a ChemiDoc system.  
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2.4 Protein extraction & analysis 
2.4.1 SDS lysis 
For western blotting, prior to lysis, cells were washed twice with ice cold PBS, 
centrifuging at 1,200 rpm for 5 minutes. Samples were then lysed with SDS lysis 
buffer (10% SDS, 0.5 M Tris pH 6.8) supplemented with 1x protease inhibitor 
cocktail (NEB; 5871S), PMSF (1 µl/ml), NaF (1 µl/ml) and Na3VO4 (2 µl/ml) for 5 
minutes at 90oC. Lysates were stored at -20oC or used immediately. Protein 
concentrations of all samples were determined using the BCA Protein Assay 
(PierceTM, 23227) and a Mithras Plate Reader (Berthold Technologies).  
 
2.4.2 Nuclear-cytoplasmic extraction 
Nuclear and cytoplasmic fractionation was carried out using the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents kit (Thermo, 78833). Cytoplasmic and 
nuclear fractions were extracted using cytoplasmic/nuclear extraction reagents 
(CER I/CER II/NER) at a volume and ratio corresponding to the initial packed cell 
pellet in µl. Lysates were stored at -20oC or used immediately. Protein 
concentrations of all samples were determined using the BCA Protein Assay 
(PierceTM, 23227) and a Mithras Plate Reader (Berthold Technologies).  
 
2.4.3 BCA assay 
BCA assay was carried out using the BCA Protein Assay Kit (PierceTM, 23227). 
Briefly, samples were diluted 1 in 5 in their corresponding diluent and boiled at 
90oC for 5 minutes. BCA standards were made up for a working range of 20-
2,000 µg/mL. Working reagent (WR) was prepared in a 1:50 ratio (reagent A: 
reagent B). Samples/BCA standards and WR were mixed 1:8 in a 96-well plate 
which was incubated for 30 minutes at 37oC. The plate was left to cool to room 
temperate for subsequent absorbance analysis using a Mithras Plate Reader 
(Berthold Technologies). 
 
2.4.4 SDS-PAGE/western blotting 
Western blots were carried out under denaturing conditions with SDS-PAGE and 
proteins were wet-transferred to nitrocellulose membranes. Membranes were 
blocked with either 5% BSA or 5% milk (for phospho-antibodies) for 1 hour at 
room temperature. Membranes were incubated at 4oC overnight with primary 
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antibodies against ZIPK at 1:1000 (Bethyl; A304-221A-1), ZIPK-T265-P at 1:500 
(Abcam; ab63395 and ThermoFisher; PA5-40234) STAT3 at 1:1000 (Santa Cruz 
Biotech; C-20: sc-482), STAT3-S727-P at 1:1000 (Abcam; ab30647), STAT3-
Y705-P at 1:1000 (CST; #9131) p65 at 1:1000 (Santa Cruz Biotech; C-20: sc-
482), H3T6-P at 1:500 (Diagenode; C15410282), H3T11-P at 1:500 (Abcam; 
ab5168), EGR1 at 1:1000 (CST; #4153), RNA pol II S2-P at 1:1000 (Abcam; 
ab5095), Vinculin at 1:10,000 (CST; #4650), HDAC2 at 1:5000 (Santa Cruz 
Biotech; C-19: sc-6296) and B-actin at 1:2000 (ThermoFisher; PA1-183). HRP-
conjugated secondary antibodies against rabbit (Jackson-ImmunoResearch; 
111-035-003) and mouse (Jackson-ImmunoResearch; 315-035-003) were used 
at 1:10,000 in 5% milk. Membranes were analysed using ECL (ThermoFisher; 
PierceTM) and a ChemiDoc system. Bands were quantified with Image LabTM 
software as indicated.     
 
2.5 Co-immunoprecipitation (Co-IP) 
2.5.1 Co-IP lysis 
For co-immunoprecipitation (co-IP), cells were lysed with cold 
immunoprecipitation buffer (IP buffer) (150 mM NaCl, 10 mM Tris-HCl pH 7.4, 1 
mM EDTA, 1 mM EGTA, 1% Triton X-100 and 0.5% NP-40) complete with 1x 
protease inhibitor cocktail (NEB; 5871S) for 30 minutes at 4oC maintaining 
agitation. Lysates were centrifuged and supernatants stored at - 80oC for co-IP. 
Protein concentrations of all samples were determined using the BCA Protein 
Assay (PierceTM) and a Mithras Plate Reader (Berthold Technologies).  
 
2.5.2 Co-IP 
Cell lysates were adjusted to 1mg/ml with IP buffer. Lysates were pre-cleared 
with Protein G DynabeadsTM (Invitrogen, 1004D) for 1 hour or overnight at 4oC 
while maintaining agitation. Supernatants were incubated with 1-5 μg of anti-ZIPK 
(Bethyl Laboratories; A304-222A-1), ZIPK-T265-P (ThermoFisher; PA5-40234), 
STAT3 (Santa Cruz Biotech; C-20: sc-482 and CST; #9139), STAT3-S727-P 
(CST; #9134), p65 (Santa Cruz Biotech; C-20: sc-372 and CST; #8242), histone 
H3 (Abcam; ab1791), RNA polymerase II (Abcam; ab817), RNA polymerase II 
S2-P (Abcam; ab5095) and HRP-conjugated anti-Rat IgG (e-Bioscience/Thermo; 
18- 4818-12) for 1 hour at 4oC maintaining agitation. The antibody-lysate immune 
complexes were captured with 12.5 μl Protein G DynabeadsTM per 100 μg lysate 
by maintaining agitation for 1 hour at 4oC. Immobilised complexes were washed 
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up to 5 times with IP buffer and eluted in 4x SDS-PAGE loading buffer (200 mM 
Tris-HCl pH 6.8, 400 mM DTT, 8% SDS, 0.4% bromophenol blue and 40% 
glycerol) at 70oC for 5 minutes. Samples were stored at -20oC or electrophoresed 
on SDS-polyacrylamide gels (PAGE) and detected with primary antibodies by 
western blot (see methods 2.4.4).  
 
2.6 RNA analysis 
2.6.1 Preparation of total RNA 
Total RNA was prepared from 105-5x106 cells. Cell pellets were washed with cold 
PBS and then resuspended in TRIzol® reagent (Invitrogen) at a volume 
according to the manufacturer’s recommendations. RNA was prepared using the 
Direct-zolTM RNA MiniPrep kit (Zymo Research) including a DNase I treatment. 
RNA was eluted in DNase/RNase-free water and concentration was determined 
using the NanoDropTM spectrophotometer. RNA was subsequently stored at -
80oC.  
 
2.6.2 cDNA synthesis 
cDNA was synthesised from 1 μg of RNA diluted in nuclease free water with 
Random Primers (Invitrogen) or Oligo(dT) (Invitrogen). Samples were incubated 
at 70oC for 5 minutes and then placed on ice for the addition of PCR master-mix: 
4 μl 5x FS buffer (Invitrogen), 1μl MLV-reverse transcriptase (Invitrogen), 0.5 μl 
RNase-Out (Invitrogen) and 0.5 μl dNTPs (Invitrogen) per reaction. The cDNA 
synthesis was carried out at 37oC for 1 hr, followed by a 5 min denaturation at 
95oC. cDNA was subsequently diluted 1:5 in 1x TE and stored at -20oC.  
 
2.6.3 RT-PCR and qPCR 
For qPCR, cDNA was diluted 1:10 in nuclease free water. 5 μl reactions were 
carried out in triplicate in clear 384-well plates. using Luna® Universal qPCR 
Master Mix (NEB) on a QuantStudio 7 Flex Real-Time PCR System 
(ThermoFisher) under the following conditions: 
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Table 3: qPCR conditions 
Temperature (oC) Time Cycles 
50 2 min x 1 
95 10 min x 1 
95 15 sec 
x 40 
60 1 min 
 
Melting curve analysis for each primer set was carried out to ensure the specificity 
of the amplification. Primers were deemed acceptable when the melting curve 
had only one peak with high amplitude (for primer sequences see Table 2). 
 
For RT-PCR, cDNA was diluted to a final concentration of 50 ng. The reactions 
were assembled on ice with 1x standard taq reaction buffer (- Mg) (NEB), 1.5 mM 
MgCl2 (NEB), 200 µM dNTPs (NEB), taq DNA polymerase at 1.25 units per 50 µl 
PCR reaction and 0.2 µM forward and reverse primers, then made up to 25 µl 
with nuclease-free water. RT-PCR reactions were carried out using a thermal 
cycler (BioRad) under the following conditions:  
 
Table 4: RT-PCR conditions 
Step Temperature (oC) Time Cycles 
Denaturation 95 30 sec x 1 
Cycling 
95 
50-54 
68 
20 sec 18-25 depending 
on linear 
amplification 
range 
30 sec 
2-3 min 
Final extension 68 5 min x 1 
Hold 4 Indefinite Indefinite 
 
RT-PCR products were run on 1.5% agarose gels for 30-40 minutes at 100 V and 
visualised with a ChemiDoc system (for primer sequences see Table 2). 
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2.6.4 qPCR analysis 
Relative expression was calculated as a ratio of specific transcript to one/several 
housekeeping genes using following formula: 2-∆Ct, where ∆Ct equals: 
 ∆:/ = :/	(-"%"	.0	8%/")"1/) − :/	(ℎ.&1"@""*8%-	-"%") 
Equation 2: ∆Ct formula for qPCR quantification. 
 
This equation utilised the following housekeeping genes: TATA-Box Binding 
Protein (TPB), protein phosphatase 6 catalytic subunit (PPP6C) or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as indicated. 
 
2.6.5 qPCR analysis – alternative splicing fold change 
To assess the impact of ZIPK inhibition on alternative splicing we used 
calculations described in Harvey and Cheng (2016) [244]. To calculate the fold 
change in alternative splicing, the quantity of each splice isoform was first 
determined using the 2-∆Ct formula, where ∆Ct equals:  
 ∆:/ = :/	(1*#8!"	81.0.)') − :/	(ℎ.&1"@""*8%-	-"%") 
Equation 3: ∆Ct formula for quantification of splice isoforms. 
 
The relative levels of different splice isoforms of the same gene were expressed 
as a ratio of one splice isoform to another using the following formula: 2−∆Ct, where 
∆Ct equals:  
 ∆:/ = (:/	8%!#&18.%	1*#8!"	81.0.)'	'ABC− :/	"D!#&18.%	1*#8!"	81.0.)'	'ABC	8%	/ℎ"	1+'"	1+'*#")	 
Equation 4: formula for quantifying the relative levels of different splice 
isoforms in relation to one another. 
 
Then, relative comparison of this ratio between different experimental samples 
was accomplished via the formula:  
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2F∆GH(IJKILMNIOH)2F∆GH(PQOHLQR)  
Equation 5: formula for comparing the ratio of splice isoforms between 
samples and control. 
 
where ∆Ct(experiment) equals: 
 (:/	8%!#&18.%	1*#8!"	81.0.)'	'ABC	8%	"D*")8'"%/+#	1+'*#"	− 	:/	"D!#&18.%	1*#8!"	81.0.)'	'ABC	8%	"D*")8'"%/+#	1+'*#")	 
 
and ∆Ct(control) equals:  
 (:/	8%!#&18.%	1*#8!"	81.0.)'	'ABC	8%	!.%/).#	1+'*#"	− 	:/	"D!#&18.%	1*#8!"	81.0.)'	'ABC	8%	!.%/).#	1+'*#") 
 
The calculation is identical when assessing exon inclusion versus intron retention 
alternatively spliced DUSP2 transcripts by replacing ‘Ct exclusion splice isoform’ 
with ‘Ct intron retained splice isoform’ in all equations. With this methodology, the 
relative levels of splice isoforms can be expressed as a ratio of one splice isoform 
to another e.g. an exon inclusion vs. exon exclusion or intron retention ratio. By 
giving the control sample a baseline value of 1, this ratio can then be compared 
between different experimental samples. 
 
2.7 Chromatin analysis 
2.7.1 Chromatin preparation 
ChIP was performed as follows: 107 cells were crosslinked with 1.5% 
formaldehyde for 8 minutes at room temperature. Cells were harvested by 
centrifugation at 400 x g for 4 minutes at 4oC and washed twice with ice cold PBS 
supplemented with 1x protease inhibitor cocktail (NEB; 5871S). Pellets were 
resuspended in 10 ml of buffer A (10 mM HEPES (pH 8), 10 mM EDTA (pH 8.0), 
0.5 mM EGTA (pH 8.0), and 0.25% Triton X-100) and incubated at 4°C for 10 min 
with gentle agitation. After centrifugation at 500 x g at 4°C for 5 min, cells were 
resuspended into 40 ml of buffer B (10 mM HEPES (pH 8), 200 mM NaC1, 1 mM 
EDTA (pH 8.0), 0.5 mM EGTA (pH 8.0), and 0.01% Triton X-100) and incubated 
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10 min, and centrifuged as before. Nuclei were sonicated in immunoprecipitation 
buffer (25 mM Tris-HCl (pH 8), 2 mM EDTA, 150 mM NaC1, 1% Triton X-100, 
0.1% sodium dodecyl sulphate and 1x protease inhibitor cocktail). Nuclei were 
sonicated for 15 (RNA polymerase ChIP) or 20 (histone H3 and transcription 
factor ChIP) cycles (30 seconds on/30 seconds off) using a Bioruptor® Pico 
sonication device (Diagenode). After centrifugation at 14,000 x g for 10 min at 
4°C, chromatin preparations were stored at −80°C. 12 µl of chromatin was taken 
and stored as input for qPCR normalisation. 
 
2.7.2 Chromatin sonication optimisation 
The optimal shearing was determined for each cell line individually. 107 cells were 
crosslinked with 1.5% formaldehyde for 8 minutes at room temperature and 
prepared for sonication as described above. Nuclei were sonicated for 10-25 
cycles with 2 cycle gaps (e.g. 16, 18, 20, 22). Sonication products were run on 
1.5% agarose gels for 40 minutes at 100 V and visualised with a ChemiDoc 
system. Optimised sonication was determined as having chromatin fragments in 
the range of 100 - 600 bp with 1000 bp as the upper limit.  
 
2.7.3 Chromatin immunoprecipitation (ChIP) 
Sonicated chromatin from 107 cells was used for each immunoprecipitation. The 
volume was adjusted to give 100 μl per IP with fresh immunoprecipitation buffer. 
Immunoprecipitation was achieved using DynabeadsTM Protein G 
(ThermoFisher) with 2.4 µg of anti-histone H3T11-P (Abcam; ab5168), anti-
histone H3T6-P (Diagenode; C15410282), anti-STAT3 (Santa Cruz Biotech; C-
20: sc-482 and CST; #9139), anti STAT3-S727-P (CST; #9134), anti-p65 (Santa 
Cruz Biotech; C-20: sc-372 and CST; #8242), anti-ZIPK (Bethyl Laboratories; 
A304-222A-1), anti-ZIPK-T265-P (ThermoFisher; PA5-40234) anti-RNA 
polymerase II (Abcam; ab817) or anti-RNA polymerase II S2-P (Abcam; ab5095) 
per 10 µl of beads. Beads were washed twice with ice cold immunoprecipitation 
buffer prior to use.  Beads and antibodies were incubated for 2 hours at 4oC with 
gentle agitation. After 2 hours the bead-antibody mixture was pelleted using a 
magnet and the beads were washed once with ice cold immunoprecipitation 
buffer. 100 µl of sonicated chromatin was added to achieve a bead to chromatin 
ratio of 1:10. Chromatin was incubated for 2 hours at 4oC with gentle agitation. 
After 2 hours, beads were pelleted using a magnet and washed once with 
washing buffer A (20 mM Tris-HCl (pH 8), 2 mM EDTA, 1% Triton X-100, 0.1% 
sodium dodecyl sulphate and 150 mM NaCl supplemented with 1x protease 
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inhibitor cocktail), once with washing buffer B (20 mM Tris-HCl (pH 8), 2 mM 
EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulphate and 500 mM NaCl 
supplemented with 1x protease inhibitor cocktail), once with LiCl buffer (0.25 M 
LiC1, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, and 10 mM Tris-
HCl (pH 8) supplemented with 1x protease inhibitor cocktail), and twice with TE 
buffer (10 mM Tris-HCl (pH 8.0) and 1 mM EDTA). The immune complexes were 
eluted by adding 50 μl of elution buffer (1% sodium dodecyl sulphate, 100 mM 
NaHCO3, 200). The cross-link was reversed at 65°C overnight. Inputs were 
treated with RNAse A for 30 minutes at 36oC and reverse-crosslinked at 65°C 
overnight with proteinase K. 
 
2.7.4 DNA purification/clean-up for ChIP-qPCR 
Reverse cross-linked DNA was purified using AxyPrepTM MAG PCR clean-up kit 
(Appleton Woods Ltd) according to manufacturer’s instructions. qPCR reactions 
were carried out using Luna® Universal qPCR Master Mix (NEB) on a 
QuantStudio 7 Flex Real-Time PCR System (ThermoFisher) (for primer 
sequences see Table 2). For ChIP-qPCR, cDNA was diluted 1:5 in nuclease free 
water while inputs were diluted 1:50. Standard curves were prepared with input 
cDNA in a 1:5 dilution series. 5 μl reactions were carried out in duplicate in clear 
384-well plates. using Luna® Universal qPCR Master Mix (NEB) on a 
QuantStudio 7 Flex Real-Time PCR System (ThermoFisher) under the same 
conditions described in methods 2.6.3. 
 
2.7.5 ChIP-qPCR analysis 
ChIP-qPCR data were analysed as follows. First, the average of duplicate Ct 
values was calculated relative to the intercept and the slope of the standard curve 
generated for each primer pair representing a genomic region with the following 
calculation, where E is a numeric constant relating to exponential growth and 
decay: 
 S =	:/	/+)-"/ − 1/+%3+)3	!&),"	8%/")!"*/1/+%3+)3	!&),"	1#.*"  
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Next, the values for E are compared for each target and control (input): 
 )"#+/8,"	+'.&%/	.0	TBC = 	 SUVWXYUSZ[\UW[]  
Equation 6: formula for quantifying relative amount of ChIP DNA detected 
by ChIP-qPCR analysis. 
 
Data were then normalised to input and expressed relative to invariant genomic 
regions CTCF1 and CTCF3 Note: Histone H3T6-P and H3T11-P ChIP was 
exclusively normalised to histone H3.
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Chapter 3 Results 1: ZIPK catalyses histone H3 threonine 
phosphorylation and regulates lymphoid cell IEG expression 
In a previous study, the Lefevre group determined that crosslinking and activation 
of the BCR induces the expression of IEGs together with phosphorylation of 
histone H3 at threonine 6 and threonine 11 (see Figure 1.7 – Figure 1.9) (Thomas 
et al., forthcoming 2020). These IEGs included genes known to promote CLL cell 
proliferation and survival – making an interesting link between H3T6-P and 
H3T11-P and IEG expression. Therefore, the group initially sought to identify the 
kinase mediating this phosphorylation through in silico kinase predication 
software (Figure 1.8). Each candidate kinase provided by the software was tested 
with a specific kinase inhibitor by looking for changes in IEG expression and a 
loss of H3T6 and T11 phosphorylation (Thomas et al., forthcoming 2020). ZIPK 
was the only kinase whose inhibition resulted in both a loss of IEG expression 
and histone phosphorylation – but it was not clear if this effect was a direct result 
of the kinase inhibition or an indirect one.  
 
ZIPK is a serine-threonine kinase which mediates a variety of cellular functions. 
These include both apoptotic and autophagic cell death [225, 229] and the 
regulation of smooth muscle contraction [222]. Upon its initial discovery ZIPK was 
reported to interact with chromatin [229]. ZIPK has been observed to 
phosphorylate H3T11 during mitosis to promote chromosome condensation 
[230], and PRK1-mediated H3T11-P has been shown to activate AR-dependent 
gene transcription [220]. However, there is no current literature linking ZIPK and 
both H3T11 and H3T6 phosphorylation during transcription.  
 
From a therapeutic view, there is an interest to studying ZIPK alongside ibrutinib 
owing to observed similarities in the reduction of these histone marks in response 
to ibrutinib treatment (Figure 1.7C-D). As ibrutinib is well known to be a successful 
CLL therapeutic, we hypothesised that whichever kinase was mediating H3T6 
and H3T11 phosphorylation could play a key role in the transcription of genes 
known to be involved in CLL pathogenesis.  
 
In summary, based on the results from the kinase prediction software and 
experiments in the Lefevre lab (Figure 1.8A), we initially wanted to question 
whether ZIPK could directly phosphorylate both H3T11-P and H3T6-P in vitro. 
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Should this be the case and in light of our preliminary observations comparing 
the ZIPK inhibitor to ibrutinib, we hypothesised that we may see similar ZIPK 
function in CLL cells, and that further study of ZIPK could be important in the 
context of CLL therapy.  
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3.1 ZIPK directly phosphorylates H3T6 and H3T11 in vitro 
Preliminary data from the Lefevre group showed that ZIPK inhibition could reduce 
phosphorylation of histone H3T6 and H3T11. In order to determine whether this 
was a direct or indirect effect we initially wanted to assess the ability of ZIPK to 
directly phosphorylate histone H3T6 and H3T11 by in vitro kinase assay.  
 
We incubated recombinant histone H3 and ZIPK proteins with ATP and examined 
the reaction over time (0-60 minutes) by dot blot, probing with antibodies against 
H3T6-P and H3T11-P (Figure 3.1B-C). ZIPK could phosphorylate both histone 
marks, showing rapid phosphorylation of H3T6 after just 5 minutes with a gradual 
increase over time from 5-60 minutes. The catalysis of H3T11 phosphorylation 
by ZIPK displayed slower kinetics, with minimal H3T11-P detectable by dot blot 
after 5 minutes. However, by 60 minutes the absolute level of H3T11-P was 
comparable to H3T6-P.  
 
We also wanted to assess the ability of ZIPK to phosphorylate H3T6 and H3T11 
in the presence of the same death associated protein kinase inhibitor (DAPKi) 
used in the preliminary experiments (Figure 3.1A) – with the expectation that by 
inhibiting ZIPK kinase activity we could impede its ability to phosphorylate 
histones. The DAPKi is noted to be an ATP-competitive and highly selective 
inhibitor of DAPK1 and DAPK3. We added the DAPKi to our kinase assay 
reactions alongside ibrutinib (Figure 3.1B-C). In this experiment, using 
recombinant proteins, we expected ibrutinib to have little impact on ZIPK kinase 
activity. The DAPKi reduces ZIPKs ability to phosphorylate H3T6 and H3T11, 
with the most significant reduction at 60 minutes in both cases. The effect is most 
profound with regard to H3T11-P. Ibrutinib has a small but non-significant (P > 
0.05) effect in all cases apart from H3T11-P at 60 minutes. This may be due to a 
combination of experimental variability and unexpected impacts arising from the 
addition of ibrutinib to the reaction e.g. stoichiometric explanations such as 
ibrutinib physically blocking the protein-protein interactions required for ZIPK-
mediated histone phosphorylation.  
 
3.1.1 ZIPK inhibition reduces the levels of active ZIPK T265-P in CLL 
cells 
A series of in vitro kinase assays have shown that ZIPK can directly 
phosphorylate histone H3 at T6 and T11 in a manner preventable by a DAPKi. In 
order to validate the results observed in Figure 3.1, and future experiments, we 
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needed to confirm that the ZIPK inhibitor was efficiently repressing ZIPK activity. 
Further, this is necessary to confirm that the loss of histone threonine 
phosphorylation observed with DAPKi treatment in Figure 3.1 is due to loss of 
ZIPK function as opposed to any off-target or alternative effects of the drug.  
 
To assess the efficacy of the inhibitor, CLL cells were treated with increasing 
doses of DAPKi (0-80 µM) for 60 minutes. The cells were then lysed for western 
blot analysis with antibodies against total ZIPK and ZIPK T265-P, an 
autophosphorylation site indicative of active ZIPK [223] (see 1.5.3 on ZIPK 
function). The protein levels of ZIPK T265-P began to decrease between inhibitor 
doses of 20 and 40 µM, with very low levels remaining at 80 µM. We recognise 
the high concentrations of DAPKi required to inhibit ZIPK phosphorylation and 
activity, especially when compared with the highly potent, small molecule 
inhibitor, ibrutinib, which has sub-nanomolar activity against BTK (IC50, 0.5 nM) 
[245]. We partly attribute this to the relatively under-developed nature of the 
DAPKi which may lack stability (this is discussed further in discussion section 
6.2.1). Therefore, off-target effects cannot be completely ruled out at the tested 
DAPKi concentrations. For the DAPKi, ERK2 has an IC50 > 10 µM, and it may 
represent the most relevant alternative target [94]. In our preliminary work we 
have previously assessed the consequences of treating CLL cells with a MEK 
inhibitor to directly inhibit ERK. In this experiment we observed no effect on EGR1 
and DUSP2 expression as well as on H3T6 and H3T11 phosphorylation after 
directly targeting MEK (Figure 1.8), suggesting that ERK might not mediate 
DAPKi effect. Total ZIPK remains unchanged throughout the experiment, 
highlighting the specificity of the inhibitor for reducing the levels of active ZIPK 
and thereby decreasing its kinase activity as seen in Figure 3.1.  
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Figure 3.1: ZIPK phosphorylates H3T6 and H3T11 in vitro. (A) DAPKi structure and kinase selectivity: (Okamoto et al. 2009 J. Med. 
Chem.) DAPKi binds to active site of protein. DAPK1 IC50 = 69nM while DAPK3 (ZIPK) IC50 = 225nM indicating moderate specificity. 
DAPK1 is silenced in CLL. (B) Kinase assay quantified by dot-blot with recombinant histone H3 and recombinant ZIPK to measure ZIPK 
kinase activity over time (5-60 minutes) with or without (negative control) ATP and in the presence of ibrutinib and DAPK inhibitor. (C) 
Kinase assay displaying histone H3 phosphorylation quantified relative to untreated assay with error bars representative of 3 independent 
experiments. Significant differences calculated using two-way ANOVA followed by Dunnett’s multiple comparison test with the untreated 
sample as control for each time point. H3T6-P P values = 0.3075 & 0.0139 (5 m), 0.4157 & 0.0021 (20 m), 0.1583 & 0.0001 (60 m) for 
untreated vs. Ibr and DAPKi respectively. H3T11-P P values = 0.6679 & 0.6844 (5 m), 0.0672 & 0.0095 (20 m), 0.0043 0.0001 (60 m) for 
the same comparisons.  
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Figure 3.2: DAPKi reduces levels of active ZIPK in CLL cells. (A) western blot displaying levels of phosphorylated/active ZIPK-T265P 
in untreated CLL cells vs. CLL cells treated with 10-80 μM DAPKi. Cells were pre-treated with DAPKi for 60 mins before anti-IgM stimulation 
of the BCR for a further 60 mins. Western blot is representative of 2 individual experiments in CLL cells and numerous other experiments 
in lymphoid cell lines. β-actin was used as a loading control and for normalisation with Image Lab software (right).  
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3.2 The role of ZIPK in BCR-mediated immediate early gene 
expression in CLL cells 
The importance of cell signalling pathways in cancer cell proliferation and survival 
is well established and this is no less true in chronic lymphocytic leukaemia (CLL). 
CLL cells in the microenvironment are influenced by a multitude of signals which 
work together to activate pro-survival and pro-proliferative gene programmes [93, 
94, 96]. 
 
The B cell receptor (BCR) pathway is critical for the development of mature, 
healthy B lymphocytes so it is not surprising that CLL cells may co-opt the 
pathway for their own malignant development [114]. CLL cells which react to 
antigen/auto-antigen crosslink the BCR on their cell surface and rapidly 
upregulate immediate early genes (IEGs). IEGs are genes which are rapidly and 
transiently upregulated in response to a variety of external stimuli [173]. The 
proteins for which IEGs code include cytoplasmic enzymes and transcription 
factors of which many are known to be oncogenic through their regulation of 
differentiation and proliferation. It is for this reason that understanding IEG 
expression, function and regulation is of interest in haematological malignancies 
where they are known to be overexpressed or dysregulated in some way.  
 
Early growth response factor 1 (EGR1) [178, 180], a key regulator of transcription, 
and dual specificity phosphatase 2 (DUSP2) [187], an important signal 
transduction enzyme and regulator of the MAPK pathway, are classical IEGs 
known to be upregulated in CLL and a variety of other haematological 
malignancies. Previous data from the Lefevre group has implicated ZIPK as a 
potential regulator of these two genes (Thomas et al., forthcoming 2020 and 
Figure 1.7 – Figure 1.9). To this end, we first aimed to assess the levels of both 
EGR1 and DUSP2 in a cohort of CLL patients by subjecting primary patient cells 
to gene expression analysis following activation of the BCR pathway. 
 
3.2.1 Immediate early gene response is dictated by IgHV status in 
CLL cells 
Before we could accurately assess CLL IEG expression in response to BCR 
signalling, we needed to understand the inherent characteristics of a CLL cell 
which can play a role in gene expression. One such factor is a CLL cells 
immunoglobulin heavy chain variable region (IgHV) status. CLL patients are 
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typically categorised into subtypes depending on the mutational status of the 
BCR present on the surface of CLL cells, which can either be mutated or 
unmutated. This refers to the stage in B cell development from which the CLL 
clone might have originated. In general, U-CLL cells arise from pre-germinal 
centre B cells and M-CLL cells result from the transformation of mature, antibody 
producing memory B cells which have undergone a germinal centre reaction (see 
1.1.3 on the germinal centre reaction). 
 
To clarify the effect of this trait on gene expression we sought to compare the 
response of primary, patient U-CLL and M-CLL cells to activation of the BCR 
pathway. Of our 10 patient cohort, 4 patients were classified  as M-CLL (P1, P6, 
P8 and P9) while the remaining 6 were U-CLL (P2-P5, P7 and P10) and all 
patients had not previously been treated for their disease. These CLL cells were 
stimulated with anti-IgM for 30 (6 U-CLL and 4 M-CLL patients) or 60 minutes (4 
U-CLL and 3 M-CLL patients) before lysis for RNA extraction. EGR1 and DUSP2 
gene expression was subsequently analysed by qPCR.  
 
The U-CLL patients showed a varied but pronounced IEG response to anti-IgM 
stimulation which is highly significant by 60 minutes (P ≤ 0.01), highlighting the 
rapid nature in which EGR1 and DUSP2 are upregulated in response to external 
stimuli and BCR pathway activation (Figure 3.3A-B). These data are in line with 
our preliminary data for EGR1 and DUSP2 anti-IgM response kinetics (Figure 
1.7). The M-CLL patients presented with two differing phenotypes displaying 
either (i) very low expression overall (P1 and P8) or (ii) chronic, mid-to-low range 
expression (P6 and P9) (Figure 3.3C-D). In both cases however, neither 
responded to anti-IgM stimulation or showed an increase in IEG expression.  
 
In an attempt to elicit a gene expression response in M-CLL cells, we stimulated 
both U and M-CLL patient cells (for direct comparison) with both anti-IgM and 
anti-IgD (Figure 3.4A-B). Anti-IgD was chosen as some M-CLL cells may have 
undergone class switch recombination during the germinal centre reaction and 
therefore express IgD B cell receptors on their cell surface, potentially explaining 
their limited response to anti-IgM stimulation. In all cases, we were unable to 
replicate the robust response seen in U-CLL patient cells stimulated with anti- 
IgM. However, anti-IgD was able to activate M-CLL cells by a small but significant 
amount at 30 minutes post stimulation for both EGR1 and DUSP2 while anti-IgM 
stimulation remained non-significant at both time points (Figure 3.4A). In the U-
CLL patients we observed the classical anti-IgM response of strong activation at 
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both time points. Anti-IgD was unable to elicit a significant gene expression 
response for DUSP2 in the U-CLL patients and we observed a small but 
significant impact on EGR1 expression at 30 minutes which was no longer 
significant by 60 minutes (Figure 3.4B). 
 
Anti-IgD was generally less effective than anti-IgM for both genes at all timepoints 
with some exceptions: notably, we observed an increase in EGR1 and DUSP2 
gene expression in M-CLL at 30 minutes only, suggesting IgD may be able to 
promote weak but rapid expression in this cell type.  
 
3.2.2 ZIPK inhibition mimics BTK inhibition in preventing CLL 
immediate early gene expression 
We have observed a mixed IEG response to anti-IgM stimulation dependent on 
the CLL subtype whereby U-CLL cells generally responded well to BCR 
crosslinking and upregulated EGR1 and DUSP2 gene expression (Figure 3.3 & 
Figure 3.4). We have also observed a loss of ZIPK kinase activity in the presence 
of the DAPKi (Figure 3.1 & Figure 3.2). With these data in mind, we wanted to 
address the effect of both ibrutinib and the DAPKi in preventing IEG expression 
in CLL cells. Firstly, in assessing U-CLL response alone we aimed to achieve a 
clearer picture of the effect of both inhibitors in the context of cells which can 
activate BCR signalling. Additionally, by examining the M-CLL response we can 
compare the effects of the inhibitors in the context of cells which may not strongly 
activate their BCR, or present with chronic activation.  
 
The small molecule inhibitor, ibrutinib, exploits the dependency of CLL cells on 
the BCR-signalling pathway by blocking BTK and shutting off the downstream 
signalling cascade [128]. It was anticipated that ibrutinib would prevent the 
expression of both EGR1 and DUSP2 – as we have concluded both genes are 
downstream of the BCR. We believe ZIPK is also downstream of the BCR, owing 
to previously identified similarities observed when treating CLL cells with ibrutinib 
and the DAPKi, and blocking ZIPK kinase activity should have a similar effect to 
ibrutinib. We therefore wanted to assess the effects of ibrutinib and the DAPKi in 
both CLL subtypes. 
 
The patient data is presented at each time point post stimulation with 7 patients, 
P4-10, with data for both 30 and 60-minute timepoints while 3 patients, P1-3, 
have data only for 30 minutes. In the U-CLL patients, we observed a significant 
  
 
81 
 
increase in EGR1 and DUSP2 (Figure 3.5A-B) gene expression at both 30 and 
60 minutes, where both genes showed higher expression at 60 minutes – 
highlighting the rapid nature in which these genes are upregulated in response 
to stimuli. The significance of the data at 30 minutes was affected by patient 4 
(green circle), who displayed slow kinetics in response to anti-IgM stimulation, 
presenting with an M-CLL like response initially but showed an 8-fold increase in 
gene expression by 60 minutes for both genes. Where the U-CLL cells had been 
pre-treated with either ibrutinib or the DAPKi, we observed a significant decrease 
in the expression of both genes (Figure 3.5A-B). The effect of both drugs was 
comparable in all cases, with EGR1 and DUSP2 gene expression reduced to a 
level comparable with that observed in the unstimulated control CLL cells, 
suggesting that ZIPK is either downstream of the BCR, or that both these proteins 
can indirectly regulate IEG expression. 
 
For the M-CLL patients there were several observations: M-CLL patients 
presented with either very low baseline IEG expression, or mid-to-low chronic 
expression – neither of which are altered by stimulation (see Figure 3.3C-D). In 
these experiments (Figure 3.5C-D), the 2 patients with very low EGR1 and 
DUSP2 gene expression showed no effect when treated with either inhibitor – it 
is expected that adding inhibitors will have no effect on CLL cells which do not 
respond to anti-IgM stimulation. More interestingly, of the 2 patients with mid-to-
low expression (P6 and P9), one (P6) shows a response to the inhibitors which 
is similar to the U-CLL patients, while the other patient (P9) is unaffected. 
Assuming EGR1 and DUSP2 expression correlates with CLL cell proliferation, 
these observations broadly fit with the literature suggesting that BTK inhibitors 
are more effective in treating those patients with U-CLL, while M-CLL patients 
show a mixed response to treatment [118]. 
 
3.2.3 In accordance with gene expression data, ZIPK inhibition 
reduces IEG protein levels in CLL cells 
We have observed a convincing decrease in IEG expression in CLL cells in 
response to ZIPK inhibition (see Figure 3.5). However, there are circumstances 
whereby the relative amount of mRNA in a cell as measured by qPCR does not 
correlate with the protein translated thereafter. Thus, we wanted to assess IEG 
protein levels to confirm if the complete loss of gene expression observed with 
ZIPK inhibition led to a corresponding downstream failure to transcribe the 
protein. U-CLL cells were pre-treated with increasing doses of the DAPKi (0-120 
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µM) for 60 minutes before stimulation with anti-IgM for 30 minutes. These cells 
were lysed for western blot and probed with antibody against EGR1.  
 
The western blots correlated with the gene expression data in two ways. We first 
reinforced that anti-IgM stimulation of the BCR activated IEGs by showing an 
increase in EGR1 protein after just 60 minutes (Figure 3.6A-B). This increase in 
protein correlated with EGR1 mRNA levels post anti-IgM stimulation. Second, at 
doses > 20 µM we observed a marked loss of EGR1 protein. These doses are 
relevant, as across all other experiments we employed a dose of 25 µM DAPKi. 
Between 20-120 µM the loss of EGR1 protein was dose dependent and 
statistically significant (Figure 3.6B). To further reinforce our observations that 
the loss of IEG expression is ZIPK-dependent we probed the same western blots 
with antibody against ZIPK-T265P. As expected, we observed a decrease in 
active ZIPK protein at doses > 20 µM (Figure 3.6A). We therefore demonstrated 
that the loss of EGR1 protein not only correlated with EGR1 mRNA in both a dose 
and time dependent manner, but that it also is directly related to the levels of 
active ZIPK in a particular sample. 
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Figure 3.3: CLL IEG response is dictated by IgHV status of the CLL cells. qPCR data analysis of EGR1 and DUSP2 gene expression 
at 30 (n = 6 patients for U-CLL and n = 4 patients for M-CLL) and 60 minutes (n = 4 patients for U-CLL and n = 3 patients for M-CLL) post 
anti-IgM stimulation in (A) (B) U-CLL or (C) (D) M-CLL cells. Expression changes were quantified using the ∆Ct method with TBP and 
PPP6C as control genes. Bars represent the grand mean of the samples. Significant differences calculated using two-way ANOVA followed 
by Dunnett’s multiple comparison test with unstimulated as control. U-CLL (EGR1) P values = 0.1961 & 0.0095 for no stim vs 30 m and 60 
m respectively. U-CLL (DUSP2) P values = 0.4818 & 0.0317 for the same comparisons. M-CLL P values not listed for clear insignificance. 
  
  
 
84 
 
 
Figure 3.4: CLL IEG response is dictated by IgHV status of the CLL cells. qPCR data analysis of EGR1 and DUSP2 gene expression 
at 30 (n = 3 patients for U-CLL and M-CLL) and 60 minutes (n = 3 patients for U-CLL and M-CLL) post anti-IgM (M) or anti-IgD (D) 
stimulation in (A) (B) U-CLL or (C) (D) M-CLL cells. CLL cells were pre-treated with ibrutinib or DAPKi for 1 hour as indicated below the 
graphs. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. Bars represent the grand mean 
of the samples. Significant differences calculated using two-way ANOVA followed by Dunnett’s multiple comparison test with unstimulated 
as control. U-CLL (EGR1, 30m) P values = 0.0001 & 0.0031 for no stim vs anti-IgM and anti-IgD respectively. U-CLL (EGR1, 60m) P values 
= 0.0001 & 0.0905 for the same comparisons. U-CLL (DUSP2, 30m) P values = 0.0001 & 0.9996 for no stim vs anti-IgM and anti-IgD 
respectively. U-CLL (DUSP2, 60m) P values = 0.0001 & 0.9999 for the same comparisons. M-CLL (EGR1, 30m) P values = 0.2942 & 
0.0046 for no stim vs anti-IgM and anti-IgD respectively. M-CLL (EGR1, 60m) not significant. M-CLL (DUSP2, 30m) P values = 0.9902 & 
0.0099 for no stim vs anti-IgM and anti-IgD respectively. M-CLL (DUSP2, 60m) not significant. 
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Figure 3.5: ZIPK inhibition mimics ibrutinib in inhibiting CLL IEG expression. qPCR data analysis of EGR1 and DUSP2 gene 
expression at 30 (n = 6 patients for U-CLL and n = 4 patients for M-CLL) and 60 minutes (n = 4 patients for U-CLL and n = 3 patients for 
M-CLL) post anti-IgM stimulation in (A) (B) U-CLL or (C) (D) M-CLL cells. CLL cells were pre-treated with ibrutinib or DAPKi for 1 hour as 
indicated below the graphs. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. Bars 
represent the grand mean of the samples. Significant differences calculated using two-way ANOVA followed by Dunnett’s multiple 
comparison test with anti-IgM as control. Patient 4 excluded from statistical analysis for M-CLL like anti-IgM response despite U-CLL 
classification. EGR1 (30 m) P values = 0.0009, 0.0015 & 0.0009 for anti-IgM vs Unstim, Ibr and DAPKi respectively. DUSP2 (30 m) P 
values = 0.0013, 0.0023 & 0.0011 for the same comparisons. EGR1 (60 m) P values = 0.0039, 0.0052 & 0.0052 for the same comparisons. 
DUSP2 (60 m) P values = 0.0204, 0.0269 & 0.0205 for the same comparisons. M-CLL P values not listed for clear insignificance. 
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Figure 3.6: ZIPK inhibition reduces the amount of EGR1 protein in CLL cells. (A) (B) Representative western blots displaying levels 
of EGR1 and ZIPK-T265-P in CLL cells pre-treated with 0-120 μM DAPKi for 60 mins and then stimulated with anti-IgM stimulation for 60 
mins. β-actin was used as a loading control. Blots are normalised to unstimulated sample (unstimulated = 1.0) with Image Lab software 
(below). Error bars are representative of 3 independent experiments. Significant differences calculated using two-way ANOVA followed by 
Dunnett’s multiple comparison test with anti-IgM stimulated 0 µM sample as control. P values = 0.0076, 0.0256 & 0.0087 for unstimulated 
0 and 80 and 120 µM samples respectively.  
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3.3 The effects of BCR pathway activation on immediate early 
gene expression in lymphoid cell lines 
Having characterised the IEG response of CLL cells in the context of BTK and 
ZIPK inhibition (Figure 3.5), we sought to select a cell line which would show the 
classical response of rapid but transient expression in order to carry out future 
experiments in a representative system. The resistance of primary CLL cells to 
viral transformation by Epstein-Barr virus (EBV) has been cited as a reason for 
the lack of cell line models which accurately represent the disease [246-248]. 
MEC1, the most well characterised CLL cell line, has the molecular features of a 
high risk U-CLL patient, including TP53 mutation, and lacks many of the other 
primary characteristics of clinical CLL [249]. Therefore, raji (EBV positive Burkitt’s 
lymphoma), ramos (EBV negative Burkitt’s lymphoma) and HBL1 (human diffuse 
large B cell lymphoma) cell lines were stimulated with anti-IgM F(ab’)2 fragment 
in order to crosslink the BCR and promote IEG expression. EGR1 and DUSP2 
gene expression was measured over time with real-time/quantitative-PCR 
(qPCR) (Figure 3.7A-C). 
 
Raji cells displayed a constitutive/underlying baseline expression of both genes 
in the absence of anti-IgM, which could be increased to higher expression levels 
with stimulation (Figure 3.7A). Ramos and HBL1 cells showed low/negligible 
levels of both genes which were dramatically increased with anti-IgM stimulation 
of the BCR – suggestive of a better model for an inducible system (Figure 3.7B-
C). Ramos cells showed upregulation of both EGR1 and DUSP2 mRNA just 15 
minutes after anti-IgM stimulation. This expression peaked at 30 minutes and 
decreased between 45-90 minutes and the induction kinetics for both genes were 
similar. Compared to ramos, HBL1 cells displayed slightly more baseline 
expression of both genes, similar to raji. However, the subsequent ceiling for 
mRNA expression post anti-IgM stimulation in HBL1 cells was almost double that 
observed in raji relative to the expression baseline (102.6% increase in HBL1 0-
30 mins compared to 61% in raji at 30 minutes post stimulation). The experiments 
with HBL1 cells included less timepoints – guided by the observations in raji and 
ramos cells suggesting the primary expression changes occur between 0-60 
minutes. The level of DUSP2 expression was generally higher in raji cells 
compared to the other cell lines. 
 
Based on these data we rejected raji cells owing to their high baseline expression 
and poor inducibility, while both ramos and HBL1 show a more usable IEG 
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response. In order to further classify which of these cell lines is most CLL-like 
with regard to IEG expression, we proceeded to assess the effects of treating 
ramos and HBL1 with ibrutinib and the DAPKi.  
 
3.3.1 The effects of BTK and ZIPK inhibition on BCR-mediated 
immediate early gene expression in lymphoid cell lines  
We have observed an effect of ibrutinib and the DAPKi on the expression of IEGs 
in CLL cells (Figure 3.5). Therefore, we similarly sought to examine the effects of 
ibrutinib and the DAPKi on BCR-mediated IEG expression, in order to utilise a 
cell line with the closest similarities to the primary patient material. 
 
Since ramos and HBL1 cells show the most promising IEG response (see Figure 
3.7), we pre-treated both cell lines with either ibrutinib or the DAPKi and assessed 
the levels of EGR1 and DUSP2 gene expression. Initially, we chose to examine 
the effects of these inhibitors at both 30 and 60 minutes post anti-IgM stimulation 
in HBL1 cells and at 60 minutes only in ramos cells. These times were selected 
as they were shown to be timepoints at which high expression of both genes was 
expected (see Figure 3.7).  
 
For HBL1 cells: the ibrutinib pre-treatment did little to prevent IEG expression, 
while DAPKi treatment prevented EGR1 and DUSP2 gene expression to levels 
comparable to the reduction observed in CLL cells i.e. unstimulated baseline 
(Figure 3.8A-B). Ibrutinib had a small but non-significant (p = 0.9960 for EGR1 
and p = 0.0599 for DUSP2) effect on IEG gene expression. In contrast, the DAPKi 
was consistently able to completely prevent IEG expression in HBL1 cells (p = 
0.0058 for EGR1 and p = 0.0002 for DUSP2). These observations suggest that 
the regulation of these exemplary IEGs is more dependent on ZIPK than BTK in 
HBL1 cells. The fact that HBL1 cells are relatively unaffected by ibrutinib 
treatment may be due to compensation from other transcription factors: while CLL 
cells rely greatly on BTK-mediated activation of transcription factors, HBL1 cells 
carry a MYD88-mutation leading to hyperactivation of NF-κB subunits [250]. 
 
For ramos cells: neither inhibitor was able to prevent IEG expression following 60 
minutes pre-treatment (Figure 3.9B). Following this observation, we decided to 
pre-treat ramos cells with ibrutinib and the DAPKi for 30 minutes and 120 
minutes, to evaluate whether shorter or longer incubation times may affect the 
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drug’s efficacy (Figure 3.9A-C). Additionally, in a further attempt to prevent ramos 
IEG expression we also treated the cells with cucurbitacin, an inhibitor of STAT3 
(STAT3i), a transcription factor and known ZIPK binding partner (Figure 3.9A-C) 
(see 1.5.6 for the relationship between ZIPK and STAT3).  
 
The response to all three inhibitors (ibrutinib, DAPKi & STAT3i) was mixed across 
all inhibition time points (30, 60 & 120 minutes). In most cases there was no effect 
in decreasing IEG expression while in some cases we observed an increase in 
gene expression, especially in those ramos cells pre-treated with the STAT3i. We 
believe that the lack of effect seen with ibrutinib and the DAPKi compared to CLL 
cells or even HBL1 may be due to the multitude of alternative signalling pathways 
which are active in ramos cells. Further, by inhibiting STAT3, we may have 
encouraged the cells to upregulate other transcription factors to compensate for 
its loss. 
 
Based on the results of these experiments, ramos cells provide an ideal model to 
study anti-IgM mediated activation of the BCR, owing to a rapid but transient IEG 
response, but are not adequate to assess the effects of BTK or ZIPK inhibition. 
HBL1 cells are a good anti-IgM responding cell line which is susceptible to ZIPK 
inhibition, and while slightly less sensitive to ibrutinib, are is the most similar to 
CLL cells for our criteria.  
 
3.3.1.1 The effects of STAT3 inhibition on IEG expression in CLL cells  
When treating ramos cells with a STAT3i (Figure 3.9), we observed that the 
inhibitor was not particularly effective at preventing IEG expression. Additionally, 
the STAT3i seemed to have the opposite effect in some cases, resulting in an 
increase in IEG expression, contrary to our initial hypothesis, that inhibition of 
STAT3 may be comparable to inhibition with ibrutinib or the ZIPK inhibitor. 
 
In order to understand the puzzling results in ramos cells, we wanted to compare 
the effect of the STAT3i in patient CLL cells. Primary cells from 4x U-CLL patients 
(P2-5) were pre-treated with either ibrutinib, the DAPKi or the STAT3i for 60 
minutes before stimulation with anti-IgM. EGR1 and DUSP2 gene expression 
was measured by qPCR (Figure 3.10A-B). For both genes, while STAT3i does 
reduce their expression somewhat, the inhibitor is generally less effective than 
either ibrutinib or the DAPKi. In one patient (P5, orange circle), we observed an 
increase in IEG expression as previously seen in ramos cells. For both genes, 
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this increase is more than double the effect seen from anti-IgM stimulation itself. 
We conclude that, similar to ramos cells, the inhibition of STAT3 may alter the 
balance between transcription factors and encourage compensation from others. 
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3.3.2 Assessing the level of ZIPK protein in lymphoid cell lines 
HBL1 and ramos cells responded differently to ZIPK inhibition: while the former 
showed a convincing loss of IEG expression, ramos cells did not respond well to 
DAPKi treatment and we did not observe a strong repression of EGR1 and 
DUSP2 expression (see Figure 3.8 & Figure 3.9). In order to understand this 
response, we sought to quantify the levels of ZIPK protein in each cell line. We 
took HBL1, ramos, raji and, for comparison, U-CLL and M-CLL cells and lysed 
them for western blot analysis. Following SDS-PAGE the blot was probed with 
antibody against ZIPK (Figure 3.11A). 
 
The western blot data showed varying levels of ZIPK expression across the cell 
lines and the absolute level of ZIPK protein may predict the efficacy of the DAPKi 
in preventing ZIPK kinase activity. Of note, ramos displayed the highest level of 
ZIPK – perhaps explaining the ineffectiveness of the DAPKi in preventing IEG 
expression. M-CLL cells showed the lowest levels of ZIPK but we do not see 
great differences between the effectiveness of the DAPKi in U-CLL vs M-CLL as 
it works well in both cases (excluding patient 9). HBL1 and raji cells had similar 
levels of ZIPK protein and are closest to the CLL cells (U-CLL in particular). This 
may explain the relative efficacy of the DAPKi in preventing IEG expression in 
HBL1 cells. We did not test the DAPKi in raji cells owing to their high baseline 
IEG expression.  
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Figure 3.7: IEG expression response in lymphoid cell lines. qPCR data analysis of EGR1 and DUSP2 gene expression at 0-90 minutes 
post anti-IgM stimulation in (A) raji, (B) ramos and 0-60 minutes in (C) HBL1 cells. Cells were taken at indicated time points for RNA 
extraction and qPCR analysis. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. Error 
bars are representative of 3 individual stimulations.  
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Figure 3.8: IEG response in HBL1 cells. qPCR data analysis of (A) EGR1 (n = 3 independent stimulations at 60 m) and (B) DUSP2 (n = 
4 independent stimulations at 60 m) gene expression in HBL1 cells pre-treated with ibrutinib or DAPKi for 60 mins and then stimulated with 
anti-IgM for 30-60 mins. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. Bars represent 
the grand mean of the samples. Significant differences calculated using two-way ANOVA followed by Dunnett’s multiple comparison test 
with anti-IgM as control. EGR1 (60 m) P values = 0.0018, 0.9960 & 0.0058 for anti-IgM vs no stim, Ibr and DAPKi respectively. DUSP2 (60 
m) P values = 0.0002, 0.0599 & 0.0002 for the same comparisons.  
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Figure 3.9: IEG response in ramos cells. qPCR data analysis of EGR1 and DUSP2 gene expression at 60 minutes post-IgM stimulation 
in ramos cells. Cells were first (before stimulation) pre-treated with either ibrutinib, the DAPKi or a STAT3i, as indicated, for either (A) 30 
(B) 60 or (C) 120 minutes. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. 
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Figure 3.10: ZIPK inhibition mimics ibrutinib in inhibiting CLL IEG expression, while S3i is less effective. qPCR data analysis of (A) 
EGR1 and (B) DUSP2 gene expression in U-CLL cells (n = 4 U-CLL patients) pre-treated with ibrutinib, STAT3i or DAPKi for 60 mins and 
then stimulated with anti-IgM for 60 mins. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control 
genes. 
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Figure 3.11: ZIPK expression in CLL and lymphoid cell lines. (A) Representative western blot displaying levels of ZIPK in unstimulated 
U-CLL, M-CLL, raji, ramos and HBL1 cells. CLL cells are representative of an individual patient while the western blot is representative of 
2 individual experiments where patients P5 and P10 (U-CLL) and patients P6 and P9 (M-CLL) were assessed. β-actin was used as a 
loading control. 
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3.4 The effects of ZIPK knockdown on global histone 
phosphorylation and immediate early gene expression 
We have observed that ZIPK inhibition is as effective as BTK inhibition in 
preventing IEG expression in CLL cells and HBL1 cells (see Figure 3.5 & Figure 
3.8). Ibrutinib, alone or in combination with other inhibitors, is the current gold 
standard treatment option for patients suffering from CLL. Accordingly, ibrutinib 
is a highly optimised drug with limited off-target effects and high specificity for 
BTK, providing a robust loss of enzymatic activity. The DAPKi, while reported to 
be selective for DAPK1 and DAPK3 over numerous other kinases, has the 
potential for more off-target effects due to its non-clinical nature. For these 
reasons, and in order to gain more insight into the cellular consequences of ZIPK 
loss, we decided to knockdown ZIPK in the HBL1 cell line via small interfering 
RNA (siRNA) and assess the effect on IEG expression. The HBL1 cell line was 
chosen for its similarities to CLL cells in the context of IEG expression and 
inhibition (see 1.1). 
 
HBL1 cells were electroporated with siRNAs directed against ZIPK and a 
negative control siRNA – an siRNA with a sequence that does not target any 
gene product to provide a baseline to compare siRNA-treated samples. In order 
to confirm the effectiveness of the knockdown, cells were taken for analysis at 
day 3 and day 5. These samples were lysed and ZIPK protein levels were 
assessed via SDS-PAGE and western blot using antibodies against ZIPK and 
ZIPK T265-P. By day 5, of the two siRNAs which were tested, both were able to 
reduce the protein levels of ZIPK and ZIPK T265-P compared to the negative 
control, with siRNA #2 the more efficient of the pair (Figure 3.12A-B). 
 
Next, we examined the effect of ZIPK knockdown on its downstream histone 
targets, H3T6-P and H3T11-P (Figure 3.12C). Western blot analysis revealed a 
loss of both histone marks with either siRNA, giving further evidence to our initial 
observations that ZIPK is indeed the histone kinase responsible for the 
phosphorylation of these targets.  
 
In order to assess the functional consequences of knocking down ZIPK with 
regard to IEG expression, we stimulated siCtrl and siZIPK-transfected HBL1 cells 
with anti-IgM 5 days post-transfection and assessed the levels of EGR1 and 
DUSP2 gene expression via qPCR (Figure 3.13A-B). For those cells transfected 
with the siRNA control, anti-IgM stimulation increased IEG expression as 
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expected. In contrast, cells which carried the ZIPK knockdown failed to induce 
expression of EGR1 and DUSP2 in response to BCR crosslinking via anti-IgM. It 
is important to note that while the reduction in gene expression was significant it 
was not as pronounced as the effect we observe when treating CLL or HBL1 cells 
with a DAPKi. Still, these data reinforced our observations that the DAPKi mimics 
ibrutinib in its ability to prevent the expression of genes important to CLL 
progression, and further highlights the role of ZIPK as a transcriptional co-
regulator. 
 
3.4.1 The effects of ZIPK inhibition on global histone H3T6 and H3T11 
phosphorylation 
Having observed that siRNA-mediated knockdown of ZIPK resulted in a loss of 
global H3T6-P and H3T11-P, we sought to compare this with the effects of the 
DAPKi. We aimed to further improve our confidence that using the inhibitor to 
prevent ZIPK activity is comparable to the effects of a loss of ZIPK protein via 
siRNA. Therefore, we pre-treated HLB1 cells (as it was the cell line used for the 
siRNA transfection) with increasing concentrations of the DAPKi (10-120 µM) for 
60 minutes before stimulation with anti-IgM to activate the BCR. Cells were lysed 
60 minutes post stimulation for SDS-PAGE and western blot analysis with 
antibodies against H3T6-P and H3T11-P (Figure 3.14A-B).  
 
In general, DAPKi treatment did reduce levels of H3T6-P and H3T11-P when 
compared with non-DAPKi treated samples (0 µM with or without anti-IgM 
treatment i.e. first two bands). We do not see a noticeable increase in either 
histone mark with anti-IgM stimulation at the global level. We hypothesise there 
may be rapid but transient increases in histone phosphorylation specifically in 
and around the loci of key IEGs which we suggest may be more visible via 
chromatin immunoprecipitation analysis and is not reflected in a western blot. 
Finally, the DAPKi-mediated loss of histone phosphorylation was not dose 
dependent e.g. we see the greatest loss of H3T6-P between 20-40 µM with partial 
recovery at 80 µM. H3T11-P follows a similar trend with less pronounced 
differences. This suggests that while the presence of the DAPKi is detrimental to 
H3T6-P and H3T11-P it is not strictly related to dose and the observed differences 
may be explained by other cellular factors e.g. cell cycling. 
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3.5 ZIPK directly interacts with histone H3 to phosphorylate 
H3T6 and H3T11 
Based on our observations that ZIPK’s ability to phosphorylate H3T6 and H3T11 
is stymied by ZIPK inhibition (3.1)  or ZIPK knockdown (3.4.1) we hypothesised 
that ZIPK that may interact with histone H3 directly to catalyse the reaction. We 
also considered early literature which suggested ZIPK was a chromatin-
associated kinase [229]. Despite this, we did not necessarily expect a positive 
result as the protein-protein interactions necessary for phosphorylation are often 
transient owing to the rapid nature of the modification, as seen in signalling 
cascades. To assess the interaction, HBL1 cells were stimulated with anti-IgM for 
60 minutes and then lysed for co-immunoprecipitation (co-IP). The lysates were 
incubated with protein G magnetic beads and then immunoprecipitated with 
antibody against histone H3. The interaction was examined by SDS-PAGE and 
western blot, using antibodies against both ZIPK and ZIPK-T265P (Figure 3.15A).  
 
In assessing the results of the co-IP, we firstly observed an increase in the level 
of active ZIPK-T265-P in the input (untreated crude cell lysate e.g. a positive 
control for the presence of ZIPK in the sample). The IgG-immunoprecipitates 
showed a negative interaction (negative control for non-specific binding). For the 
co-IP itself, the interaction between total ZIPK and histone H3 was largely 
negative, or very faint. However, we observed a positive result, suggesting strong 
interaction, with active/phosphorylated ZIPK and histone H3, regardless of anti-
IgM stimulation of the BCR. This suggests that ZIPK specifically interacted with 
chromatin when it was enzymatically active, or that a closed chromatin 
configuration makes it difficult to pull down inactive ZIPK. 
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Figure 3.12: ZIPK knockdown reduces level of ZIPK and its histone targets. Western blots of HBL1 cells transfected with siRNAs 
against ZIPK (#1 and #2) and with a non-specific control siRNA (siCtrl). On day 5 post transfection cells were harvested and lysates probed 
with antibodies against (A) ZIPK, ZIPK-T265-P, (C) histone H3T6-P and histone H3T11-P. (B) β-actin was used as a loading control and 
for normalisation to siCtrl using Image Lab software (right). Blots are representative of 3 independent transfections. Significant differences 
calculated using two-way ANOVA followed by Dunnett’s multiple comparison test. P values for ZIPK expression normalised to siCtrl = 
0.0036 & 0.0004 for siCtrl vs. siZIPK #1 & siZIPK #2 respectively. 
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Figure 3.13: ZIPK knockdown mimics DAPKi treatment in preventing IEG expression. qPCR analysis of (A) EGR1 and (B) DUSP2 
gene expression in HBL1 cells transfected with siRNAs against ZIPK (#1 and #2) and with a non-specific control siRNA (siCtrl). On day 5 
post transfection, HBL1 cells were stimulated with anti-IgM for 1 hour and then harvested for analysis. Expression changes were quantified 
using the ∆Ct method with TBP, GAPDH and PPP6C as control genes. Error bars representative of 3 independent transfections. Significant 
differences calculated using two-way ANOVA followed by Dunnett’s multiple comparison test with anti-IgM stimulated siCtrl as control. P 
values for EGR1 = 0.0082 & 0.0009 for siCtrl vs. siZIPK #1 & siZIPK #2 respectively. P values for DUSP2 = 0.8242 and 0.0995 for the 
same comparisons. 
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Figure 3.14: ZIPK inhibition reduces levels of H3T6-P and H3T11-P. Western blots displaying levels of (A) H3T11-P and (B) H3T6-P in 
untreated CLL cells vs. CLL cells treated with 0-80 μM DAPKi for 60 mins before anti-IgM stimulation of the BCR for a further 60 mins. 
Western blot is representative of 2 individual experiments in CLL cells. Histone H3 was used as a loading control. 
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Figure 3.15: ZIPK directly interacts with histone H3 to phosphorylate histones. (A) Co-immunoprecipitation of CLL cells stimulated 
with anti-IgM for 60 mins as indicated. Immunoprecipitates from histone H3 pulldown were analysed by SDS-PAGE followed by Western 
blot probing for ZIPK-T265P. Untreated, crude cell lysate was used as positive control (input) and IgG beads were used for negative control 
(Ctrl IgG). Blot is representative of 3 independent co-IP experiments. Western blot is cropped due to different exposure times for input and 
co-IP lysates. 
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Chapter 4 Results 2: ZIPK is required for the effective 
transcription of critical CLL immediate early genes  
Transcriptional regulation is not solely dependent on transcription factor-promoter 
binding but involves a host of transcriptional co-activators, co-repressors and 
chromatin remodelling enzymes which mediate the dynamic processes 
controlling transcription. 
 
4.1 The dynamic interaction between ZIPK and STAT3 
Signal transducer and activator of transcription 3 (STAT3) is a well-known 
member of the STAT3 protein family. These proteins are transcription factors 
which mediate a variety of critical cellular pathways and mechanisms with 
functions ranging from growth, proliferation and programmed cell death [238]. 
STAT3 plays an important role in the development of healthy B cells and it is often 
seen overexpressed in a variety of cancers [251], including CLL [111, 116, 252, 
253]. It has been well demonstrated that STAT3 is activated downstream of the 
BCR signalling pathway [115] and numerous proteins have been shown to 
interact with STAT3 to regulate its activity through controlling when and where 
STAT3 signalling is required. This can include mediating STAT3 crosstalk with 
other signalling pathways and guiding STAT3 to activate transcription at its target 
binding sequences [254]. 
 
ZIPK has been reported to preferentially (over other STATs) interact with and 
phosphorylate STAT3 specifically at its serine 727 residue (STAT3 S727-P) 
[116]. This finding was of particular interest to us as in CLL patients STAT3 is 
preferentially and constitutively phosphorylated at S727 over its typical 
phosphorylation sites such as tyrosine 705 (STAT3 Y705-P). These observations 
led us to consider the ZIPK-STAT3 interaction in CLL. We hypothesised that the 
loss of IEG expression seen in the context of ZIPK inhibition may be linked to the 
ZIPK-STAT3 interaction, and that STAT3 may well be a candidate transcription 
factor responsible for the activation of our IEGs of interest. In summary, while the 
ZIPK-STAT3 interaction and STAT3 S727-P have been implicated in CLL as 
separate entities, and both ZIPK and STAT3 have been reported to be 
upregulated in CLL, at time of writing there is no literature on the interaction 
between ZIPK and STAT3 in CLL. 
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4.1.1 STAT3 is activated in response to BCR signalling  
In order to begin studying the ZIPK-STAT3 interaction in CLL, we first wanted to 
understand the kinetics of STAT3 activation after stimulation of the BCR via anti-
IgM stimulation. For this, CLL and HBL1 cells (cell line chosen for its similarities 
to CLL cells – see Chapter 3 Results 1) were stimulated with anti-IgM for 30 
minutes before lysis for western blot analysis. Blots were probed with antibodies 
against total STAT3, STAT3 Y705-P and/or STAT S727-P.  
 
In HBL1 cells, we observed a marked increase in STAT3 S727-P by 30 minutes 
with even greater levels of phosphorylation by 60 minutes (Figure 4.1A). In 
contrast, STAT3-Y705-P had slower kinetics showing no increase in 
phosphorylation until 60 minutes – at which point it was comparable to the levels 
of STAT3-S727-P (Figure 4.1A). We hypothesise this may suggest a sequential 
activation of phosphorylation sites on STAT3 in response to BCR activation in 
HBL1 cells. In CLL cells we saw a moderate increase in the levels of STAT3-
S727-P in response to anti-IgM signalling at 30 minutes post-stimulation (Figure 
4.1B), this is similar to the response observed in HBL1 cells. These data 
suggested a rapid activation of STAT3 signalling in response to anti-IgM 
stimulation of the BCR and confirmed that STAT3 is activated downstream of the 
BCR in HBL1 and CLL cells. 
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Figure 4.1: STAT3 is activated by BCR signalling in HBL1 and CLL cells. Western blot showing levels of STAT3 phosphorylation at 
tyrosine 705 and serine 727 in (A) HBL1 and (B) CLL cells. HBL1 and CLL cells were treated with anti-IgM as indicated and harvested at 
30 and/or 60 minutes. β-actin was used as a loading control. 
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4.1.2 ZIPK interacts directly with STAT3 in CLL cells and lymphoid 
cell lines 
In order to assess the interaction between ZIPK and STAT3 in the context of CLL 
and BCR signalling, we stimulated CLL cells with anti-IgM for 30 minutes and 
lysed the cells for reciprocal co-IP. The lysates were incubated with Protein G 
magnetic beads and then immunoprecipitated with antibodies against ZIPK and 
STAT3. STAT3 immunoprecipitates were analysed by SDS-PAGE with anti-ZIPK 
antibody and ZIPK immunoprecipitates with anti-STAT3 antibody. Input samples 
corresponding to untreated CLL cell lysate (with and without anti-IgM stimulation) 
were run as a positive control (no inputs were included for the ibrutinib/DAPKi 
conditions due to 1) limited CLL cell counts and 2) lack of physical space on the 
gel to run all the samples simultaneously). SDS-PAGE and western blot analysis 
showed that ZIPK and STAT3 complex together in CLL cells (Figure 4.2A-B). The 
interaction could be slightly strengthened by anti-IgM stimulation of the BCR, 
suggesting a functional impact of BCR cross-linking on the ZIPK-STAT3 
interaction. In the STAT3 pull-down, we saw the most pronounced anti-IgM 
dependent increase in the ZIPK-STAT3 interaction (Figure 4.2B upper panel).  
 
We next assessed the interaction between STAT3 and active ZIPK 
phosphorylated at T265 (Figure 4.2B). When specifically probing for 
phosphorylated ZIPK the interaction was weaker and could not be as clearly 
increased by anti-IgM stimulation. We also pulled down with phosphorylated 
STAT3 (STAT-S727-P) and assessed its interaction with phosphorylated ZIPK 
(Figure 4.2C). While the proteins still appeared to interact, we did not observe the 
anti-IgM dependent increase as seen above. 
 
To remain consistent in our assessment of HBL1 cells, we also sought to examine 
the ZIPK-STAT3 interaction in this cell line. We first assessed the interaction 
between active ZIPK and both total STAT3 and STAT3-S727-P (Figure 4.2D). In 
HBL1, we observed ZIPK-STAT3 interaction and although it appeared weaker 
than in CLL, the interaction remained anti-IgM dependent. We also observed an 
increase in the interaction when we performed ZIPK-T265-P pull-down and 
assessed binding of STAT3-S727-P. We have shown that upon anti-IgM 
stimulation of the BCR, STAT3-S727-P levels are increased in CLL cells (Figure 
4.1B). This suggested that not only is more STAT3 phosphorylated as a result of 
BCR crosslinking, but that more of the active protein then interacted with ZIPK 
and ZIPK-T265-P. We also sought to examine this interaction reciprocally, pulling 
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down with STAT3-S727-P antibody and assessing the levels of total ZIPK and 
ZIPK-T265-P (Figure 4.2E). In these experiments, the interaction remained anti-
IgM dependent for the two phosphorylated proteins (Figure 4.2E lower panel), but 
was clearly weaker between STAT3 S727-P and total ZIPK (Figure 4.2E upper 
panel).  
 
We also assessed the interaction in ramos cells. When pulling down with total 
ZIPK and assessing the interaction of STAT3 and STAT3-S727-P we observed 
a strong anti-IgM dependent increase (Figure 4.2F). We did not observe an anti-
IgM dependent increase in the reciprocal experiment when pulling down with 
STAT3 antibody (Figure 4.2G). The cuts between input/IgG/pull-down in the co-
IP western blots shown in Figure 4.2 & Figure 4.3 are due to either having to alter 
the saturation for faint input samples or were necessary to re-order the bands in 
order to maintain consistency between sample/condition order across the figures. 
Full, un-cut co-IP western blots can be found in Appendix 8.2. 
 
4.1.3 ZIPK-STAT3 interactions are inhibited by both BTK and ZIPK 
inhibition 
Having shown that BCR stimulation could promote ZIPK-STAT3 interactions in a 
seemingly functional, anti-IgM dependent manner, we sought to understand if this 
interaction was preventable though inhibition of either ZIPK or BTK function. 
Therefore, we pre-treated CLL cells with either ibrutinib or the DAPKi for 1 hour 
before anti-IgM stimulation. After 45 minutes the cells were then lysed for co-IP. 
In our first experiment we sought to assess the interactions reciprocally between 
total ZIPK and STAT3 (Figure 4.3A-B). First, we confirmed our observations from 
the previous experiment that anti-IgM stimulation increased the ZIPK-STAT3 
interaction. When the CLL cells were pre-treated with ibrutinib the interaction 
appeared to increase, but only after anti-IgM stimulation. We observed little effect 
on the interaction for CLL cells pre-treated with the DAPKi. Of note, when we 
pulled down with ZIPK and assessed the total STAT3 interaction we observed 
that addition of the DAPKi reduced the interaction to a level comparable with the 
unstimulated control: but only in the presence anti-IgM stimulation 
 
Our previous experiments have indicated that in examining the interaction 
between the phosphorylated proteins we observed the largest variation after anti-
IgM stimulation (Figure 4.2D lower panel, Figure 4.2E lower panel, Figure 4.2F), 
suggesting that it may be the active, phosphorylated forms of the proteins which 
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play the most dynamic roles in the interaction and are the most important 
functionally. Therefore, we decided to assess the interactions between ZIPK and 
ZIPK-T265-P and STAT3-S727-P (Figure 4.3C-D). We observed the expected 
increase in the level of STAT3-S727-P in both inputs following anti-IgM 
stimulation, indicating the CLL cells have been activated. The co-IP showed the 
expected increase in ZIPK-STAT3-S727-P interaction following anti-IgM 
stimulation (Ctrl). The addition of ibrutinib or the DAPKi resulted in a decrease in 
interaction, with the greatest loss observed after DAPKi treatment. When the CLL 
cells were not stimulated with anti-IgM both inhibitors showed less of an impact 
on ZIPK and STAT3-S727-P interaction. 
 
We saw similar results for the ZIPK-T265-P immunoprecipitates (Figure 4.3D). 
Anti-IgM stimulation increased the interaction between active ZIPK-T265-P and 
active STAT3-S727-P (Ctrl). The addition of ibrutinib decreased this interaction 
to a level comparable with unstimulated cells without drug treatment (Ctrl; no 
stim). Ibrutinib treatment also reduced the interaction in absence of anti-IgM 
stimulation, in contrast with the results we obtained with total ZIPK where no 
change in interaction was observed (Figure 4.3A-B).  
 
4.1.4 The effect of ZIPK inhibition on STAT3 phosphorylation in CLL 
and lymphoid cells 
We have demonstrated that STAT3 is activated in response to anti-IgM 
stimulation, with residues Y705 and S727 showing phosphorylation after 30-60 
minutes (Figure 4.3).  Further, activation of BCR signalling increased the 
interaction between STAT3 and ZIPK and this could be inhibited by ibrutinib or 
DAPKi treatment (Figure 4.2 & Figure 4.3). Consequently, we wanted to assess 
whether or not inhibition of ZIPK would impact STAT3 phosphorylation directly, 
perhaps providing an explanation for the loss in interaction. CLL, ramos and 
HBL1 cells were pre-treated with increasing concentration of the DAPKi (10-120 
µM) for 60 minutes before stimulation with anti-IgM. Cells were lysed for western 
blot analysis, probing with antibody against STAT3 S727-P. 
 
For both CLL and HBL1 cells, we observed only a small decrease in STAT3 
phosphorylation in response to ZIPK inhibition, which was most evident only at 
the highest concentration (120 µM) (Figure 4.4A-B). Overall this decrease was 
not significant and it appeared that while ZIPK inhibition could impact ZIPK-
STAT3 interaction, the level of phosphorylation was not affected. Further, the 
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anticipated activation of STAT3 S727-P, as seen previously (Figure 4.1), was not 
observed, with the cells having been stimulated for 30 minutes in both 
experiments. These data demonstrated the heterogenous response of different 
CLL patients to anti-IgM stimulation of the BCR – it is possible we may have 
observed a stronger STAT3 S727-P response after 60 minutes. 
 
Next, we wanted to compare these data with the same experiments performed in 
ramos cells, which we have already shown to have a very robust anti-IgM 
response. In ramos, STAT3 S727-P was not inducible and increasing the 
concentration of DAPKi increased the amount of STAT3 S727-P (Figure 4.4C). 
This result was unexpected, and to assess this further we examined the same 
ramos lysates for STAT3 Y705-P. Interestingly, we observed the same trend for 
this phosphorylation mark, although Y705-P was slightly more inducible by anti-
IgM stimulation (Figure 4.4C). Indeed, when quantified, the level of STAT3 Y705-
P correlated with the dose of DAPKi. In an effort to understand these data, we 
also assessed the levels of ZIPK T265-P in response to the inhibitor to confirm 
its specific function in this cell type (Figure 4.4C). We observed that the 
anticipated decrease in ZIPK T265-P was marginal in ramos cells, suggesting 
that this cell line does not respond well to the DAPKi, especially when compared 
to the data from CLL cells (Chapter 3 Results 1). These data might be explained 
by the gene expression data from ramos cells (Chapter 3 Results 1), whereby 
ZIPK inhibition had either no effect on IEG expression or in some cases, 
increased it. Further, we have shown that of all our tested cell lines and primary 
cells, ramos displayed the highest levels of ZIPK (Figure 3.11), suggesting that 
our DAPKi may have been unable to overcome the high protein expression in this 
cell type. 
 
Based on the data for STAT3 phosphorylation in response to DAPKi from HBL1, 
ramos and CLL cells we concluded that the total loss of IEG expression observed 
in response to the drug is not likely linked to a loss of STAT3 phosphorylation; 
but may still be linked to the reduction in ZIPK-STAT3 interaction observed in our 
co-IP experiments.  
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Figure 4.2: ZIPK and STAT3 interact in CLL and lymphoid cell lines. Co-immunoprecipitation of (A) (B) (C) CLL, (D) (E) HBL1 and (F) 
(G) ramos cells stimulated with anti-IgM for 1 hour as indicated. Immunoprecipitates from ZIPK, STAT3, STAT3 S727-P and ZIPK T265-P 
pulldown were analysed by SDS-PAGE followed by Western blot probing for ZIPK, ZIPK T265-P, STAT3 and STAT3 S727-P. Untreated, 
crude cell lysate was used as positive control (input) and IgG beads were used for negative control (Ctrl IgG). Blots are representative of 
2-3 independent co-IP experiments. Western blots are cropped due to different exposure times between input and co-IP lysates or due to 
the order of samples on the original membrane. See full uncropped examples in Appendix 8.2. 
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Figure 4.3: ZIPK-STAT3 interaction can be prevented by ZIPK or BTK inhibition. Co-immunoprecipitation of (A) (B) (C) (D) CLL cells 
pre-treated with either ibrutinib or DAPKi for 60 mins and then stimulated with anti-IgM for 60 mins as indicated. Immunoprecipitates from 
ZIPK, STAT3 and ZIPK T265-P pulldown were analysed by SDS-PAGE followed by western blot probing for ZIPK, STAT3 and STAT3 
S727-P. Untreated, crude cell lysate was used as positive control (input) and IgG beads were used for negative control (Ctrl IgG). Blots 
are representative of 2 independent co-IP experiments. Western blots are cropped due to different exposure times for input and co-IP 
lysates. (E) Interactions were normalised relative to Ctrl (relative value = 1.0) for quantification using Image Lab software. Western blots 
are cropped due to different exposure times between input and co-IP. Original membranes in panels (A) (B) and (C) were cut between Ctrl, 
Ibr and DAPKi to reorganise the bands for consistency. See full uncropped examples in Appendix 8.2. 
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Figure 4.4: The effects of ZIPK inhibition on STAT3 phosphorylation. (A) western blot displaying levels of STAT3-S727P in HBL1 cells 
pre-treated with 0-120 μM DAPKi for 60 mins and then stimulated with anti-IgM for 30 mins, as indicated. β-actin was used as a loading 
control and for normalisation with Image Lab software (right). (B) western blot displaying levels of STAT3-S727P in CLL cells pre-treated 
with 0-120μM DAPKi for 60 mins and then stimulated with anti-IgM for 30 mins, as indicated. NS, no stimulation. β-actin was used as a 
loading control and for normalisation with Image Lab software (right). (C) western blots displaying levels of STAT3, STAT3-Y705-P, STAT3-
S727-P and ZIPK-T265-P in ramos cells pre-treated with 0-120 μM DAPKi for 60 mins and then stimulated with anti-IgM for 30 mins, as 
indicated. NS, no stimulation. β-actin was used as a loading control and for normalisation with Image Lab software (below).
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4.2 STAT3 binds IEG promoters in response to BCR activation 
We have determined that ZIPK and STAT3 interact after BCR cross-linking in 
CLL cells – an interaction which could be reduced by ibrutinib or DAPKi treatment 
(Figure 4.2 & Figure 4.3). We have shown that ZIPK inhibition could completely 
prevent IEG expression in CLL despite little to no impact on STAT3 
phosphorylation (Chapter 3 Results 1 & Figure 4.4). In order to increase our 
understand of how STAT3 may play a role in the mechanism of IEG-repression 
mediated by DAPKi, we wanted to assess the role of STAT3 in the transcriptional 
regulation of the two IEGs studied.  
 
To understand how a loss of ZIPK function might impact the gene expression of 
our model genes, EGR1 and DUSP2, we assessed STAT3-DNA binding through 
a series of ChIP experiments. STAT3 is a known regulator or EGR1, but not 
DUSP2, which is considered to be regulated by NF-κB family members. 
Therefore, most of the experiments were performed looking at the EGR1 locus. 
We designed a series of primers to cover regions around the loci of both genes 
using publicly available data [255] and ChIP-seq databases [256] as a guide to 
probe for regions where STAT3 was predicted to bind.  
 
Cells from a U-CLL patient (CLL P3) were stimulated with anti-IgM for 60 minutes 
before formaldehyde-induced cross-linking and ChIP analysis using antibodies 
against STAT3 and STAT3-S727-P to pull-down protein-associated DNA of 
interest. The ChIP-qPCR analysis revealed that STAT3 predominantly binds in 
response to BCR crosslinking at a region 1.0 kb upstream (3’) of the EGR1 
transcription start site (TSS) (Figure 4.5A). This region is one of several predicted 
STAT3-binding promoters. There was further STAT3 binding at a predicted 
enhancer region (-6.1 kb) and in the gene body itself (+2.2 kb); yet in both cases 
the enrichment is approximately half of what we observed at -1.0 kb. STAT3-
S727-P had a similar but mirrored profile with strong binding at -6.1 kb and less 
at -1.0 kb, with a comparable amount in the gene body (+2.2 kb) in response to 
anti-IgM stimulation (Figure 4.5A). The fact that the active, phosphorylated form 
of STAT3 preferentially binds the enhancer could have functional consequences 
but this conclusion would require further investigation. 
 
Total STAT3 displayed relatively poor binding at the DUSP2 locus with a two-fold 
increase seen at +4.2 kb from the TSS in absence of stimulation (Figure 4.5B). 
STAT3-S727-P displays moderate binding just downstream of the DUSP2 
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transcription end site (TES; +2.4 kb) (Figure 4.5B). We hypothesised that the 
transcription factor binding observed in the gene bodies of both genes could be 
attributed to the presence of an intronic enhancer [257] or chromatin looping and 
other higher order architectural changes to the epigenetic landscape which may 
bring the promoter region in close contact with the gene body.  
 
4.2.1 The effects of ibrutinib and DAPKi on STAT3 IEG binding 
Having begun to assess STAT3 binding in CLL cells, we moved to examine the 
effect of both the DAPKi and ibrutinib on STAT3-DNA binding at IEG loci. We 
took U-CLL patient cells (CLL P5) and pre-treated them with either ibrutinib or the 
DAPKi for 60 minutes. The cells were then stimulated for a further 60 minutes 
with anti-IgM to activate STAT3. The cells were then crosslinked and lysed for 
ChIP following our standard protocol.  
 
The ChIP-qPCR data for CLL P5 showed some similarities to the data for CLL 
P3: notably that the region -1.0 kb from the EGR1 TSS seemed to be the area of 
most STAT3 enrichment (Figure 4.6A). However, there were also inconsistencies 
when comparing the ChIP data between individual patients, for example: we did 
not observe a BCR-dependent increase in binding for STAT3 or STAT3-S727-P 
and instead observed the presence of STAT3 at the EGR1 locus in absence of 
BCR stimulation. The inhibitors (ibrutinib and the DAPKi) did appear to reduce 
the level of STAT3 binding for STAT3-S727-P but had less effect for total STAT3. 
In this experiment, we also observed a stronger enrichment for STAT3 at the 
DUSP2 locus – with recruitment to the predicted promoter region -0.6 kb 
upstream of the DUSP2 TSS (Figure 4.6B). This recruitment was inhibited by 
both ibrutinib and the DAPKi. However, no binding was observed for 
phosphorylated STAT3 at the DUSP2 locus.  
 
We similarly carried out ChIP-qPCR analysis using HBL1 cells to assess STAT3-
binding. In this experiment, we treated some of the cells with a DAPKi to 
understand whether or not a loss of ZIPK function could impact STAT3 binding. 
While the data were predominantly negative, we observed enrichment of STAT3 
upstream of the EGR1 TSS at -1.3 kb in HBL1 cells (Figure 4.6C). This region is 
300 base pairs upstream of the promoter-associated binding region we observed 
in CLL cells. The purported enhancer was negative for STAT3 binding in HBL1 
cells (data not shown), suggesting this enhancer may be CLL-specific. The 
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DAPKi had a small effect in reducing STAT3 binding, which was slightly reduced 
at the -1.3 kb region upstream of the EGR1 TSS after treatment with DAPKi. 
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Figure 4.5: STAT3 binds IEG promoters in CLL cells. ChIP-qPCR data assessing levels of STAT3 and STAT3 S727-P at the (A) EGR1 
and (B) DUSP2 gene loci at 30 minutes post stimulation with anti-IgM. The values on the x axis refer to specific gene regions relative to 
the transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). CTCF1/3 (C1/C3) were used 
as negative control regions which are not indicated on the gene schematics. Error bars correspond to variations in the ChIP-qPCR repeats. 
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Figure 4.6: STAT3 binds IEG promoters in CLL cells. ChIP-qPCR data assessing levels of STAT3 and STAT3 S727-P at the (A) EGR1 
and (B) DUSP2 gene loci in CLL or (C) HBL1 cells. Cells were pre-treated with either 1 µM ibrutinib (green) or 25 µM DAPKi (red) for 60 
mins as indicated and then stimulated with anti-IgM for 30 mins. The values on the x axis refer to specific gene regions relative to the 
transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). CTCF1/3 (C1/C3) were used as 
negative control regions which are not indicated on the gene schematics. Error bars correspond to variations in the ChIP-qPCR repeats.
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4.3 Combined anti-IgM/CD40L stimulation increases IEG 
expression in an additive and/or synergistic fashion in CLL 
cells and lymphoid cell lines 
Our combined co-IP, western blot and ChIP data for STAT3 suggested it may 
well function as one of the transcription factors responsible for the activation of 
IEGs known to promote CLL cell proliferation. However, it is not STAT3 but NF-
κB subunits which are thought to be the predominant transcription factor acting 
on DUSP2 transcription. Current literature suggests that STAT3-NF-κB crosstalk 
can synergistically promote gene expression in CLL [111, 112, 258] and we 
therefore wanted to probe the effects of activating the NF-κB pathway alongside 
the BCR pathway in our system.  
 
We began by assessing EGR1 and DUSP2 gene expression after addition of both 
CD40L and anti-IgM with the aim of activating both NF-κB subunits and STAT3, 
in the chosen lymphoid cell lines. We have previously assessed that ramos cells 
were the strongest anti-IgM responders (Chapter 3 Results 1) and would provide 
a clear baseline to examine the CD40L effect in IEG expression. Therefore, 
ramos cells were stimulated with anti-IgM, CD40L or both for 0-90 minutes with 
samples taken every 15 minutes for gene expression analysis. Samples were 
lysed for RNA extraction followed by cDNA synthesis and qPCR analysis (Figure 
4.7A). The data in ramos cells showed the classical anti-IgM activation of EGR1 
and DUSP2, which peaked at 30 minutes and gradually decreased over the 90 
minute time-course. CD40L stimulation alone elicited a similar peak expression 
response to anti-IgM with slightly slower kinetics which peaked at 45 minutes for 
both genes. Of note, DUSP2 gene expression showed more than a two-fold 
increase in the context of CD40L stimulation versus anti-IgM stimulation – lending 
credence to our hypotheses that DUSP2 is an NF-κB target gene. When 
combining anti-IgM and CD40L, we observed an additive (30 mins) and 
eventually synergistic (45 mins) expression response for both genes which 
peaked at 45 minutes. Dual stimulation (DS) strongly promoted expression of 
both genes, in comparison to CD40L alone which had a strong effect on DUSP2 
expression only.  
 
Next, we assessed the IEG expression response to CD40L in HBL1 cells (Figure 
4.8A-B). In replicate experiments stimulating HBL1 for 60 mins, we observed the 
same additive effect of CD40L when combined with anti-IgM. As in ramos, 
DUSP2 gene expression displayed the greatest synergistical activation from 
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combining the two stimulants. EGR1 is less CD40L dependent in HBL1 cells than 
in ramos cells, whereby dual-stimulation only marginally increased overall EGR1 
gene expression.  
 
Subsequently, we wanted to assess the CD40L effect in CLL cells (Figure 4.9A-
D). We took the cells from 3 U-CLL (CLL P4, 5 and 7) and 2 M-CLL patients (CLL 
P6 and 8) and stimulated them as described above, taking RNA samples at 30 
and 60 minutes. In the U-CLL cells, the results were similar to HBL1. The qPCR 
data for EGR1 after dual stimulation showed a small additive effect on gene 
expression at 30 minutes which was lost by 60 minutes. DUSP2 however, as in 
HBL1 and ramos cells, showed a strong additive response at 30 and 60 minutes 
with the addition of CD40L with anti-IgM, and a stronger overall response to 
CD40L alone (Figure 4.9A). The M-CLL cells showed a typical non-response to 
anti-IgM but were stimulated by CD40L to levels of gene expression that 
exceeded the small increase seen by the addition of IgD (Chapter 3 Results 1). 
After dual-stimulation, marginally lower gene expression was observed in these 
M-CLL cells (Figure 4.9B). Overall, for both CLL subtypes, DUSP2 gene 
expression benefited primarily from the addition of CD40L while EGR1 remained 
predominantly anti-IgM dependent (Figure 4.9C-D). 
 
4.3.1 ZIPK inhibition can overcome dual anti-IgM/CD40L stimulation 
to reduce IEG expression 
Having determined that dual anti-IgM/CD40L stimulation could boost IEG 
expression in CLL and lymphoid cell lines, we wanted to assess if expression 
could be impacted through pre-treatment with either ibrutinib or the DAPKi. These 
experiments are particularly important in the context of mechanisms of acquired 
resistance to ibrutinib such as activating mutations in signalling pathways parallel 
to the BCR pathway such as the CD40 pathway [143, 146, 147].  
 
We took the cells from 3 U-CLL (CLL P4, 5 and 7) and 2 M-CLL patients (CLL P6 
and 8) and pre-treated them with ibrutinib or the DAPKi for 60 minutes. The cells 
were then stimulated with both anti-IgM and CD40L with samples taken at 30 and 
60 minutes for gene expression analysis. The qPCR data reveals that ZIPK 
inhibition blocked both EGR1 and DUSP2 gene expression (Figure 4.10A-B). 
Both U- and M-CLL cells were affected similarly with all 5 patients showing a 
complete and significant loss of IEG expression. For the cells pre-treated with 
ibrutinib, we observed only a partial reduction of IEG expression (Figure 4.10A-
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B). In conclusion, while these inhibitors had a completely comparable effect when 
used on cells which had undergone anti-IgM stimulation alone (Chapter 3 Results 
1), ibrutinib could not block dual activation in contrast to DAPKi, which appeared 
to have a broader repressive potential. 
 
Finally, we took HBL1 cells and pre-treated them with either ibrutinib or the 
DAPKi. Following this, the cells were stimulated with anti-IgM, CD40L or both and 
samples were taken at 60 minutes post-stimulation for RNA analysis. For both 
EGR1 and DUSP2, we observed that the DAPKi could overcome dual anti-
IgM/CD40L stimulation while ibrutinib could not, as observed for CLL cells (Figure 
4.10C-D). As seen in Chapter 3 Results 1 when comparing CLL to HBL1 cells, 
ibrutinib was not as effective at preventing IEG expression. CD40L stimulation 
alone primarily promoted DUSP2 gene expression, and both inhibitors could 
moderately reduce this expression – while the DAPKi remains the more effective 
of the pair. 
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Figure 4.7: Combined anti-IgM/CD40L stimulation increases IEG expression in an additive and/or synergistic fashion in ramos 
cells. (A) qPCR data analysis for EGR1 and DUSP2 gene expression over time (0-90 minutes) in ramos cells stimulated with either anti-
IgM, CD40L or both, as indicated. Error bars representative of 3 independent experiments. Expression changes were quantified using the 
∆Ct method with TBP and PPP6C as control genes. 
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Figure 4.8: Combined IgM/CD40L stimulation increases IEG expression in HBL1 cells. qPCR data analysis for (A) EGR1 and (B) 
DUSP2 gene expression in HBL1 cells stimulated with either anti-IgM, CD40L or both, as indicated, for 60 minutes. Error bars representative 
of 3 independent experiments. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. 
Significant differences calculated using two-way ANOVA followed by Dunnett’s multiple comparison test with unstimulated as control. EGR1 
P values = 0.0018 & 0.0000 for no stim vs anti-IgM and anti-IgM/CD40L respectively. DUSP2 P values = 0.0002 & 0.0002 for the same 
comparisons. 
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Figure 4.9: Combined IgM/CD40L stimulation increases IEG expression in CLL cells. qPCR data analysis for EGR1 and DUSP2 gene 
expression in (A) U-CLL and (B) M-CLL cells stimulated with either anti-IgM, CD40L or both, as indicated, for 30-60 minutes. Bars 
representative of the grand mean. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes. 
Significant differences calculated using two-way ANOVA followed by Dunnett’s multiple comparison test with unstimulated as control. EGR1 
P values = 0.4606, 0.1451, 0.0189 & 0.0466 for no stim vs anti-IgM/CD40L (30m), anti-IgM (60m) and anti-IgM/CD40L (60m) respectively. 
DUSP2 P values = 0.7479, 0.0398, 0.0236 & 0.0053 for the same comparisons. qPCR data analysis for (C) EGR1 and (D) DUSP2 gene 
expression in U-CLL/M-CLL cells stimulated with either anti-IgM, CD40L or both, as indicated, for 30-60 minutes. Bars representative of 
the grand mean. Expression changes were quantified using the ∆Ct method with TBP and PPP6C as control genes.  
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Figure 4.10: ZIPK inhibition can overcome dual anti-IgM/CD40L stimulation, while ibrutinib cannot. qPCR data analysis for EGR1 
and DUSP2 gene expression in (A) (B) U/M-CLL (black circles for U-CLL and green circles for M-CLL) and (C) (D) HBL1 cells. Both CLL 
and HBL1 cells were pre-treated with ibrutinib or DAPKi for 60 mins. CLL cells were then stimulated with anti-IgM/CD40L for 30-60 mins. 
HBL1 cells stimulated with either anti-IgM, CD40L or both for 60 mins. Bars representative of the grand mean. Expression changes were 
quantified using the ∆Ct method with TBP and PPP6C as control genes. Significant differences calculated using two-way ANOVA followed 
by Dunnett’s multiple comparison test with anti-IgM/CD40L as control. CLL cell statistics: EGR1 P values = 0.0626, 0.0054, 0.1893 & 
0.0245  for anti-IgM/CD40L vs ibrutinib and DAPKi at 30 and 60 minutes, respectively. DUSP2 P values = 0.1713, 0.0086, 0.1507 & 0.0064 
for the same comparisons. HBL1 cell statistics: EGR1 P values = 0.9960, 0.0058, 0.0069, 0.5620, 0.2339 & 0.0001 for ctrl vs ibrutinib and 
DAPKi with anti-IgM, CD40L and anti-IgM/CD40L stimulation, respectively. DUSP2 P values = 0.0599, 0.0002, 0.0004, 0.0001, 0.0383 & 
0.0001 for the same comparisons.
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4.4 The cellular consequences of dual anti-IgM/CD40L 
stimulation  
We have shown that targeting ZIPK kinase activity prevented the anti-
IgM/CD40L-mediated activation of IEGs known to promote CLL cell proliferation, 
whereas ibrutinib does not.  
 
It has been shown that cooperative/dual stimulation can allow one transcription 
factor to assist the loading of another onto the chromatin at promoters and/or 
enhancers to promote synergistic gene expression [259]. In particular, there are 
genes whose expression has been shown to be enhanced by the cooperative 
effects of STAT3 and NF-κB subunit p65 (RelA) [259]. As p65 is known to be 
activated downstream of CD40, we naturally sought to assess whether p65 was 
playing a role in enhancing the gene expression of our model IEGs in cooperation 
with STAT3. We initially chose to carry out these experiments in both CLL and 
ramos cells, selecting ramos as they showed more pronounced IEG activation in 
response to dual stimulation compared to HBL1. Further, the data from Figure 
4.4 showed an increase in phosphorylated STAT3 in response to the DAPKi in 
ramos cells. In light of this experiment, we wanted to understand if ZIPK inhibition 
could impact p65-induced transcription in ramos cells; as increased STAT3 
phosphorylation was anti-correlated with IEG expression. 
 
4.4.1 Combined anti-IgM/CD40L stimulation increases p65 nuclear 
localisation 
First, we wanted to assess whether p65 was activated in response to anti-IgM, 
CD40L or, specifically, after dual anti-IgM/CD40L stimulation. P65 migration from 
the cytoplasm to the nucleus is a hallmark of NF-κB activation as it indicates 
degradation of the IκB proteins responsible for the cytoplasmic sequestration of 
p65 [105].  
 
We stimulated ramos cells with either anti-IgM, CD40L or both for 45 minutes 
(time at which dual stimulation-induced gene expression peaked) and then lysed 
the cells for nuclear-cytoplasmic separation and western blot. While the levels of 
cytoplasmic p65 protein remain stable throughout all stimulation conditions, we 
observed a marked increase in levels of nuclear p65 in response to CD40L 
stimulation (Figure 4.11A-B). Anti-IgM stimulation alone does very little to 
increase p65 nuclear localisation, but when combined with CD40L we observed 
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an additive increase in p65 translocating to the nucleus. These data showed that 
dual anti-IgM/CD40L stimulation could promote an increase in p65 nuclear 
localisation. 
 
4.5 The effects of combined anti-IgM/CD40L stimulation on 
transcription factor binding 
We have observed an anti-IgM/CD40L-mediated increase in p65 nuclear 
localisation (Figure 4.11). In order to determine if this correlated with an increase 
in p65 recruitment to the EGR1 and DUSP2 loci we performed a series of ChIP 
experiments. Moreover, we wanted to assess whether or not STAT3-DNA binding 
could be impacted by the addition of CD40L. Our previous STAT3 ChIP data 
provided a basis for our understanding of how STAT3 could regulate EGR1, but 
were not fully conclusive.  
 
Increasing our understanding of how these transcription factors promote IEG 
expression in response to anti-IgM and/or CD40L stimulation will help to unravel 
how repression of ZIPK enzymatic activity in CLL cells can prevent the 
transcription of these genes. Therefore, the next sections present ChIP-qPCR 
data for (i) p65 and (ii) STAT3 at the DUSP2 and EGR1 loci in turn in both (i) 
ramos and (ii) CLL cells.  
 
4.5.1 The effects of combined anti-IgM/CD40L stimulation on p65-
DNA binding at the DUSP2 locus 
First, we wanted to continue our assessment of p65 in response to dual 
stimulation. We took ramos cells and stimulated them with either anti-IgM, CD40L 
or both for 45 minutes, taking samples for ChIP analysis at 30 and 45 minutes. 
We used antibody against p65 to assess binding across both the EGR1 and 
DUSP2 loci. 
 
The ChIP-qPCR data showed a strong p65 binding at the region -0.6 kb upstream 
from the DUSP2 TSS when the cells are treated with CD40L or the anti-
IgM/CD40L combination (Figure 4.12A-B). The p65 binding increased over time 
from 30-45 minutes for both CD40L alone and after dual stimulation (3 fold and 2 
fold respectively). It is interesting to note the correlation between this data and 
the p65 nuclear localisation, specifically: anti-IgM stimulation alone had no effect 
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on p65-DNA binding at the DUSP2 promoter, but when used in conjunction with 
CD40L we saw a strong synergistic effect – also as reflected in the gene 
expression. Notably, this binding enrichment (almost 40 fold over the CTCF 
controls) was far stronger than any of our previous anti-IgM induced STAT3 
binding and highlights the NF-κB-driven nature of DUSP2. We concluded that 
increased nuclear localisation correlated with increased p65-DNA binding and 
upregulation of EGR1 and DUSP2 gene expression.  
 
Having determined the effects of dual anti-IgM/CD40L stimulation on ramos cells 
we moved to assess the effect of the same activation in U-CLL cells. U-CLL cells 
(patient P7) were either pre-treated with ibrutinib, the DAPKi or neither and then 
stimulated with anti-IgM/CD40L for 45 minutes. The ChIP-qPCR data showed 
similar binding of p65 to the region -0.6 kb from the DUSP2 TSS (Figure 4.12C). 
We first observed that, in CLL, p65 was bound prior to anti-IgM/CD40L 
stimulation. Further, p65 binding after dual stimulation was considerably weaker 
than that observed in ramos cells. This suggested that the activation of the NF-
κB pathway may be less robust in CLL cells after dual stimulation compared to 
the ramos cell line, or that the kinetics of p65-binding are considerably slower. 
The ChIP-qPCR data also showed that while the DAPKi had little effect on p65 
binding at the DUSP2 promoter, we observed a pronounced increase in response 
to ibrutinib treatment. While it is difficult to conclude with certainty the reason 
behind this increase, we hypothesised that ibrutinib-mediated prevention of 
STAT3-binding could shift the transcription factor balance, promoting an 
alternative p65-mediated increase in DUSP2 gene expression. 
  
However, we must take into account the potential technical limitations of 
performing ChIP experiments in primary CLL cells compared to cell lines. Such 
limitations included the limited number of primary CLL cells which were available 
for these analyses, promoting a lack of reproducibility for these data (a point 
which is relevant to all the CLL ChIP data in this chapter). Further, when working 
with a primary cell line which is adverse to cell culture, there is an inherent 
likelihood that the cells which are harvested for ChIP experiments will not be as 
healthy as those from a traditional, immortalised cell line. Indeed, without the 
ability to reproduce these data in other patients, we cannot say with certainty why 
ibrutinib promotes p65 binding or why there is a discord between the data from 
ramos cells above (Figure 4.12A-B). There is particularly interest in repeating this 
experiment with the cells from those patients who are resistant to ibrutinib to 
assess whether or not long-term shutdown of the BCR pathway can promote the 
activation of alternative transcription factors such as p65. 
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4.5.2 The effects of combined anti-IgM/CD40L stimulation on p65-
DNA binding at the EGR1 locus 
In addition to examining the dynamics of p65-DNA binding at the DUSP2 locus, 
we also used a series of primers in and around the EGR1 locus to assess p65 
binding at this IEG. 
 
Ramos cells were treated with either anti-IgM and/or CD40L for 60 minutes and 
prepared for ChIP analysis with antibodies against p65. In replicate experiments 
we saw some variation in p65 binding at the EGR1 promoter. Firstly, the majority 
of p65 binding at the EGR1 locus was around the -1.0 and 1.3 kb regions 
upstream of the TSS (Figure 4.13A-C) – the same regions where we saw STAT3 
binding under anti-IgM stimulation. This correlation suggests these regions may 
contain some cis-regulatory elements which are important to EGR1 expression. 
In the first experiment, we saw comparable levels of p65 enrichment at the 
regions -1.3 and -1.0 kb from the TSS for all conditions, including without 
stimulation, and a CD40L-dependent enrichment at the region -0.4 kb from the 
TSS (Figure 4.13A). Our second experiment compared unstimulated cells with 
dual anti-IgM/CD40L stimulated cells (Figure 4.13B). In this experiment, for 
similarities, we saw a 3-fold increased stimulation-dependent response in p65-
DNA binding at the -1.0 kb region and further, weaker, binding at the +3.8 kb 
region or at the 3’ end of the gene. However we no longer observed the CD40L-
dependent enrichment at the -0.4 kb region. 
 
Finally, we took the CLL cells from a U-CLL patient (CLL P7) and prepared them 
for ChIP analysis. The cells were either pre-treated with ibrutinib, the DAPKi or 
neither and then stimulated with anti-IgM/CD40L for 45 minutes (Figure 4.13C). 
The ChIP-qPCR data for CLL P7 was consistent with our DUSP2 CLL ChIP data 
(Figure 4.13A) in that we observed p65 bound at the -1.3 kb region independently 
of anti-IgM/CD40L stimulation. Ibrutinib was able to prevent this binding while the 
DAPKi did not – suggesting the DAPKi mechanism of action in preventing p65-
mediated IEG expression was not outright linked to preventing p65 binding. 
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Figure 4.11: Combined anti-IgM/CD40L stimulation increases p65 nuclear 
localisation. (A) cytoplasmic and nuclear extracts from ramos cells were 
subjected to SDS-PAGE for western blot analysis. Cells were stimulated for 1 
hour with either anti-IgM, CD40L or both as indicated. (B) HDAC2 and vinculin 
were used as loading controls for cytoplasmic and nuclear extracts respectively 
and for normalisation with Image Lab software (below). Error bars from 2 
representative experiments. 
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Figure 4.12: The effects of combined IgM/CD40L stimulation on p65 DUSP2 DNA binding. ChIP-qPCR data assessing levels of p65-
binding across the DUSP2 locus. Ramos cells were stimulated with anti-IgM, CD40L or both and samples were taken for ChIP analysis at 
(A) 30 and (B) 45 minutes. (C) CLL cells were pre-treated with either 1 µM ibrutinib (green) or 25 µM DAPKi (red) for 60 mins as indicated 
and then stimulated with combined anti-IgM/CD40L for 45 minutes. The values on the x axis refer to specific gene regions relative to the 
transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). CTCF1/3 (C1/C3) were used as 
negative control regions which are not indicated on the gene schematics. Error bars correspond to variations in the ChIP-qPCR repeats.  
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Figure 4.13: The effects of combined IgM/CD40L stimulation on p65 EGR1 DNA binding. ChIP-qPCR data assessing levels of p65-
binding across the EGR1 locus. (A) (B) Ramos and (C) CLL cells were stimulated with anti-IgM, CD40L or both for 45 minutes. CLL cells 
were pre-treated with either 1 µM ibrutinib (green) or 25 µM DAPKi (red) for 1 hour as indicated before anti-IgM/CD40L stimulation. The 
values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene 
schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. 
Error bars correspond to variations in the ChIP-qPCR repeats.
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4.5.3 The effects of combined anti-IgM/CD40L stimulation on STAT3-
DNA binding at the EGR1 locus 
To assess the effect of combined anti-IgM/CD40L stimulation on STAT3-DNA 
binding we took a similar approach as to that described above for p65. We initially 
took ramos cells and stimulated them with either anti-IgM, CD40L or both for 45 
minutes taking samples for ChIP analysis at 30 and 45 minutes. We used 
antibodies against STAT3, STAT3-Y705-P and STAT3-S727-P to assess binding 
across the EGR1 locus. We chose to include both phosphorylation sites as while 
S727-P is known to activate transcription in CLL, Y705-P is more often 
phosphorylated in correlation with STAT3 activity in other diseases/tissues.  
 
The ChIP-qPCR data showed that at 30 minutes post-stimulation STAT3 and 
STAT3-Y705-P were bound -1.0 kb from the EGR1 TSS independent of anti-IgM 
and CD40L stimulation while STAT-S727-P was inducible at this region (-1.0 kb) 
and at the regions -0.4 and -0.2 kb from the TSS  (Figure 4.14A-C). 
 
Next, we again took the cells from U-CLL patient 7 and prepared them for ChIP 
analysis. The cells were either pre-treated with ibrutinib, the DAPKi or neither and 
then stimulated with anti-IgM and CD40L for 45 minutes (Figure 4.15A-B). As 
seen in the ramos cells, STAT3 appeared to be present at the region -1.3 kb from 
the TSS prior to stimulation and was not inducible while STAT3-S727-P 
recruitment increased after dual anti-IgM/CD40L stimulation. Both ibrutinib and 
DAPKi treatment inhibited the recruitment of STAT3-S727-P (Figure 4.15B). 
These data suggested that STAT3-S727 phosphorylation played an important 
role in CLL cell transcriptional activation and that its targeting at IEG promoters 
could be prevented by ibrutinib and the DAPKi. However, these data must be 
considered with our observations for p65 binding at the DUSP2 promoter (Figure 
4.12C). Here, we observed a strong increase in p65 recruitment to the region -
0.6 kb upstream from the DUSP2 TSS in the presence of ibrutinib suggesting the 
loss of BTK-mediated STAT3 activation could shift the balance of key 
transcription factors in CLL and promoted compensation from other 
transcriptional activators such as p65. 
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4.5.4 The effects of combined anti-IgM/CD40L stimulation on STAT3-
DNA binding at the DUSP2 locus 
While we have shown that combined anti-IgM/CD40L stimulation predominantly 
induces p65 DNA-binding to the DUSP2 promoter, we sought to also assess 
STAT3-binding for comparison. We previously analysed STAT3 binding to the 
DUSP2 locus in CLL cells (P3 and P5) in the context of anti-IgM stimulation alone 
(see Figure 4.5 & Figure 4.6) and the data were not particularly clear. We 
stimulated ramos cells with both anti-IgM and CD40L and prepared them for ChIP 
analysis using antibodies against STAT3 and STAT3-S727-P (Figure 4.16A-B). 
The ChIP-qPCR revealed that in the ramos cells the majority of STAT3 and 
phosphorylated STAT3 was present independently of stimulation all across the 
gene body (regions +2.4 and +3.1 kb downstream of the TSS). However, at the 
promoter region -0.6 kb upstream of the TSS, dual anti-IgM/CD40L stimulation 
increased the level of phosphorylated STAT3-S727. Noting the data from Figure 
4.12 in which dual anti-IgM/CD40L stimulation induced a large increase in p65 
binding at the -0.6 kb region, the presence of STAT3 in this region both with and 
without stimulation suggested evidence for the notion of one transcription factor 
assisting the loading of another [259].  
 
Next, and in order to directly compare the data for STAT3-binding in CLL cells at 
the DUSP2 locus under anti-IgM stimulation alone, we took cells from a U-CLL 
patient (CLL P7) and prepared them for ChIP analysis (Figure 4.17A-B). The 
ChIP-qPCR data in CLL provided some differences and some similarities to that 
observed in ramos. Of the similarities, we observed the same lack of total STAT3 
before stimulation at the -0.6 kb promoter region and demonstrated similarly 
inducible STAT3-S727-P. Here, addition of both stimulating agents caused an 
increase in the DNA binding of the phosphorylated form of the protein. The main 
difference between ramos and CLL in this experiment, is that we did not observe 
STAT3 or STAT3-S727-P bound in the absence of stimulation. We also observed 
an increase in STAT3-S727-P binding within the gene body and 5’ regions after 
dual stimulation. The observed STAT3-S727-P binding after stimulation could be 
prevented by either inhibitor (Figure 4.17B). This is similar to the observations at 
the EGR1 promoter, whereby both inhibitors could efficiently prevent STAT3-
S727-P binding at the 1.3 kb region upstream of the EGR1 TSS (Figure 4.15B).  
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4.6 The effects of combined anti-IgM/CD40L stimulation on 
H3T6-P and H3T11-P deposition at IEG loci 
We have assessed the effect of combining anti-IgM and CD40L stimulation on 
expression of IEGs as well as the DNA-binding of the proteins responsible for 
their transcription. ZIPK inhibition could reliably prevent expression of EGR1 and 
DUSP2 in CLL cells after BCR cross-linking and/or CD40 activation (Figure 4.10). 
In some cases, ZIPK inhibition could also reduce transcription factor binding i.e. 
p65 at the DUSP promoter (Figure 4.12C) and STAT3-S727-P at the EGR1 
(Figure 4.15B) and DUSP2 promoters (Figure 4.16D). We next wanted to 
determine whether or not these effects were linked to ZIPKs function as a histone 
kinase by assessing the levels of H3T6-P and H3T11-P in the context of dual 
anti-IgM and CD40L stimulation. 
 
Ramos cells were stimulated with anti-IgM and/or CD40L for 45 minutes and 
prepared for ChIP analysis using antibodies against both histone marks (Figure 
4.18A-B). The ChIP-qPCR data showed mixed synergy between the two 
stimulants. For H3T6-P, the regions +3.8 kb from the EGR1 TSS and -
0.6/+2.4/+3.1 kb from the DUSP2 TSS showed increased histone 
phosphorylation in the context of dual anti-IgM/CD40L stimulation. However the 
H3T6-P data for DUSP2 were difficult to interpret due to the low levels of 
enrichment. For H3T11-P, we observed histone phosphorylation in the gene body 
after anti-IgM stimulation alone (region +2.2 kb) and accumulation in the 3’ end 
of the gene (region +3.8 kb) after CD40L addition. For DUSP2, H3T11-P 
placement across the entire locus consistently required the addition of CD40L.  
 
Finally, HBL1 cells were prepared for ChIP after pre-treatment with ibrutinib, the 
DAPKi or neither for 60 minutes and then stimulated with both anti-IgM and 
CD40L for 45 minutes (Figure 4.19A-B). The ChIP-qPCR data showed that under 
dual stimulation conditions the DAPKi is generally more effective at preventing 
H3T6-P and H3T11-P deposition, especially at the regions where the histone 
phosphorylation is strongest e.g. EGR1 +3.8 kb and DUSP2 -0.6/-0.3 kb.  
 
It is interesting to note the effect of ibrutinib at the DUSP2 promoter region (-0.6 
kb), where we observed that the drug promoted phosphorylation of both histone 
marks (Figure 4.19B). The appearance of activatory histone phosphorylation after 
drug treatment could potentially be linked with the effect ibrutinib had on p65-
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binding at this region in CLL whereby the inhibitor appeared to activate alternate 
transcription factors as a result of shutting off those mediated by BTK. 
 
Taken together, we showed that while ibrutinib is effective at preventing STAT3 
DNA binding and histone modifications at the EGR1 locus, it may have a 
tendency to shift the transcriptional balance. This is particularly true for the NF-
κB mediated DUSP2, where treatment with the drug increased histone deposition 
and p65 binding at the DUSP2 promoter. These data could help us to understand 
why ibrutinib was ineffective against anti-IgM/CD40L-mediated IEG expression 
while the DAPKi appears repress both signalling pathways.  
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Figure 4.14: The effects of combined IgM/CD40L stimulation on STAT3 EGR1 DNA binding. ChIP-qPCR data assessing levels of (A) 
STAT3, (B) STAT3 Y705-P and (C) STAT3 S727-P in ramos cells at the EGR1 gene locus at 30 minutes post stimulation with either anti-
IgM, sCD40L or both, as indicated. The values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in 
kilobases (kb) as indicated on the gene schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which 
are not indicated on the gene schematics. Error bars correspond to variations in the ChIP-qPCR repeats. 
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Figure 4.15: The effects of combined IgM/CD40L stimulation on STAT3 EGR1 DNA binding. ChIP-qPCR data assessing levels of (A) 
STAT3 and (B) STAT3 S727-P binding across the EGR1 locus. CLL cells were pre-treated with either 1 µM ibrutinib (green) or 25 µM 
DAPKi (red) for 60 mins as indicated before stimulation with both anti-IgM/CD40L for 45 mins. The values on the x axis refer to specific 
gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). 
CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. Error bars correspond to 
variations in the ChIP-qPCR repeats. 
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Figure 4.16: The effects of combined IgM/CD40L stimulation on STAT3 DUSP2 DNA binding. ChIP-qPCR data assessing levels of 
(A) STAT3 and (B) STAT3 S727-P binding across the DUSP2 locus. Ramos cells were stimulated with both anti-IgM/CD40L for 45 mins. 
The values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene 
schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. 
Error bars correspond to variations in the ChIP-qPCR repeats. 
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Figure 4.17: The effects of combined IgM/CD40L stimulation on STAT3 DUSP2 DNA binding. ChIP-qPCR data assessing levels of 
(A) STAT3 and (B) STAT3 S727-P binding across the DUSP2 locus. CLL cells were pre-treated with either 1 µM ibrutinib (green) or 25 µM 
DAPKi (red) for 1 hour as indicated and then stimulated with both anti-IgM/CD40L for 45 mins. The values on the x axis refer to specific 
gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). 
CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. Error bars correspond to 
variations in the ChIP-qPCR repeats. 
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Figure 4.18: Comparing anti-IgM and sCD40L stimulation on the deposition of H3T6-P and H3T11-P at IEG loci in ramos cells. 
ChIP-qPCR data assessing levels of H3T6-P and H3T11-P at the (A) EGR1 and (B) DUSP2 gene loci. Ramos cells were treated with 
either anti-IgM, CD40L or both as indicated for 45 mins. The values on the x axis refer to specific gene regions relative to the transcription 
start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control 
regions which are not indicated on the gene schematics. Error bars correspond to variations in the ChIP-qPCR repeats. 
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Figure 4.19: The effects of dual anti-IgM/CD40L stimulation on H3T6-P and H3T11-P histone modifications in HBL1 cells. ChIP-
qPCR data assessing levels of H3T6-P and H3T11-P at the (A) EGR1 and (B) DUSP2 gene loci. HBL1 cells were pre-treated with either 
1 µM ibrutinib (green) or 25 µM DAPKi (red) for 1 hour as indicated before stimulation with combined anti-IgM/CD40L for 45 minutes. The 
values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene 
schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. 
Error bars correspond to variations in the ChIP-qPCR repeats.
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Chapter 5 Results 3: The role of ZIPK in RNA polymerase II 
recruitment and pre-mRNA processing 
In chapter 2, we examined the effects and implications of ZIPK and its inhibition 
on gene expression via the analysis of transcription factor binding to cis-
regulatory elements in response to BCR cross-linking and CD40 activation, 
specifically within the loci of our studied IEGs. While transcription is not 
necessarily correlated with transcription factor recruitment, its examination can 
help us to understand this key aspect of the cascade of events necessary for 
controlling gene expression. Additionally, transcription factor binding to cis-
regulatory elements is usually associated with the recruitment of RNA 
polymerase II (RNA pol II), one of the three eukaryotic RNA polymerases 
responsible for the transcription of messenger RNAs [260]. RNA pol II recognises 
the promoter region upstream of the transcription start site of a gene, unwinds 
the DNA duplex and initiates transcription of RNA. Subsequently, the elongation 
complex proceeds through the gene before dissociating via a termination signal, 
releasing the transcribed RNA for pre-mRNA processing [260].  
 
The stages of RNA pol II-mediated transcription are marked by phosphorylation 
changes to the carboxyl-terminal domain (CTD) of RNA pol II. RNA pol II CTD is 
observed to be phosphorylated at serine 5 (RNA pol II S5-P) at the 5’ end of 
genes and is associated with transcription initiation [190, 261]. Serine 5 
phosphorylation is gradually lost as RNA pol II elongates through the gene, 
replaced with CTD phosphorylation at serine 2 (RNA pol II S2-P). RNA pol II S2-
P is indicative of active transcription as the polymerase elongates through the 
gene body [190, 261]. 
 
Having examined the transcription factors involved in EGR1 and DUSP2 
transcription we wanted to move further down the transcription cascade in order 
to more clearly understand the activation of our model IEGs. Therefore, we 
decided to assess the recruitment of RNA pol II and RNA pol II S2-P to the locus 
of each gene and examine and compare the effects of ibrutinib and DAPKi 
treatment on such recruitment. These question are particularly interesting in the 
context of immediate early gene expression: IEGs show rapid pre-mRNA 
induction and RNA pol II recruitment compared to secondary/delayed response 
genes [193]. In fact, it has been suggested that RNA pol II may be poised at the 
promoter regions of some IEGs before cellular stimulation and transcription factor 
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activation in order to provide a ‘ready-to-go’ RNA pol II [191-193]. Further, IEGs 
have a distinct genomic architecture and chromatin structure to facilitate their 
rapid transcription characterised by bivalent promoters poised for rapid activation 
[191].  
 
5.1 RNA polymerase II recruitment to IEG loci 
We have now investigated the recruitment of transcription factors to the promoter 
regions of EGR1 and DUSP2 in response to BCR activation and observed mixed 
response to the addition of ibrutinib or DAPKi treatment (see Chapter 4 Results 
2). In order to fully understand the transcription and activation of our model IEGs, 
we sought to profile RNA pol II and RNA pol II S2-P recruitment in CLL cells 
following anti-IgM crosslinking of the BCR. 
 
The cells from a U-CLL patient (P3) were stimulated with anti-IgM for 30 minutes 
to activate transcription. These cells were then lysed and prepared for ChIP 
analysis with antibodies against RNA pol II (total RNA pol II – will recognise all 
forms of the enzyme) and RNA pol II S2-P. Broadly, we expected to observe total 
RNA pol II localised around the gene promoters/upstream of the TSS and RNA 
pol II S2-P in the gene bodies as an indication of active transcriptional elongation. 
 
The ChIP-qPCR data for RNA pol II at the EGR1 locus post anti-IgM stimulation 
showed recruitment of the polymerase to the regions -6.1, -1.0 and -0.85 kb 
upstream of the TSS as well as +2.2 kb downstream of the TSS (Figure 5.1A). 
All of the regions downstream of the TSS where we observed recruitment of the 
polymerase were regions which we have previously identified and associated 
with transcription factor binding (particularly STAT3 – see Figure 4.5). The ChIP-
qPCR data for the elongating polymerase (S2-P) showed recruitment primarily in 
the gene body (+2.2 and +3.8 kb) and 3’ of the TES (+4.2 kb) with additional 
recruitment upstream of the TSS, closer to the promoter region (-1.0 kb) (Figure 
5.1A). The data for DUSP2 were similar (Figure 5.1B): total RNA pol II was 
recruited primarily upstream of the TSS (-0.3 kb) and receded along the gene 
body, whilst elongating RNA pol II S2-P was bound all across the gene body (+2.4 
kb) and 3’ of the TES (+3.1 and 4.2 kb). Enrichment of RNA pol II downstream of 
the TES could be attributed to a variety of technical or biological factors. In 
analysing RNA pol II recruitment by ChIP the chromatin sample could contain 
large pieces of DNA meaning there is potential for detecting RNA pol II 
transcribing nearby genes. Additionally, termination of elongating RNA pol II can 
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occur hundreds of bases downstream of the 3’ end site [262]. Taken together 
these data exemplified classical transcription of our model IEGs.  
 
5.1.1 The effects of combined dual anti-IgM/CD40L stimulation on 
RNA polymerase II recruitment to IEG loci   
Having determined that anti-IgM stimulation of the BCR promotes a classical RNA 
pol II response at the EGR1 and DUSP2 loci, we sought to assess the effects of 
combining dual anti-IgM/CD40L stimulation on the transcriptional activation of 
both genes.   
 
The cells from a U-CLL patient (P3) were stimulated with anti-IgM and CD40L for 
30 minutes to activate transcription. These cells were then lysed and prepared 
for ChIP analysis with antibodies against RNA pol II and RNA pol II S2-P. The 
ChIP-qPCR data showed a strong recruitment of RNA pol II to the EGR1 and 
DUSP2 promoter regions (see EGR1 -1.3, -1.0, -0.85, -0.4 kb and DUSP2 -0.6, -
0.3, -0.1 kb) and RNA pol II S2-P elongating in the gene bodies (see EGR1 +2.2, 
+3.8, +4.2 kb and DUSP2 +3.1, +4.2 kb) after stimulation (Figure 5.2A-B). These 
data showed accumulating RNA pol II S2-P at, and beyond, the 3’ end of both 
genes. Further, it is worth noting the enrichment values in this experiment were 
significantly higher when compared to anti-IgM stimulation alone for the same 
sample (see Figure 5.1). While this could be attributed to variable experimental 
response to stimuli, it  suggested a synergistic impact of combining dual anti-
IgM/CD40L on transcriptional activation of EGR1 and DUSP2.  
 
These data suggested that a poised RNA pol II was present at IEG promoters 
prior to stimulation and demonstrated textbook recruitment of the polymerase to 
gene promoter regions followed by RNA pol II S2-P elongating through the gene 
body and 3’ end of the gene. 
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Figure 5.1: RNA pol II recruitment to IEG loci. ChIP-qPCR data assessing RNA pol II and RNA pol II-S2P binding across the (A) EGR1 
and (B) DUSP2 locus in CLL cells. CLL cells were stimulated with anti-IgM for 45 mins. The values on the x axis refer to specific gene 
regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics below (not to scale). CTCF1/3 
(C1/C3) were used as negative control regions which are not indicated on the gene schematics. Error bars correspond to variations in the 
ChIP-qPCR repeats. 
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Figure 5.2: RNA pol II recruitment to IEG loci in the context of combined anti-IgM/CD40L stimulation. ChIP-qPCR data assessing 
RNA pol II and RNA pol II-S2P binding across the (A) EGR1 and (B) DUSP2 locus in CLL cells. CLL cells were stimulated with combined 
anti-IgM/CD40L for 45 mins. The values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases 
(kb) as indicated on the gene schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not 
indicated on the gene schematics. Error bars correspond to variations in the ChIP-qPCR repeats. 
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5.2 BTK and ZIPK inhibition differentially effect RNA 
polymerase II recruitment to IEG loci  
We have demonstrated that RNA polymerase II recruitment to the EGR1 and 
DUSP2 loci occurred rapidly after anti-IgM and/or CD40L stimulation. In order to 
further understand how ZIPK affects the transcriptional activation of our model 
IEGs we aimed to compare the effects of ibrutinib and DAPKi on RNA pol II 
recruitment. 
 
We took the cells from a U-CLL patient (P5) and pre-treated them with either 
ibrutinib or DAPKi before stimulation with anti-IgM for 30 minutes. The cells were 
then prepared for ChIP analysis with antibodies against RNA pol II and RNA pol 
II S2-P. The ChIP-qPCR data showed clear recruitment of RNA pol II to EGR1 
and DUSP2 promoters (see enrichment at EGR1 -1.0, -0.85 kb and DUSP2 -0.6, 
-0.3 kb) and RNA pol II S2-P elongating through the gene bodies (see enrichment 
at EGR1 +2.2, +3.8, +4.2 kb and DUSP2 +2.4, +3.1, +4.2 kb) (Figure 5.3A-B). 
Ibrutinib could prevent this recruitment throughout both genes, in correlation with 
our previous data that showed ibrutinib was effective at overcoming anti-IgM-
mediated stimulation of IEG transcription in CLL cells (see Chapter 3 Results 1). 
DAPKi treatment however did not affect RNA pol II (S2-P) recruitment – with only 
a slight decrease observed at the DUSP2 locus (Figure 5.3B). These data 
suggested that a loss of ZIPK function prevented IEG expression through post-
transcriptional mechanisms, in a way that leaves RNA pol II recruitment mostly 
unaffected. Alternatively, we could not rule out that DAPKi may have trapped the 
elongated polymerase within gene bodies, with this block in transcriptional 
elongation being undetectable by ChIP. 
 
5.2.1 Comparing the effects of BTK and ZIPK inhibition on RNA 
polymerase II recruitment to IEG loci in the context of combined 
anti-IgM/CD40L stimulation 
Having demonstrated that Ibrutinib can prevent RNA polymerase II recruitment 
to IEG loci while DAPKi does not (see Figure 5.3), we wanted to assess if these 
inhibitors would have a similar effect after stimulation with combined anti-
IgM/CD40. 
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We took the cells from a U-CLL patient (P7) and pre-treated them with either 
ibrutinib or DAPKi before stimulation with dual anti-IgM/CD40L for 30 minutes. 
The cells were then prepared for ChIP analysis with antibodies against RNA pol 
II and RNA pol II S2-P. Without the inhibitors we observed a classical RNA 
polymerase recruitment with elongating S2-P localised in the gene bodies and 3’ 
of the TES (see enrichment at EGR1 +2.2, +3.8, +4.2 kb and DUSP2 +2.4, +3.1, 
+4.2 kb). After combined anti-IgM/CD40L stimulation ibrutinib was less effective 
at preventing the recruitment of RNA pol II and RNA pol II S2-P to both the EGR1 
and DUSP2 loci. In particular, we observed no effect of ibrutinib on RNA pol II 
recruitment 5’ of the EGR1 TSS (regions -1.0 and -0.85 kb) or at any regions 
across the DUSP2 locus (Figure 5.4A-B). Similarly, RNA pol II S2-P recruitment 
was mostly unaffected across the DUSP2 locus with partial loss observed at the 
region 3.1 kb downstream of the TSS (Figure 5.4A-B). In contrast, RNA pol II S2-
P recruitment was fully prevented across the EGR1 locus, as observed for anti-
IgM stimulation alone (see Figure 5.3).  
 
At the EGR1 locus, DAPKi treatment either had no effect (regions +2.2 and +4.2 
kb) or induced an accumulation of RNA pol II/RNA pol II S2-P compared to no 
drug (regions -1.0, -0.85 and +3.8 kb) (Figure 5.4A). For DUSP2, we observed 
similar results with the DAPKi – either no effect (regions +2.4 and +3.1 kb) or 
increased RNA pol II recruitment compared to no drug (regions -0.6 and -0.3 kb). 
RNA pol II S2-P recruitment was the most variable, with a combination of regions 
unaffected (region -0.6 kb), increased (regions -0.3 kb) or decreased (regions 
+2.4, +3,1 and +4.2 kb) in response to DAPKi treatment (Figure 5.4B). These 
variations may represent experimental variability and from these data we can only 
conclude that DAPKi treatment does not fully repress RNA pol II S2-P 
recruitment. 
 
The reason why Ibrutinib was able to prevent RNA pol II S2-P across the EGR1 
locus while having little effect on EGR1 gene expression (see Chapter 4 Results 
2) was unclear. Clearly, Ibrutinib was least effective at preventing RNA pol II 
recruitment to DUSP2 under dual anti-IgM/CD40L stimulation. We hypothesised 
these differences may arise from contrasting RNA pol II recruitment dynamics 
which could be dependent on the signalling pathway and downstream TFs (e.g. 
CD40L/NF-kB versus BCR/STAT3) at the DUSP2 and EGR1 loci. 
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5.2.2 Examining RNA polymerase II recruitment to IEG loci in HBL1 
cells 
Having assessed RNA polymerase II recruitment to IEG loci in CLL cells, we 
wanted to continue our assessment of the HBL1 cell line by carrying out further 
ChIP experiments. HBL1 cells were pre-treated with either ibrutinib or DAPKi 
before stimulation with dual anti-IgM/CD40L for 30 minutes. The cells were then 
prepared for ChIP analysis with antibodies against RNA pol II and RNA pol II S2-
P. 
 
As expected, the ChIP-qPCR data showed RNA pol II and RNA pol II S2-P 
binding at IEG promoters in gene bodies (Figure 5.5A-B). Ibrutinib was able to 
prevent RNA pol II (S2-P) recruitment to some 5’ and gene body regions (see 
EGR1 -1.0, +2.2 and DUSP2 -0.6, +2.4 kb) and also caused an accumulation of 
RNA pol II in the 3’ end of the gene (see regions EGR1 +3.8 and DUSP2 +3.1 
kb). DAPKi treatment had either no effect or caused a locus-wide accumulation 
of RNA polymerase. These data suggested that the effect of the DAPKi was 
similar between HBL1 and primary CLL cells and that ZIPK was functioning in a 
similar manner in both cell types. Again, it was unclear how Ibrutinib was able to 
prevent RNA pol II recruitment to IEG loci, while it simultaneously was not able 
to prevent transcription of EGR1 and DUSP2 in the context of dual anti-
IgM/CD40L stimulation in HBL1 cells.  
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Figure 5.3: Differential effects of ibrutinib and DAPKi treatment on RNA polymerase II recruitment in CLL cells. ChIP-qPCR data 
assessing RNA pol II and RNA pol II S2-P binding across the (A) EGR1 and (B) DUSP2 locus in CLL cells. Cells were pre-treated with 
either 1 µM ibrutinib (green) or 25 µM DAPKi (red) for 1 hour as indicated and then stimulated with anti-IgM for 45 minutes. The values on 
the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene schematics 
below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. Significant 
differences were calculated using two-way ANOVA followed by Dunnett’s multiple comparison test for n = 2 independent experiments 
where 1 representative example is shown in the figure with error bars corresponding to variations in the ChIP-qPCR repeats. 
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Figure 5.4: Differential effects of ibrutinib and DAPKi treatment on RNA polymerase II recruitment in CLL cells. ChIP-qPCR data 
assessing RNA pol II and RNA pol II S2-P binding across the (A) EGR1 and (B) DUSP2 locus in CLL cells. Cells were pre-treated with 
either 1 µM ibrutinib (green) or 25 µM DAPKi (red) for 1 hour as indicated and then stimulated with anti-IgM/CD40L for 45 minutes. The 
values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene 
schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. 
Error bars correspond to variations in the ChIP-qPCR repeats for n = 1 experiment. 
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Figure 5.5: Differential effects of ibrutinib and DAPKi treatment on RNA polymerase II recruitment in HBL1 cells. ChIP-qPCR data 
assessing RNA pol II and RNA pol II S2-P binding across the (A) EGR1 and (B) DUSP2 locus in HBL1 cells. Cells were pre-treated with 
either 1 µM ibrutinib (green) or 25 µM DAPKi (red) for 1 hour as indicated and then stimulated with anti-IgM/CD40L for 45 minutes. The 
values on the x axis refer to specific gene regions relative to the transcription start site (TSS) in kilobases (kb) as indicated on the gene 
schematics below (not to scale). CTCF1/3 (C1/C3) were used as negative control regions which are not indicated on the gene schematics. 
Significant differences were calculated using two-way ANOVA followed by Dunnett’s multiple comparison test for n = 3 independent 
experiments where 1 representative example is shown in the figure with error bars corresponding to variations in the ChIP-qPCR repeats. 
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5.3 The effects of ZIPK inhibition on the processing of primary 
mRNA transcripts 
Since treatment of CLL cells with DAPKi prevents IEG expression (see Figure 
3.5) but did not seem to impact on RNA pol II elongation (see Figure 5.4), we 
sought to assess the effect of ZIPK inhibition on steps post-elongation: 
specifically focussing on the processing of primary mRNA transcripts. The 
processing or maturation of primary mRNA precursors often will occur 
simultaneously with their transcription by RNA polymerase II [200, 263]. The co-
transcriptional nature of pre-mRNA processing requires alterations to the 
chromatin structure by histone-modifying enzymes for the recruitment and action 
of both the RNA polymerase II itself and a raft of RNA processing factors for 
splicing, intron removal, 3’ end processing and 5’ capping [203].  
 
We therefore sought to examine any effect of ZIPK inhibition on the processing 
of pre-mRNA for these reasons: 
I. ZIPK inhibition does not prevent RNA pol II S2-P in the gene bodies of 
IEGs suggesting that its mechanism of action may occur post elongation. 
II. ZIPK is a chromatin modifying enzyme and accurate changes to the 
chromatin structure play a role in the processing of primary mRNA 
transcripts.  
 
5.3.1 RT-PCR highlights RNA processing defect caused by a loss in 
ZIPK function 
In order to examine the effect of ZIPK inhibition on mRNA processing, we used 
conventional RT-PCR to compare the effect of DAPKi on mature mRNA and 
primary mRNA transcripts. CLL cells (P7) were pre-treated with either ibrutinib or 
DAPKi for 1 hour, stimulated with dual anti-IgM/CD40L for 1 hour before lysis for 
RNA extraction. cDNA synthesis was carried out with either an oligo-dT (O-dT) 
or random primers. The random primers would amplify both processed mRNA 
and unprocessed pre-mRNA, while the O-dT would only amplify polyadenylated 
transcripts. This would allow us to determine whether or not an mRNA processing 
defect occurring as a result of ZIPK loss takes place pre- or post-polyadenylation. 
Samples were analysed with RT-PCR using primers designed for full length, 
processed mRNA and several primers designed to span intron/exon boundaries 
or fully intronic regions in order to analyse the level of primary transcripts (Figure 
5.6A). 
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We observed an increase in EGR1 and DUSP2 gene transcription following dual 
anti-IgM/CD40L stimulation (Figure 5.6B top left panel). Ibrutinib had a limited 
effect on IEG expression under these stimuli, as observed earlier via qPCR (see 
Figure 3.8), while DAPKi treatment reduced the level of processed, mature 
mRNA, as expected. DAPKi treatment only impacted the level of primary 
transcripts when the reverse transcription was carried out with an oligo-dT, when 
we used random primers there was no effect of DAPKi treatment with a slight 
increase/accumulation of primary transcript for primers EGR1 +1.0 and DUSP2 
+0.5 (Figure 5.6B bottom left panel, bottom right panel). There was an effect of 
the DAPKi on the intro/exon boundary primer DUSP2 +1.1 (Figure 5.6B top right 
panel), but the primary transcript was not reduced to a level comparable with 
processed DUSP2 mRNA. 
 
These data suggested an effect of ZIPK inhibition on mRNA processing of 
primary transcripts which impacted on the processing steps pre-polyadenylation, 
such as 5’ capping or splicing, although it should be noted that these steps often 
occur concurrently. 
 
5.3.2 qPCR demonstrates that DAPKi treatment does not prevent 
primary mRNA transcript formation, but leads to their 
accumulation 
Having used RT-PCR to determine that DAPKi treatment impacted on mRNA 
processing we wanted to confirm these observations with qPCR. First, we took 
the cells from a CLL patient (P7) and pre-treated them with either ibrutinib or 
DAPKi for 1 hour before stimulation with anti-IgM for 30 minutes. The cells were 
then lysed for RNA extraction and qPCR analysis. The qPCR data showed an 
increase in both processed mRNA and unprocessed pre-mRNA upon anti-IgM 
stimulation for both EGR1 and DUSP2 (Figure 5.7A). Ibrutinib and DAPKi pre-
treatment reduced the levels of both processed mRNA and unprocessed pre-
mRNA, but we observed that the DAPKi was less effective at inhibiting primary 
transcript. This was particularly true for DUSP2 where after DAPKi treatment 
there was a considerable increase/accumulation of primary transcript compared 
with mature mRNA (Figure 5.7A). To more clearly understand the difference 
between ibrutinib and DAPKi treatment on primary transcript we can compare the 
relative change between the anti-IgM stimulated sample without drug vs. the anti-
IgM stimulated sample pre-treated with either ibrutinib or the DAPKi (where 
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relative change was defined as ΔCt drug treated sample / ΔCt un-drugged 
sample) (Figure 5.7B). By viewing the qPCR data in this way, we observed that 
ibrutinib affected the processed mRNA and unprocessed pre-mRNA to a similar 
extent. However, the DAPKi-dependent reduction in RNA production was at least 
2-fold less effective for primary transcripts compared to processed mRNA, for all 
primers tested.  
 
We have shown that the DAPKi had the same effect on recruitment of RNA pol II 
(S2-P) in both CLL and HBL1 cells (see Figure 5.3-Figure 5.5). Having 
determined that ZIPK inhibition impacted on pre-mRNA processing post 
elongation in CLL cells we wanted to assess if the same was true in HBL1. 
Therefore, HBL1 cells were pre-treated with either ibrutinib or DAPKi for 1 hour 
before stimulation with dual anti-IgM/CD40L for 30 minutes. The cells were then 
lysed for RNA extraction and qPCR analysis. The qPCR data showed that DAPKi 
can prevent transcription of processed mRNA while ibrutinib cannot (Figure 
5.7C), as expected from previous experiments with combined anti-IgM/CD40L 
stimulation (see Figure 4.10). By taking the data in Figure 5.7C and giving the 
unstimulated control a value of 1.0, we compared the effects of the two inhibitors 
more clearly. In this way, we observed that DAPKi treatment resulted in an 
accumulation of EGR1 primary transcript, even in unstimulated conditions (Figure 
5.7D).  The effect was less strong for DUSP2, but we still observed that the DAPKi 
had less impact on primary transcripts compared to mature mRNA (Figure 5.7D). 
The impact of DAPKi on primary transcripts was observed more strongly in HBL1 
compared to CLL cells – here we showed that loss of ZIPK function either had 
little impact on unprocessed mRNA or caused a slight increase/accumulation of 
the primary transcript, as observed by RT-PCR (see Figure 5.6B). These data 
confirmed our observations in CLL cells by RT-PCR and qPCR that ZIPK 
inhibition blocked processing of the pre-mRNA primary transcripts.  
 
5.3.3 The effects of ZIPK knockdown on the processing of IEG 
primary transcripts 
We have shown that loss of ZIPK function prevented the normal processing of 
both EGR1 and DUSP2 primary mRNAs in CLL and HBL1 cells, demonstrating 
that DAPKi treatment can cause an accumulation of the unprocessed version of 
these transcripts (see Figure 5.6 & Figure 5.7). We have previously shown that 
siRNA-mediated knockdown of ZIPK mimics the effects of DAPKi treatment in 
HBL1 cells with regard to IEG transcription and histone phosphorylation (see 
Figure 3.12 & Figure 3.13). We now sought to assess whether the effect of ZIPK 
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knockdown would be comparable to DAPKi with regard to abnormal mRNA 
processing to determine if it was a direct effect of this inhibitor on ZIPK function.  
 
HBL1 cells were electroporated with siRNAs directed against ZIPK and a 
negative control siRNA – an siRNA with a sequence that does not target any gene 
product to provide a baseline to compare siRNA-treated samples. Day 5 post 
transfection, the cells were stimulated with anti-IgM for 60 minutes and then lysed 
for RNA extraction and qPCR analysis. As shown by qPCR previously, we 
observed that ZIPK knockdown mimicked DAPKi in preventing IEG transcription 
i.e. there was a decrease in processed mRNA in the cells transfected with siRNAs 
directed against ZIPK (Figure 5.8A-B). For EGR1, we observed an accumulation 
of primary transcript (Figure 5.8A) as observed in the HBL1 qPCR experiment 
(see Figure 5.7C). The data for DUSP2 were less convincing in these series of 
knockdown experiments due to large variation between duplicate transfections, 
shown with the error bars for both primary transcripts (Figure 5.8B). The data for 
the intronic primer (DUSP2 +0.8 kb) when compared with the processed mRNA 
showed, more convincingly, how a loss of ZIPK function led to impaired pre-
mRNA processing. To summarise, ZIPK knockdown had similarities to DAPKi 
treatment with regard to ZIPKs impact on pre-mRNA processing, particularly for 
EGR1. 
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Figure 5.6: RT-PCR highlights RNA processing defect caused by a loss in ZIPK kinase activity. (A) EGR1/DUSP2 gene schematics 
showing introns and exons. Primer locations for qPCR and RT-PCR indicated by vertical arrows and blue boxes. Numbers after gene 
names correspond to the position of the primers in and around the gene relative to the transcription start site (TSS), where + denotes 3’ of 
the TSS and – denotes 5’ of the TSS. (B) Reverse-transcription PCR (RT-PCR) analysis comparing levels of processed EGR1/DUSP2 
mRNA (top left) with EGR1/DUSP2 primary transcript levels (bottom left, top right, bottom right). CLL cells were pre-treated with either 
ibrutinib or the DAPKi for 60 mins as indicated and then stimulated with anti-IgM and sCD40L for 60 mins to activate IEG expression. 
Extracted RNA was reverse transcribed with either random primer (RP) or oligo-dT, subjected to RT-PCR and analysed by agarose gel 
electrophoresis. 
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Figure 5.7: DAPKi is less effective at inhibiting IEG primary transcript than mature mRNA in CLL cells while Ibrutinib effects 
mature mRNA & primary transcripts similarly. (A) qPCR analysis of EGR1/DUSP2 primary transcript (shades of blue) vs processed 
mRNA (red) from CLL cells pre-treated with either 1 µM ibrutinib or 25 µM  DAPKi for 60 mins and then stimulated with or without anti-IgM 
for 60 mins as indicated. Error bars representative of n = 3 independent experiments. (B) Relative change between anti-IgM stimulated 
and anti-IgM stimulated pre-treated with either Ibrutinib/DAPKi samples (relative change = ΔCt drug treated sample/ΔCt un-drugged 
sample). C1 and C3  (CTCF1/3) are controls for genomic DNA contamination. (C) qPCR analysis of EGR1/DUSP2 primary transcript 
(shades of blue) vs processed mRNA (red) from HBL1 cells pre-treated with either 1 µM ibrutinib or 25 µM  DAPKi for 60 mins and then 
stimulated with or without anti-IgM/CD40L for 60 mins as indicated. (D) The data from (C) presented as fold change relative to 
control/unstimulated sample (= 1.0). 
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Figure 5.8: ZIPK knockdown mimics DAPKi treatment in preventing IEG expression via impacting pre-mRNA processing. qPCR 
analysis of (A) EGR1 and (B) DUSP2 mRNA/pre-mRNA from HBL1 cells transfected with siRNAs against ZIPK. 3 days after transfection, 
the cells were stimulated with or without anti-IgM for 60m. Numbers after gene names correspond to the position of the primers in and 
around the gene relative to the transcription start site (TSS), where + denotes 3’ of the TSS and – denotes 5’ of the TSS. Error bars are 
representative of 3 (EGR1) and 2 (DUSP2) individual transfections. 
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5.4 The effects of ZIPK inhibition on alternative splicing 
Having determined that ZIPK inhibition or loss of function prevented pre-mRNA 
processing of IEG nascent transcripts, we wanted to further understand which 
aspect of processing may be primarily affected by loss of ZIPK kinase activity. 
The three main events needed to faithfully process a primary mRNA transcript 
into mature mRNA are 5’ capping, 3’ processing (cleavage/polyadenylation) and 
splicing [263]. All three events have been shown to be interpedently stimulated 
by different regions of the CTD domain of RNA polymerase II [261, 264].  
 
We sought to determine whether ZIPK inhibition could impact splicing. As IEGs, 
both DUSP2 and EGR1 are short genes with only a few exons to ensure the rapid 
transcription necessary for their immediate function [177]. EGR1 is a simple gene 
with only 2 exons and has no functional alternate spice isoforms. DUSP2 
however, has variable exons (exons 2 and 3) which can give rise to a shorter 
transcript upon their exclusion (data accessible at NCBI AceView [255]). Further, 
DUSP2 intron retention (intron 3) has also been shown to give rise to a functional 
protein [265]. We designed primers to detect both the exon exclusion and intron 
retention transcripts to examine alternative splicing of DUSP2 in the context of 
ZIPK inhibition (Figure 5.9A for primer design).  
 
First, to understand the relative levels of the spliced/unspliced/alternatively 
spliced DUSP2 isoforms, HBL1 cells were stimulated with either anti-IgM alone, 
combined anti-IgM/CD40L, or neither for 1 hour before lysis for RNA extraction 
and qPCR analysis. The qPCR data detected a small amount of transcripts 
containing the retained intron with a more significant number of transcripts which 
were alternatively spliced with exon exclusion/skipping. Under all conditions there 
was a higher level of spliced DUSP2 mRNA compared to the alternatively spliced 
or unspliced transcript (Figure 5.9B).  
 
To understand the effect of ZIPK inhibition on alternative splicing we repeated the 
experiment pre-treating HBL1 cells with either ibrutinib or DAPKi for 1 hour before 
stimulation. In order to assess the impact of ZIPK inhibition on splicing, we 
examined the change in the ratio of splice isoforms between the control 
(stimulated, un-drugged) and ibrutinib/DAPKi-treated samples. In short, the 
relative levels of splice isoforms can be expressed as a ratio of one splice isoform 
to another e.g. an exon inclusion (spliced) vs. exon exclusion or intron retention 
ratio (unspliced/alternatively spliced). By giving the control sample a baseline 
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value of 1, this ratio can then be compared between different experimental 
samples e.g. ibrutinib vs. DAPKi-treated (see Methods 2.6.5 for detailed 
calculations).  
 
The qPCR data expressed in this way showed that the ratio of exon inclusion 
transcripts (spliced transcripts) to alternatively spliced transcripts is increased in 
DAPKi treated samples when compared with control or ibrutinib treated samples 
(Figure 5.10A). We observed that the value for ibrutinib treated cells was close to 
the baseline value of 1, suggesting that BTK inhibition affected both isoforms to 
the same degree and that the ratio between isoforms remains similar as 
transcription was decreased (Figure 5.10A). This is in agreement with ibrutinib’s 
mechanism of action in preventing transcription via inhibition of the upstream 
BCR signalling pathway. Conversely, while DAPKi treatment inhibited 
transcription of the full-length DUSP2 isoform it even more strongly inhibited 
alternative splicing of the exon excluded isoform. In the DAPKi treated cells the 
ratio was increased and strongly skewed away from the alternatively spliced 
isoform (Figure 5.10A). The same trend holds true when comparing exon 
included transcripts (spliced transcript) with intron retained transcripts (Figure 
5.10B). 
 
These data continue to lend evidence to the fact that ZIPK inhibition negatively 
impacted on pre-mRNA processing. While it remained unclear exactly how loss 
of ZIPK prevents faithful pre-mRNA processing, we have now observed an impact 
on both alternative splicing and an accumulation of both EGR1 and DUSP2 
primary transcript in the context of ZIPK inhibition (Figure 5.7).  
 
5.5 ZIPK regulates RNA processing through a direct interaction 
with RNA polymerase II 
We have shown links between ZIPK function and pre-mRNA processing (Figure 
5.6-Figure 5.10) and discussed how the processing of nascent transcripts was 
often coupled to and happened simultaneously with RNA pol II-mediated 
transcription. Further, many proteins responsible for pre-mRNA processing 
interact directly with the CTD domain of RNA pol II. In order to further understand 
the role of ZIPK in the transcription of our IEGs we prepared HBL1 cells for co-IP 
to assess a potential interaction between ZIPK and RNA pol II. The cells were  
pre-treated with or without DAPKi for 1 hour and then stimulated with anti-IgM for 
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30 minutes before co-IP lysis and immunoprecipitation with antibodies against 
both total RNA pol II and elongating RNA pol II S2-P. 
 
The co-IP data showed that ZIPK interacted directly with both RNA pol II and 
RNA pol II-S2P in an anti-IgM dependent manner whereby stimulation increased 
the interaction, particularly for RNA pol II S2-P (Figure 5.11A-B). Further, the 
interaction with RNA pol II S2-P can be marginally decreased by ZIPK inhibition 
(Figure 5.11B). The signal in the IgG control suggests some non-specific pull-
down in this experiment, but the smudged band shaping is not indicative of a false 
positive result, especially when compared with the pronounced bands in the co-
IP. 
 
These data suggested that the impact on pre-mRNA processing resulting from a 
loss of ZIPK function may be linked to its inability to interact with the elongating 
polymerase. We also cannot rule out that ZIPK may interact with elements of the 
processing machinery; the raft of proteins known to bind the RNA pol II CTD, but 
this requires further investigation. 
 
5.5.1 ZIPK inhibition leads to an accumulation of elongating RNA pol 
II S2-P 
We have shown that: 
I. ZIPK can interact directly with RNA pol II (S2-P) in an anti-IgM dependent 
manner and that this interaction can be prevented by DAPKi treatment 
(see Figure 5.11). 
II. ZIPK inhibition will either have no effect on or lead to an accumulation of 
RNA pol II (S2-P) at IEG loci (see Figure 5.3-Figure 5.5). 
 
To further understand the impact of ZIPK inhibition on RNA pol II recruitment to 
IEG loci we sought to assess the level of RNA pol II S2-P after DAPKi treatment 
by western blot. We pre-treated HBL1 cells with increasing concentrations of 
DAPKi (0-120 µM) for 1 hour before stimulation with anti-IgM for 30 minutes and 
subsequent lysis for western blot analysis with antibody against RNA pol II S2-P. 
At concentrations of DAPKi greater than 20 µM we observed a small increase in 
the levels of RNA pol II S2-P which may represent an accumulation of the 
polymerase in the context of ZIPK loss of function (Figure 5.12A-B). These data 
reinforced the link between ZIPK activity and the functionality of RNA pol II which 
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we have demonstrated through both accumulation of the polymerase itself and 
via interference in transcription coupled pre-mRNA processing. 
 
In this chapter we have shown that ZIPK appeared to directly interact with RNA 
pol II and its inhibition had an impact on pre-mRNA processing steps post-RNA 
pol II S2-P elongation.  
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Figure 5.9: Primer design for DUSP2 alternative splicing. (A) DUSP2 gene schematic showing introns and exons (indicated by numbers 
in bold), variable exons (exons 2-3) and 3 sets of primers. Primers for mRNA were designed as follows: primers spanning exons 3-4 to 
detect transcripts which have included the variable exons (top), primers spanning exons 1-4 to detect transcripts which have excluded or 
skipped the variable exons (middle) and primers bridging the junction between exon 3 and intron 3 to detect the alternatively spliced intron 
retained DUSP2 transcript (bottom). (B) qPCR data showing the level of constitutively (exon inclusion; exon_in) and alternatively spliced 
(exon exclusion; exon_ex or intron retention; in_ret) mRNA in HBL1 cells stimulated with anti-IgM or anti-IgM/CD40L for 30 mins.
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Figure 5.10: ZIPK inhibition reduces levels of alternative splicing. (A) (B) qPCR analysis comparing levels of full length DUSP2 mRNA 
with alternatively spliced DUSP2 mRNA. HBL1 cells were treated with either ibrutinib (green) or DAPKi (red) and stimulated with anti-IgM 
(black). To calculate the fold change in splicing, first, the ratio of splice isoforms is compared through the equation 2−∆Ct, where ∆Ct = (Ct 
exon inclusion mRNA − Ct exon exclusion/retention mRNA). This ratio is then compared to the value obtained for the same calculation for 
the control sample through the following equation: 2−∆Ct(experiment)/2−∆Ct(control), where ∆Ct(experiment) = (Ct inclusion splice isoform mRNA in 
experimental sample − Ct exclusion/retention splice isoform mRNA in experimental sample) and ∆Ct(control) = (Ct inclusion splice isoform 
mRNA in control sample − Ct exclusion/retention splice isoform mRNA in control sample) (see methods for more details on the calculations). 
In this way we can calculate the fold change in full length/intron retention ratio compared to the control sample. In giving the control sample 
ratio a value of 1, we observe that the value for ibrutinib remains close to this number, suggesting BTK inhibition effects both transcripts 
equally. DAPKi treatment however dramatically increases the ratio between alternatively and normally transcript transcripts, suggesting an 
impact on pre-mRNA processing/alternative splicing.  
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Figure 5.11: ZIPK interacts directly with RNA pol II (S2-P) in HBL1 cells. Co-
immunoprecipitation of HBL1 cells stimulated with anti-IgM for 1 hour as 
indicated. HBL1 cells were pre-treated with DAPKi for 1 hour where indicated. 
Immunoprecipitates from (A) RNA polymerase II and (B) RNA polymerase II S2-
P pulldown were analysed by SDS-PAGE followed by Western blot probing for 
ZIPK. Untreated, crude cell lysate was used as positive control (input) and IgG 
beads were used for negative control (Ctrl IgG). Blots are representative of 3 
independent co-IP experiments. 
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Figure 5.12: RNA polymerase II-S2P is observed to accumulate in the 
context of ZIPK inhibition. (A) (B) Western blot in HBL1 cells showing the effect 
of ZIPK inhibition on protein level of RNA Pol II-S2P with 1 hour anti-IgM 
stimulation of the BCR as indicated. β-actin was used as a loading control and 
for normalisation with Image Lab software (right). 
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Chapter 6 Discussion 
6.1 Summary of principle findings 
Zipper-Interacting Protein Kinase (ZIPK)/Death-Associated Protein Kinase 3 
(DAPK3) is a serine-threonine kinase known for its roles in apoptosis, but initially 
identified as a chromatin-associated enzyme with chromatin modifying potential 
[229]. Here, we show that ZIPK is recruited to the transcriptional machinery in 
response to BCR cross-linking where it targets histone H3 at threonine 6 and 11 
within the body of immediate early genes (IEGs) involved in CLL pathogenesis. 
These histone post translational modifications (PTMs) are correlated with IEG 
transcription and DAPK inhibition prevents their expression. 
 
We confirmed that ZIPK interacted with the non-histone substrates, RNA 
polymerase II and STAT3 and we demonstrated that the latter is also recruited to 
IEGs downstream of the BCR. Further, we showed that dual anti-IgM/CD40L 
stimulation increased IEG expression in CLL in an additive fashion through the 
activation of transcription factors such as the NF-κB subunit P65. In this context, 
and unlike ibrutinib, the ZIPK inhibitor was capable of overcoming combined anti-
IgM/CD40L-mediated IEG expression. Despite a complete loss of IEG 
transcription, RNA polymerase II recruitment and elongation were unperturbed 
by ZIPK inhibition. However, the loss of functional ZIPK impacted co-
transcriptional processing of nascent RNA, resulting in a loss of IEG pre-mRNA 
processing.  
 
From a clinical standpoint, we have determined that DAPK inhibition has similar 
outcomes to ibrutinib with regard to CLL cell proliferation in vitro and repression 
of IEGs transcribed in response to activation of the BCR pathway. Further, we 
have shown that DAPK inhibition appeared to have a broader effect in repressing 
pathways involved in cancer proliferation than ibrutinib – specifically CD40-
mediated NF-κB pathway activation 
 
Our principle findings are summarised in Figure 6.1. 
  
 
 
 
174 
 
6.2 Discussion 
6.2.1 DAPK inhibition as an alternative to ibrutinib in CLL? 
ZIPK has previously been implicated as having both oncogenic and tumour 
suppressing functions. For example, a loss of ZIPK function has been associated 
with reduced apoptosis in squamous cell carcinoma [231], increased tumour 
invasion in gastric cancer [232] and increased levels of cell survival, proliferation 
and resistance to chemotherapy in colon, lung and ovarian cancers [233]. 
Conversely, expression of ZIPK has been linked to metastasis via activation of 
AKT and NF-κB signalling in gastric cancer [234] and with an ability to provide a 
growth advantage to prostate cancer cells through androgen receptor gene 
regulation [220]. 
 
In our work in CLL, we have implicated ZIPK function as pro-proliferative, 
whereby DAPK inhibition reduces CLL cell proliferation with an apparent increase 
in apoptosis (Thomas et al., forthcoming 2020) and a reduction in IEG 
expression/histone PTM deposition (Results Figure 3.5 & Figure 3.14). 
Additionally, we observed a potentially synergistic effect on CLL cell proliferation 
and apoptosis when combining DAPKi with the CLL therapeutic, ibrutinib. 
Ibrutinib treatment generally had a similar outcome to DAPK inhibition while their 
mechanism of action differs and DAPKi had a broader repressive ability and could 
prevent both BCR- and CD40-mediated IEG expression.  
 
When discussing the impact of DAPK inhibition on CLL and HBL1 cell 
proliferation, apoptosis and IEG expression we must also address the doses of 
DAPKi necessary to achieve comparable or superior results to ibrutinib. Our 
working dose for DAPKi treatment was 20 µM, significantly higher than the 1 µM 
ibrutinib which was used throughout the project. Firstly, our initial kinase assay 
(Results Figure 3.1) demonstrated that the commercial DAPKi is not the most 
refined or potent inhibitor and may lack stability, as H3T6-P was only partially 
repressed in this experiment when compared to H3T11-P. Although, we observed 
a similar relative impact of siZIPK on H3T6-P by western blot (Results Figure 
3.12) suggesting this histone PTM may be harder to prevent by ZIPK inhibition or 
may be compensated for by another kinase. Our commercially available DAPKi 
is being compared to ibrutinib, the gold standard CLL therapeutic used in the 
clinic for thousands of patients worldwide which has been rigorously refined 
through numerous clinical trials. While ibrutinib off-target effects are being 
addressed through the development of highly-specific second generation BTKi 
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such as acalabrutinib and zanubrutinib, such considerations have not been made 
for the DAPKi.  
 
Of potential DAPKi off-target effects [266], ERK may be the most relevant to our 
work considering ERK has been shown to be phosphorylated and activated by 
anti-IgM stimulation of the BCR in CLL [267]. In the same study, ERK 
phosphorylation was shown to be also be attenuated by ibrutinib treatment. 
However, the authors used a co-culture NLC model system to model the lymph 
node microenvironmental niche. They observed that ERK phosphorylation was 
markedly decreased in the absence of NLC co-stimulation, suggesting that in an 
in vitro system like ours without co-culture, ERK phosphorylation may play a less 
significant role. Another study demonstrated that while a proportion (~50%) of 
their CLL patients presented with constitutive ERK phosphorylation, these 
patients where characterised by an unresponsiveness to BCR triggering by anti-
IgM in vitro [268]. Typically, our U-CLL patients responded well to anti-IgM 
signalling (CLL P4 as the exception), perhaps suggesting a lack of phospho-ERK. 
Nevertheless, future work with DAPKi would require screening for off target 
effects on ERK and others proteins.  
 
As discussed, BTK is an important signalling molecule towards the top of the BCR 
pathway and is implicated in the pathogenesis of several B-cell malignancies. 
Targeting BTK with ibrutinib provided a breakthrough in the treatment CLL, but 
cases of resistance associated with mutations in BTK and the downstream 
signalling molecule PLCγ2, are now emerging [138]. Further, there are reports of 
resistance which cannot be explained by genetic alterations [139-141]. In fact, 
recent studies indicate that alternative, pro-proliferative signalling pathways, 
primarily NF-κB, could compensate for the inactivation of BCR signalling [142, 
143]. Our own data demonstrated strong binding of the NF-κB subunit p65 at the 
DUSP2 promoter, replacing STAT3, in the presence of ibrutinib. This could 
suggest that the loss of BTK-mediated STAT3 activation promoted compensation 
from other transcription factors such as p65 (Results Figure 4.12).  
 
For additional examples, it has been reported that toll-like receptor (TLR) 
signalling, which can activate NF-κB in the lymph node, is only partially repressed 
by ibrutinib [142]. Similarly, ibrutinib does not prevent transcription in response to 
CD40 activation and this has been described by others [138] and demonstrated 
by us. CD40 is a key regulator of B cell proliferation and known to activate NF-κB 
[269]. ZIPK is activated downstream of BTK and PLCγ2, and was effective at 
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inhibiting both BCR and CD40-mediated IEG expression, suggesting that it could 
be an attractive alternative to ibrutinib, particularly in CLL cells for which relapse 
is correlated with mutations of both upstream proteins.  
 
ZIPK mediating the pre-mRNA processing of NF-κB target genes downstream of 
CD40 activation suggested it might also regulate NF-κB genes activated by other 
stimuli. In our work we examined IEG expression in response to anti-IgM, anti-
IgD and CD40L, but the canonical and non-canonical NF-κB pathways can 
additionally be activated by tumour necrosis factor (TNF), interleukin 1 (IL-1), 
lipopolysaccharide (LPS) and via micro-environmental agonists such as CpG-
oligodeoxynucleotides. It has been shown that ZIPK also regulates pro-
inflammatory genes in response to TNF-dependent activation [270] as well as in 
response to interferon-gamma (IFNγ) [271]. This suggests that ZIPK may be 
effective in preventing the pre-mRNA processing of many NF-κB target genes, 
regardless of the upstream activation pathway. From a clinical standpoint, NF-κB 
hyper-activation is common in many cancers and ZIPKs efficacy in preventing 
expression of NF-κB target genes presents an interesting and novel therapeutic 
option. Such pan-NF-κB deactivation could be considered dangerous to ‘normal’ 
cells which rely on NF-κB for various physiological processes. However, we 
suggest DAPK inhibition may be uniquely effective in cells with DAPK1 silencing 
(discussed in 6.2.2), and appears to be able to block transcription with a wider 
effect than ibrutinib, and this may provide a therapeutic window for ZIPK 
inhibitors.  
 
6.2.2 DAPK inhibition as a therapeutic option for DAPK1-silenced 
cancers 
DAPK1, the first member of the death-associated protein kinase family, can 
induce apoptosis in response to the IFNγ [272], TNF and FAS pathways [273]. 
Studies suggest that the DAPK family members form a unique hierarchy to 
regulate apoptosis and their activation is mediated not only by upstream signals 
but also through interactions with other DAPK proteins. DAPK1 and ZIPK directly 
interact to regulate their activity whereby they form a death-associated multi-
protein complex to regulate apoptosis [274]. DAPK1 can phosphorylate and 
regulate ZIPKs cellular localisation and it has been suggested that the 
cytoplasmic localisation of ZIPK may be imperative for its pro-apoptotic activity 
[218]. Silencing of DAPK1 via hypermethylation of its promoter has been 
observed in cancers such as CLL [91] and DLBCL [92] and is suggested to 
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influence tumour progression, aggressive disease, metastasis and is generally a 
marker of poor survival [275]. The profound effect of DAPK1 hypermethylation in 
virtually all cases of sporadic CLL [91, 276] was exemplified by work showing that 
reconstitution of DAPK1 activity in CLL cells could selectively promote leukaemia 
cell killing [277]. It was demonstrated that reactivated DAPK1 was able to 
promote both conventional, caspase dependent apoptosis and autophagy of CLL 
cells even with the most adverse cytogenetic prognostic features. 
 
ZIPK and DAPK1 share a cooperative relationship in normal tissue whereby both 
proteins synergise to induce cell death [218]. Work has shown that the presence 
of both proteins is required for effective apoptosis and that DAPK1 and ZIPK 
physically interact via their kinase domains [218]. This physical interaction allows 
DAPK1 to phosphorylate ZIPK at threonine 299 (ZIPK T299-P) in its catalytic 
domain. Phosphorylation of the T299 residue has been shown to promote 
cytoplasmic localisation of ZIPK [278]. The T299 residue has been shown to be 
adjacent to ZIPKs nuclear localisation sequence (NLS) and the authors 
hypothesised that when phosphorylated it may mask the NLS-function. Indeed, 
additional mutational analysis studies showed that loss of ZIPK T299-P induced 
a redistribution of ZIPK to the nucleus [222]. Logically, with DAPK1 silenced in 
diseases like CLL, ZIPK will lack substantial T299-P and the associated 
cytoplasmic localisation and cell death functions associated with DAPK1-ZIPK 
synergy.  
 
In addition to transphosphorylation by DAPK1, ZIPK possesses an 
autophosphorylation site in its kinase domain at threonine 265 (ZIPK T265-P), 
which has been shown to be critical for ZIPK kinase activity [223]. Further 
mutational analyses showed that ZIPK lacking T265-P was unable to effectively 
promote cell death and ZIPK-mediated STAT3 activation was impaired in the 
absence of T265 phosphorylation [223]. The same group also showed that 
leukaemia inhibitory factor (LIF) and interleukin-6 (IL-6) were able to activate and 
promote phosphorylation of ZIPK at T265, demonstrating the ability for ZIPK to 
be activated in response to stimuli, as we have also shown using anti-IgM (ZIPK 
in signalling is expanded on in discussion 6.2.3). It is worth noting that it has been 
shown that both DAPK1 and ZIPK are unable to phosphorylate any other 
members of the DAPK protein family, highlighting the specificity of this functional 
interaction. 
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In summary, based on the existing evidence regarding the ZIPK-DAPK1 
relationship, we suggest that depending on the state of DAPK1 silencing, ZIPK 
could function to either induce cell death (with DAPK1 expression) or promote 
proliferation and survival (with DAPK1 silencing). Without DAPK1-mediated ZIPK 
T299-P, ZIPK appears to be no longer regulated in a pro-apoptotic manner in the 
cytoplasm and may be equally present in the nucleus. Nuclear localisation could 
encourage alternative ZIPK functions including the phosphorylation of histones 
and ZIPK-STAT3 dependent gene expression, culminating in a pro-proliferative 
phenotype. This is evidenced by DAPKi treatment of CLL cells preventing the 
activation of pro-proliferative IEGs (Results Figure 3.5), preventing CLL and 
HBL1 cell proliferation and promoting CLL cell apoptosis (Thomas et al., 
forthcoming 2020). Due to the resounding evidence in the literature, we did not 
check our CLL samples for DAPK1 expression. However, if this gene was 
expressed in some CLL cells, and considering its function as described above, it 
would be very unlikely that targeting it with our DAPK inhibitor would produce the 
anti-proliferative and pro-apoptotic effects which we have observed and attributed 
to a loss of ZIPK function. 
 
Therapeutically, this suggests the possibility of testing ZIPK inhibitors in other 
malignancies characterised by DAPK1 silencing. For example, outside of CLL, 
DAPK1 promoter methylation is associated with the severity of the malignancy in 
various cancers including DLBCL [92], gastrointestinal [275], lung [279], urinary 
tract carcinomas [280], oesophageal and squamous cell carcinomas [281], head 
and neck [282], thyroid [283] and even in the brain metastases of solid tumours 
[284]. In the majority of these cancers DAPK1 is thought to function as a tumour 
suppressor which can suppress metastasis and tumour proliferation, together 
with ZIPK, via its apoptosis-inducing abilities. It is interesting to consider that ZIPK 
inhibitors may have a repressive function that is restricted to DAPK1-silenced 
cells, where ZIPK may potentially be functioning in a pro-proliferative fashion. We 
would recommend screening ZIPK inhibitors for anti-proliferative effects in 
models of those diseases listed above.  
 
Mechanistically, we can consider the signalling pathways which may be inhibited 
by ZIPK inhibition. As previously stated, constitutive BCR or NF-κB pathway 
activation is known to be pro-proliferative in many cancers, including CLL, and 
we have shown that ZIPK inhibition can prevent both anti-IgM and CD40L-
mediated IEG expression. However, targeting NF-κB in particular is difficult to its 
important roles in many normal physiological processes, particularly in preventing 
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inflammation [285]. Similarly, the BCR pathway is vital for the maturation and 
development of healthy B cells. Our data suggests that ZIPK inhibition may 
repress these pathways only in cells with aberrant epigenetic silencing of DAPK1 
while sparing cells in which DAPK1 is normally expressed. In summary, we have 
shown that ZIPK is a potential target in CLL and more generally in cancers 
characterised by DAPK1-silencing, which is often a marker of poor prognosis. 
 
6.2.3 ZIPK is a signalling-histone kinase  
ZIPK has previously been classified as a pro-apoptotic kinase involved in both 
caspase-dependent and independent pathways [224] as well as an alternative 
mechanism through autophagic cell death [286]. However, this enzyme was 
initially identified as a chromatin-associated enzyme phosphorylating the core 
histones H2A, H3 and H4 [229]. More specifically, ZIPK has been shown to 
phosphorylate histone H3 at T11 in a mitotic context where it modifies histones 
at specific regions of centromeric chromatin [230]. ZIPK has not previously been 
shown to phosphorylate histone H3 at threonine 6 and this is a novel finding. The 
H3T6-P modification has, however, been previously implicated in mediating gene 
activation through its phosphorylation by protein kinase C beta I (PKCß-I) [213]. 
In this example, transcription is promoted via H3T6-P directly preventing LSD1 
from demethylating H3K4 during androgen receptor gene activation. This 
mechanism for H3T6-P-mediated gene activation differs to that which we have 
described via pre-mRNA processing, but it does implicate this histone mark as 
activatory. 
 
It is worth noting that in our preliminary work we did consider whether or not PKC 
or other kinases, which were predicted to/and have previously been show to, 
phosphorylate H3T6 and H3T11 were functioning in our system. Among these 
kinases are MEK2, RSK1/2 and various PKCs, all of which are known to function 
downstream of the BCR signalling pathway. In order to confirm that ZIPK was 
uniquely responsible for targeting IEGs downstream of the BCR for histone 
PTMs, inhibitors targeting other kinases were tested for their ability to inhibit 
expression of EGR1 and DUSP2 and phosphorylation of H3T6 and H3T11 along 
these genes. We tested Gö6983, a pan-PKC inhibitor, RSK inhibitor II, a pan-
RSK inhibitor, and U0126, a MEK1/2 inhibitor. None of these inhibitors 
significantly inhibited the expression of EGR1 and DUSP2 or prevented histone 
H3 phosphorylation after anti-IgM stimulation (Thomas et al., forthcoming 2020). 
These data confirmed to us that downstream of the BCR in CLL, ZIPK is solely 
implicated in mediating IEG expression via H3T6 and H3T11 phosphorylation. 
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We have shown for the first time that ZIPK is activated in response to BCR cross-
linking and recruited to the transcriptional machinery where it interacts with RNA 
pol II in an anti-IgM dependent manner. Such BCR-dependent ZIPK:RNA pol II 
interaction correlated with IEG mRNA induction kinetics, providing further 
evidence that ZIPK is activated downstream of the BCR to mediate transcription. 
Previously, ZIPK had been identified as activated downstream of both TNF-α and 
IFN-γ. In the context of TNF, ZIPK was shown to mediate the phosphorylation of 
p38 and Akt as well as reactive oxygen species (ROS) production induced by 
TNF-α. This study showed for the first time how ZIPK could regulate TNF-α 
inflammatory responses via ROS-mediated mechanisms. Conversely, IFN-γ 
activates a kinase cascade which sees DAPK1 activate ZIPK and in turn 
phosphorylate the ribosomal protein L13a, whose phosphorylation is essential for 
the translational repression of inflammatory genes by the interferon gamma 
activated inhibitor of translation (GAIT) complex. Interestingly, in this example, 
GAIT-dependent inactivation of ZIPK can then reactive gene expression as 
required by the cell, demonstrating a unique regulatory axis that first represses, 
then re-permits inflammatory gene expression. While these mechanisms are 
diverse and differ from our proposed model suggesting ZIPK mediates pre-mRNA 
processing to regulate gene expression, they highlight the dynamism of ZIPK 
function and how its role can differ based on DAPK1 expression, subcellular 
localisation and stimulation source.  
 
STAT3 is well-reported to be activated in response to BCR signalling, as shown 
by us (Results Figure 4.1) and others [111, 115]. Further, ZIPK has previously 
been reported to interact with STAT3 and catalyse the phosphorylation of serine 
727 [228]. In addition, STAT3 has been shown to be uniquely phosphorylated at 
S727 in CLL and it has been specifically implicated in binding DNA and activating 
pro-proliferative gene programmes in the disease [116]. We combined this 
available data and assessed ZIPK-STAT3 interaction in CLL cells, which has not 
previously been reported.  
 
We confirmed the interaction in primary cells and demonstrated a BCR-inducible 
interaction between ZIPK and the CLL-specific phosphorylated form of STAT3. 
These data connected aspects of ZIPK biology which have previously been 
reported in isolation. In addition, this provided further evidence that ZIPK is 
downstream of the BCR pathway and its activity is inducible. Specifically, the 
ZIPK:STAT3 S727-P interaction showed the greatest inducibility post-BCR 
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activation and this interaction was also strongly reduced by ZIPK inhibition. We 
showed a small decrease in the levels of STAT S727-P when CLL cells are 
treated with ZIPK inhibitor, but a strong, BCR-dependent, loss of ZIPK:STAT3 
interaction and loss of STAT3 S727-P binding at IEG promoters in response to 
ZIPK inhibition. These data suggest that the ZIPK:STAT3 relationship is not 
completely S727-P dependent. However, while ZIPK inhibition does not prevent 
S727 phosphorylation it does impact STAT3:ZIPK interaction and STAT3 S727-
P nuclear function. It is possible that there are compensatory STAT3 
phosphorylation events which maintain S727-P in the presence of ZIPK inhibition 
and/or that the ZIPK interaction is not strictly necessary for S727-P. Indeed, it has 
been suggested that constitutive STAT3 S727-P is maintained in CLL cells by an 
intrinsic, but unknown, mechanism [116] and it is likely that ZIPK is not required 
for this step. However, we can hypothesise that without the ZIPK interaction 
which is lost as a result of DAPK inhibition, STAT3 is unable to effectively target 
and bind IEG promoters to activate gene transcription. 
 
We have previously discussed ZIPK cellular localisation with regard to DAPK1 
and ZIPK T299-P phosphorylation, and can now consider localisation of ZIPK in 
its relationship with STAT3. Studies on STAT3 phosphorylation in CLL have 
shown that STAT3 S727-P has both a cytoplasmic and a nuclear fraction [116]. 
However, the mechanism of serine-phosphorylated STAT3 nuclear translocation 
in CLL is unknown and the study suggested an unidentified adapter may bind 
STAT3 to mediate its transport. We, and others, have previously shown that ZIPK 
is also present in both cellular compartments [278] (data not shown). As 
discussed, we have observed that DAPK inhibition impacts the ZIPK:STAT3 
S727-P interaction and reduces STAT3 S727-P DNA-binding at IEG promoters. 
These data suggest that ZIPK function, while dispensable for STAT S727 
phosphorylation, could be necessary for effective STAT3 nuclear shuttling and 
IEG promoter targeting. 
 
There is some evidence to suggest ZIPK is also activated in response to CD40L 
stimulation. We have demonstrated ZIPK inhibition was able to overcome 
CD40L-mediated IEG expression (Results Figure 4.10) and H3T6/T11 
phosphorylation (Results Figure 4.19). The fact that H3T6 and H3T11 
phosphorylation was found in IEG loci in response to CD40L stimulation 
(particularly DUSP2) does lend evidence to support that ZIPK can be activated 
by CD40. If our hypotheses for ZIPK function as a signalling-histone kinase and 
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transcriptional co-activator are correct, it may well be activated to some degree 
in response to a variety of stimuli. 
  
Considering the ZIPK:STAT3 interaction was increased following BCR 
crosslinking, we wanted to assess any potential interactions between ZIPK and 
NF-kB subunit p65 post CD40L stimulation. We could not confirm with certainty 
that ZIPK and p65 interacted in CLL or HBL1 cells (data not shown). The fact that 
ZIPK inhibition could impair CD40L/NF-kB-mediated activation of IEGs despite 
any interaction with NF-kB proteins suggested that the NF-kB-mediated 
transcriptional activation of our IEGs functions in a way which does not require 
ZIPK directly interacting with the transcription factor, as we have observed for 
STAT3. Interestingly, work has highlighted a previously unreported relationship 
between NF-κB and STAT3 in CLL which we can consider in this context. The 
study showed that the high levels of constitutive STAT3 S727-P in CLL also 
induced high levels of unphosphorylated STAT3 (U-STAT3) which bound to NF-
κB dimers p65/p50 in competition with IκB [258, 287]. These U-STAT3/NF-κB 
complexes could translocate to the nucleus and bind NF-κB target genes to 
induce their transcription. With this in mind, STAT3 and NF-κB co-regulation has 
previously been observed in CLL [111, 112] and in our own work we have 
demonstrated an additive/synergistic effect of combining anti-IgM/CD40L 
stimulation on IEG expression. Taken together, these data suggest that a 
complex, STAT3-cooperative, NF-κB activation mechanism exists in CLL. 
 
We hypothesise that the loss of ZIPK:STAT3 interaction and STAT3 S727-P DNA 
binding may impact NF-κB activation. For example, by disrupting the ZIPK:STAT3 
interaction, potential ZIPK-mediated STAT3 nuclear shuttling and STAT3 
promoter binding, we may in turn impact NF-κB recruitment and/or activation. 
Indeed, work has demonstrated the concept of transcription factor assisted 
loading, and the notion of partner/pioneer transcription factors, whereby one 
transcription factor binds a specific motif and mediates chromatin modifications 
to allow the binding of another [288-290]. Specifically, NF-κB can bind and prime 
enhancers, evidenced by increased H3K27ac, to facilitate STAT3 binding and 
promote synergistic gene expression [259]. We can only begin to hypothesise on 
the complex nature of transcription factor loading in CLL with our limited ChIP 
data for STAT3 and p65. Complete ChIP-seq profiling of these transcription 
factors in the context of BCR/CD40 activation with and without ZIPK inhibition 
may provide a clearer picture on how loss of ZIPK function impacts their DNA 
binding. 
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6.2.4 ZIPK in the coupling of RNA polymerase II transcription 
elongation with pre-mRNA processing 
We have implicated ZIPK as a signalling histone kinase downstream of the BCR 
which interacts with RNA pol II and phosphorylates histones to promote IEG 
expression. As discussed, there are a variety of other histone kinases which have 
been reported to phosphorylate histones, directly modulate gene expression and 
also interact with and/or phosphorylate non-histone substrates (see 1.3.3 on 
signalling kinases) and ZIPK is not the first of this class of enzyme which has 
been implicated in a relationship with the transcription machinery.  
 
PIM1, JAK2 and IKKα all show chromatin modifying activity linked to 
transcriptional elongation. PIM1 is recruited by MYC to catalyse H3S10-P at 
MYC-target genes, and it has been shown that H3S10-P was necessary for 
subsequent loading of positive transcription elongation factor b (P-TEFb) – a 
protein complex necessary to release paused RNA pol II into active elongation 
[170, 291, 292]. Tousled-like kinase (TLK1) has also been shown to stimulate 
H3S10-P in human epithelial cells and therefore may play a similar histone-kinase 
role as PIM1 [293]. JAK2 is a well-known signalling kinase which can directly 
phosphorylate H3T41 to exclude HP1α from chromatin, thus preventing the 
activation of gene expression programmes [171]. Similarly, IKKα has been 
reported to be directly recruited to the promoter of NF-kB target genes to 
phosphorylate H3S10-P for P-TEFb loading and RNA pol II elongation [168]. In 
addition, IKKα was shown to travel with elongating RNA pol II S2-P and HP1γ 
during transcription through the gene body [168]. We performed ZIPK ChIP 
experiments to determine if, and where, ZIPK bound the loci of our model IEGs 
(data not shown) with the aim of understanding whether or not ZIPK behaved like 
IKKα. The ZIPK ChIP data was difficult to analyse and the biggest challenge 
stemmed from the fact that there are no commercially available ChIP grade 
antibodies raised against ZIPK and we used antibodies validated for co-IP 
instead. Thus, while we could not confidently say whether ZIPK travels with the 
RNA pol II molecule, we have shown that they interact, and we observed H3T6-
P and H3T11-P in the gene body regions where RNA pol S2-P is actively 
elongating the nascent transcript. In summary, this class of signalling enzyme 
mediates gene expression through various methods of facilitating transcription 
elongation by RNA pol II.  
 
One of our more interesting observations was that ZIPK inhibition could prevent 
IEG expression in CLL and HBL1 cells despite having seemingly no effect on 
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RNA pol II recruitment and elongation. This data led us to investigate ZIPKs role 
in pre-mRNA processing and conclude that ZIPK function was required for the 
accurate processing of IEG nascent transcripts. Maturation of pre-mRNA 
precursors often occurs simultaneously with, and mechanically coupled to, 
transcription by RNA pol II. The co-transcriptional overlap in these two processes 
enhances the accuracy and efficiency of pre-mRNA processing [263]. Further, 
these processes occur both on and in the vicinity of the chromatin: which plays a 
role in coordinating them [203, 294]. One of the first studies to demonstrate co-
transcriptional splicing used electron microscopy of chromatin spreads from 
embryonic Drosophila melanogaster to show that intron looping occurred in the 
presence of RNA pol II-DNA complexes, joined to the elongating transcript, 
suggesting that splicing takes place prior to transcript release from the RNA pol 
II complex [295]. 
 
In brief, the maturation of most pre-mRNAs requires the attachment of a 7-
methylguanosine cap to the 5′ end of the transcript, splicing to excise introns and 
ligate exons, and formation of a 3′ end site by cleavage and addition of a non-
templated poly(A) tail [263]. The co-transcriptional processing of pre-mRNA is 
mediated by a raft of proteins which interact with the CTD domain of RNA pol II. 
The CTD domain acts as a platform to recruit and directly interact with a variety 
of capping, splicing and 3’ end processing factors to the transcription elongation 
complex [261]. It has been suggested that the CTD phosphorylation occurring 
during the transcription cycle forms a ‘CTD code’ which guides the numerous 
processing factors on and off the transcription elongation complex platform as 
required [264].   
 
Our data suggested that without ZIPK function there is an accumulation of 
unprocessed pre-mRNA and ZIPK inhibition greatly reduced the ratio of DUSP2 
alternate splice isoforms. Outside of our work, a potential role for H3T6-P and 
H3T11-P in controlling mRNA processing has not been reported. However, as 
discussed previously (see 1.4.4.2 on pre-mRNA processing) histone 
modifications are reported to play a large and well-reported role in pre-mRNA 
splicing, typically associated with alternative splicing. For example, H3K36me3 is 
often found enriched in exons while H3K9me2/3 and H3K27me2/3 have been 
shown to be preferentially excluded from these regions [201, 296]. One study 
showed that H3K27me3 and H3K36me1 were systemically replaced by 
H3K36me3 and H3K27me1 during transcription and their levels reflected the 
expression level of the gene. This study also demonstrated a difference in the 
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levels of H3K36me3 in alternatively spliced exons, whereby less of the histone 
modification was found at less-included exons [297]. This work suggested that 
the histone marks which guide alternative splicing can be actively set during 
transcription to guide pre-mRNA processing. We observed an impact of ZIPK 
inhibition on DUSP2 alternative splicing and it is possible that catalysis of 
H3T6/T11 phosphorylation is an important priming event for accurate splicing. In 
light of such data, it would be interesting to assess if ZIPK inhibition could impact 
H3K36 methylation in exonic regions. In addition, particular DUSP2 splice 
isoforms are generated via exon skipping and another study has shown that 
H3K4me1 as well as H3K36me3 can play a dominant role in skipped exon 
selection in mammalian development and in the brain [298] 
 
It is worth considering that IEGs show rapid pre-mRNA induction and RNA 
polymerase recruitment compared to secondary/delayed response genes [173]. 
IEGs have a distinct genomic architecture and chromatin structure to facilitate 
their rapid transcription characterised by bivalent promoters poised for rapid 
activation [191]. Consequently, ZIPK inhibition may be particularly effective 
against the pre-mRNA processing of this class of gene: but genome-wide 
expression analysis would be required to confirm this (see 6.3.2 future direction).  
 
Alternatively, it cannot be excluded that ZIPK could directly target non-histone 
substrates outside of STAT3 and RNA pol II such as proteins of the processing 
machinery. In addition to ZIPK itself, there is evidence to support the notion that 
its downstream histone targets, H3T6-P and H3T11-P, can act as a platform for 
splice factors to bind either directly or via intermediary chromatin-binding proteins 
which in turn recruit the splice factors. For example, the capping machinery binds 
both the CTD of RNA pol II and also H3K4me3 found at promoter regions [299]. 
Similarly, the chromatin remodelling ATPase CDH1 is recruited to active genes 
by binding H3K4me3 where it interacts with U2 spliceosome components [205]. 
Additionally, it was shown that HP1γ interacts with H3K9me3 in alternative exons 
in the CD44 gene in human cells only when phosphorylated, a process which is 
controlled upstream by PKC. Interestingly, it was shown that the presence of 
HP1γ at alternative splice sites not only mediates the inclusion of variable exons 
but also impacts RNA pol II processivity, which was found to be enriched at HP1γ 
bound regions [210]. We can hypothesise that ZIPK or H3T6/T11-P may mediate 
the binding of splicing factors during co-transcriptional pre-mRNA processing, 
based on our data demonstrating that that loss of ZIPK strongly impacts 
alternative splicing of DUSP2 and leads to an accumulation of unprocessed 
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transcripts. In our data we show that RNA pol II is unaffected in IEG gene bodies 
following ZIPK inhibition but we cannot accurately infer elongation speed from 
these experiments. Considering HP1γ-binding demonstrates how chromatin 
modifying enzymes mediating splicing can impact RNA pol II processivity, 
elongation rate experiments may be interesting in the context of loss of ZIPK 
function (see future direction 6.3.3) 
 
We observed that in some cases of dual anti-IgM/CD40L stimulation ibrutinib was 
able to prevent RNA pol II S2-P recruitment, particularly at EGR1, but had little 
impact on gene expression. In these experiments we sometimes saw RNA pol II 
accumulation in the 3’ end of our model IEGs. These data were confusing and 
we can only hypothesise on their meaning. As we observed unchanged RNA pol 
II bound upstream of the TSS at the EGR1 promoter it is plausible that the IEG 
elongation kinetics are slightly altered with dual stimulation. This is somewhat 
evident when comparing IEG expression between anti-IgM alone and dual anti-
IgM/CD40L where the peak expression came after 30 and 45 minutes 
respectively (Results Figure 4.7). These differences may arise from contrasting 
RNA pol II recruitment dynamics which could be dependent on the signalling 
pathway and downstream TFs (e.g. CD40L/NF-kB versus BCR/STAT3) at 
DUSP2 and EGR1. As ibrutinib only inhibited the BCR/STAT3-mediated IEG 
expression in the context of dual stimulation, we may be observing a specific 
CD40/NF-kB RNA pol II recruitment signature, typified by slower/less RNA pol II 
S2-P recruitment and elongation through the gene body. These kind of 
hypotheses could be examined in future work considering transcription 
elongation speeds in the context of different pathway activation and inhibitor 
treatment (see future direction 6.3.3). 
 
We can hypothesise how ZIPK catalysing H3T6 and H3T11 phosphorylation in 
the gene bodies of IEGs ensures the processing of their pre-mRNA. ZIPK may 
be recruited by STAT3 and NF-kB to catalyse H3T6-P and H3T11-P at target 
genes and/or also travel with the elongating RNA pol II like IKKα in order to 
mediate the recruitment of processing factors to the RNA pol II CTD. Additionally, 
RNA pol II-associated ZIPK, or H3T6-P/H3T11-P, may directly target the pre-
mRNA processing machinery or act as a platform for its recruitment, in a similar 
fashion to CDH1, HP1γ and H3K4me3 recruiting splicing factors. On the other 
hand, the presence of ZIPK, H3T6-P and H3T11-P may exclude proteins or 
histone modifications inhibitory to gene expression from the chromatin around 
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IEGs, like JAK2. Further work is required to fully understand the mechanism of 
ZIPK-mediated IEG pre-mRNA processing (see 6.3 future direction). 
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Figure 6.1: Model summarising the potential involvement of ZIPK in the co-
transcriptional recruitment and function of factors coupling transcription & 
RNA processing.  
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6.3 Future directions & limitations 
Our work has identified a novel role for ZIPK in gene expression through histone 
phosphorylation-mediated regulation of pre-mRNA processing. The data 
presented focuses on two IEGs activated downstream of the BCR which are 
known to play a role in CLL pathogenesis. In order to expand on our work, 
investigation into the areas described below, which were outside the scope of this 
project, would help to develop and increase our understanding of ZIPK function 
and its potential as a therapeutic. Of note, for almost all of the techniques and 
thoughts described below, the principle caveats for their execution comprise 
either technical limitations or the expense associated with the experiments.  
 
6.3.1 ZIPK inhibition versus knockdown versus knockout 
In our work, we used a commercially available ATP-competitive ZIPK inhibitor 
(DAPKi) to prevent ZIPK kinase activity. This inhibitor prevented ZIPK function at 
doses of >25 µM (Results Figure 3.2) and effectively inhibited CLL cell 
proliferation in a manner comparable with ibrutinib when used at this dose 
(Thomas et al., forthcoming 2020). The dose of DAPKi we utilised is high when 
compared with many commercially available targeted inhibitors which we must 
attribute to its unrefined, non-commercial nature. It is worth noting another ZIPK 
inhibitor (HS38) was synthesised to examine the involvement of ZIPK in the 
regulation of smooth muscle contraction [300] and it could be beneficial to 
compare and contrast this inhibitor with our own. 
 
We also used siRNAs directed against ZIPK to block its expression at the mRNA 
level, thus preventing its activity, in HBL1 cells (Results Figure 3.12). While 
sufficient for our work, future experiments could potentially benefit from more 
efficient ZIPK inhibition. Notably, the use of shRNA directed against ZIPK or 
CRISPR technology. Like siRNA, shRNA takes advantage of endogenous 
cellular machinery to silence gene expression. However, shRNA is transfected 
into the cell via vector-based approaches and can be used to study long-term 
effects through incorporation into the genome. Considering our siRNA efficiency, 
use of shRNA-mediated knockdown could allow us to stably prevent ZIPK 
expression over a longer period of time for further study. In contrast to both, gene 
knockout approaches like CRISPR [301] lead to complete elimination of gene 
function. Considering the biological limitations of transient siRNA knock-down, 
use of CRISPR-cas9-mediated ZIPK gene knockout could provide us with a more 
complete picture of the effects of loss of ZIPK function. In addition, we used HBL1 
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cells for our siRNA-mediated ZIPK knockdown to study ZIPK function. From a 
CLL therapeutic point of view, using any of the above technologies in primary 
cells would be both beneficial but also technically challenging. 
 
6.3.2 Genome-wide studies  
While EGR1 and DUSP2 are exemplary model IEGs to study ZIPK molecular 
mechanisms, next-generation sequencing experiments could increase our 
understanding of ZIPK function on a genome-wide scale. 
 
RNA-sequencing (RNA-seq) allows the entire transcriptome to be quantified in a 
high-throughput manner, providing a precise readout of the levels of transcripts 
and their isoforms present in a cell [302]. For us, there are many advantages in 
being able to look genome-wide at genes which are downregulated in response 
to a loss of ZIPK function. Principally, by comparing cells (either HBL1 or CLL) 
prepared with the technologies described above (DAPKi, si/shRNA, CRISPR) to 
‘normal’ cells we could theoretically assess, genome-wide, the types of genes 
which are effected by a loss of ZIPK function. This could be particularly interesting 
when we consider ZIPKs impact on IEGs and ask the question: does ZIPK 
preferentially effect the processing of short, low exon number, IEGs specifically? 
RNA-seq would allow us to assess all genes and transcripts effected by a loss of 
ZIPK function and determine whether slower, secondary response and delayed 
genes are also affected.  
 
Similarly, ChIP-sequencing (ChIP-seq) comparing cells lacking functioning ZIPK 
with ‘normal’ cells would allow us to expand from our model IEGs and assess 
H3T6 and H3T11 phosphorylation genome-wide. By combining data from RNA-
seq and ChIP-seq, in the same way we have combined qPCR and ChIP data, we 
could identify genes whose activation is marked by H3T6 and H3T11 
phosphorylation – and assess whether or not these genes can be downregulated 
by ZIPK inhibition. These type of experiments would allow us to better understand 
the characteristics of genes which are regulated by ZIPK and which pathways 
they are downstream of. Further, ChIP-seq focussing on the transcription factors 
STAT3 and NF-κB could help us to understand how these proteins work in 
concert to mediate synergistic gene expression in CLL, a topic we touched upon 
in this work. 
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6.3.3 ZIPK in transcription coupled-processing 
We have implicated ZIPK as playing a role in the pre-mRNA processing of IEGs 
downstream of the BCR. We have shown that ZIPK inhibition impacts the 
effectiveness of pre-mRNA processing through the detection of an accumulation 
of unprocessed transcripts and impaired alternative splicing. It was however 
beyond the scope of this project to delve into this mechanism further, and attempt 
to identify more precisely how ZIPK inhibition prevents faithful co-transcriptional 
processing of primary transcripts.  
 
RNA-immunoprecipitation (RIP) can be used to map RNA-protein interactions by 
cross-linking RNA molecules to RNA-binding proteins (RBPs) in a similar way 
that ChIP assesses DNA-protein interactions [303]. RIP utilises a specific 
antibody against the protein of interest to pull down RBP and target-RNA 
complexes and precisely map RBP-binding sites. Any RNA that is associated with 
this protein complex will also be isolated and can be further analysed by qPCR. 
There are a  raft of proteins involved in the processing of pre-mRNA, but by 
screening key members of the processing machinery by RIP we could potentially 
determine whether a loss of ZIPK function prevents their interaction with the pre-
mRNA. Similarly, it would be interesting to assess whether or not ZIPK interacts 
directly with the unprocessed pre-mRNA itself or whether its effect on processing 
is mediated instead by interactions with members of the processing machinery.  
 
Further concerning the involvement of ZIPK on coupled transcription and mRNA 
processing, 4sUDRB-seq can measure global transcription elongation speed and 
the rate of RNA pol II transition into active elongation, and how these factors 
effect total mRNA production [304]. The technique uses reversible inhibition of 
transcription elongation with DRB combined with a pulse of 4-thiouridine (4sU) to 
tag newly transcribed RNA which can be subsequently captured and sequenced.  
For us, this protocol could allow for the purification of all the nascent pre-mRNA 
transcripts which persist in the presence of ZIPK inhibition. These kind of 
experiments would allow us to learn more about ZIPKs mechanism of action with 
regard to pre-mRNA processing as well as identify the types of genes whose 
primary transcripts remain unprocessed following ZIPK inhibition. 
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6.3.4 ZIPK in-vivo studies 
From a future therapeutic perspective, to understand how ZIPK inhibitors may be 
used to treat CLL or even other diseases in which DAPK1 is silenced, in-vivo 
models would be a necessary and highly information step. The use of murine 
models to study the biology of disease is well document and remains essential to 
understand and improve treatment and therapy [305].  
 
Poor engraftment by CLL cells into mice has limited the utility of xenograft models 
for the disease [306] but nevertheless there are several mouse models used to 
study CLL [307]. Of these, the TCL1 transgenic mice [308] and 13q14-deletion 
models [309] have been comprehensively studied and show close resemblance 
to the human disease. For us, such mice may require further genetic engineering 
to prevent DAPK1 expression. Thereafter, survival of CLL-mice treated with or 
without ZIPK inhibitors could be compared. Further, the efficacy of ZIPK inhibitors 
in mice modified to present with other unfavourable prognostic markers e.g. p53 
mutation, could be considered.  
 
In summary, future work researching the use of ZIPK inhibitors to treat disease, 
especially ibrutinib resistant CLL with BTK or PLCg2 mutations, would require the 
study with in vivo mouse models.   
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6.4 Concluding remarks 
In conclusion, our work suggests that ZIPK functions as one of the final 
downstream enzymes in the transcription cascade of at least the BCR and NF-
kB pathways, required for successfully orchestrating the co-transcriptional 
processing of nascent pre-mRNA transcripts into mature mRNA.  
 
Mechanistically, we implicate ZIPK as a signalling-histone kinase which can 
directly regulate gene expression through a role in pre-mRNA processing, modify 
histone H3 at threonine 6 and threonine 11 and also interact with non-histone 
substrates including STAT3 and RNA polymerase II.  
 
Clinically, we demonstrate that ZIPK inhibition can outperform ibrutinib in blocking 
pro-proliferative gene expression when the upstream signalling originates from 
an alternative non-BCR source, such as CD40. As ZIPK seems to function far 
downstream of both BTK and PLCγ2, and its inhibition is effective against both 
BCR and CD40-mediated signals, our data suggests that ZIPK inhibition could 
be an alternative to ibrutinib treatment in CLL and other DAPK1-silenced 
malignancies.
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Chapter 8 Appendix 
8.1 Appendix 1 – uncropped western blots 
 
Appendix 1.1: uncropped western blots demonstrating one representative example per antibody for (A) ZIPK (B) ZIPK T265-P (C) EGR1 
(D) H3T11-P (E) H3T6-P and (F) histone H3.  
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Appendix 1.2: uncropped western blots demonstrating one representative example per antibody for (A) beta-actin (B) RNA pol II S2-P 
(C) STAT3 (D) STAT3 Y705-P and (E) STAT3 S727-P. 
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Appendix 1.3: uncropped western blots demonstrating one representative example per antibody for (A) p65 (nuclear) (B) p65 
(cytoplasmic) (C) HDAC2 and (D) vinculin. 
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8.2 Appendix 2 – uncropped co-IPs 
 
Appendix 2.1: uncropped/uncut co-IPs corresponding to (A) Figure 4.2A and (B) (C) Figure 4.2B. Red boxes indicate faint input samples. 
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Appendix 2.2: uncropped/uncut co-IPs corresponding to (A) Figure 4.2C and (B) (C) (D) Figure 4.2D. Red boxes indicate faint input 
samples. 
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Appendix 2.3: uncropped/uncut co-IPs corresponding to (A) (B) Figure 4.2F and (C) (D) Figure 4.2G. Red boxes indicate faint input 
samples. 
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Appendix 2.4: uncropped/uncut co-IPs corresponding to (A) Figure 4.3A (B) Figure 4.3B (C) Figure 4.3C and (D) Figure 4.3D. Red boxes 
indicate faint input samples. 
